

Plaintiff's Smith Master Exhibit List (04/27/2010)

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX0040		000006-85BAH-00046	000006-85BAH-00655	610	Medical Records: Baptist Hospital	Smith Medical Records
PX0041		000006-82BAH-00001	000006-82BAH-00012	12	Medical Records: Baptist Hospital Pathology	Smith Medical Records
PX0042		000006-78BAH-00001	000006-78BAH-00033	33	Medical Records: Baptist Hospital Psychiatric	Smith Medical Records
PX0043		000006-52FMB-00007	000006-52FMB-00056	50	Medical Records: Berklacich, Frank MD	Smith Medical Records
PX0044		000006-45BCB-00001	000006-45BCB-00097	97	Medical Records: Blue Cross Blue Shield of TN	Smith Medical Records
PX0045		SmithMED00002		149	Medical Records: Cato, James MD	Smith Medical Records
PX0046		000006-36CMD-00051	000006-36CMD-00063	13	Medical Records: Centennial Medical Center	Smith Medical Records
PX0047		000006-64CMD-00064	000006-64CMD-00217	154	Medical Records: Centennial Medical Center	Smith Medical Records
PX0048		000006-68CMMS-00001	000006-68CMMS-00001	11	Medical Records: Centers for Medicare Medicaid Services	Smith Medical Records
PX0049		000006-48CRSA-00001	000006-48CRSA-00011	11	Medical Records: Colon & Rectal Surgery Associates	Smith Medical Records
PX0050		000006-126MAC-00001	000006-126MAC-00004	4	Medical Records: Crawford, Myles DC	Smith Medical Records
PX0051		SmithMED00003		2	Medical Records: Eckerd Drug #3483 Pharmacy	Smith Medical Records
PX0052		000006-58ECK-00003	000006-58ECK-00006	4	Medical Records: Eckerd Drugs Pharmacy	Smith Medical Records
PX0053		SmithMED00004		1	Medical Records: Eckerd Drugs Pharmacy	Smith Medical Records
PX0054		000006-83MOM-00001	000006-83MOM-00005	5	Medical Records: Forensic Medical Autopsy	Smith Medical Records
PX0055		SmithMED00006		19	Medical Records: Forensic Medical Autopsy	Smith Medical Records
PX0056		SmithMED00007		1	Medical Records: Hampf, Carl MD	Smith Medical Records
PX0057		000006-53CAH-00001	000006-53CAH-00025	25	Medical Records: Hampf, Carl MD	Smith Medical Records
PX0058		000006-60CAH-00026	000006-60CAH-00028	3	Medical Records: Hampf, Carl MD	Smith Medical Records
PX0059		000006-38WBH-00002	000006-38WBH-00009	8	Medical Records: Harwell, William B., Jr. MD	Smith Medical Records
PX0060		000006-39WBH-00010	000006-39WBH-00027	18	Medical Records: Harwell, William B., Jr. MD	Smith Medical Records
PX0061		000006-51HVC-00001	000006-51HVC-00004	4	Medical Records: Heart & Vascular Clinic	Smith Medical Records
PX0062		000006-50HVC-00001	000006-50HVC-00016	16	Medical Records: Heart & Vascular Clinic	Smith Medical Records
PX0063		000006-67HMA-00001	000006-67HMA-00001	36	Medical Records: Heritage Medical Associates	Smith Medical Records
PX0064		000006-42HMA-00076	000006-42HMA-00267	192	Medical Records: Heritage Medical Associates	Smith Medical Records
PX0065		SmithMED00008		168	Medical Records: Heritage Medical Associates	Smith Medical Records
PX0066		SmithMED00009		19	Medical Records: Heritage Medical Assocs	Smith Medical Records
PX0067		000006-129HMA-00304	000006-129HMA-00312	9	Medical Records: Heritage Medical Assocs	Smith Medical Records
PX0068		SmithMED00024		1	Medical Records: Heritage Medical Assocs	Smith Medical Records
PX0069		SmithMED00010		2	Medical Records: Kaswinkel, Daryl MD	Smith Medical Records

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX0070		000006-47LVC-00001	000006-47LVC-00029	29	Medical Records: Loden Vision Center	Smith Medical Records
PX0071		SmithMED00011		24	Medical Records: Mackey, Edward MD	Smith Medical Records
PX0072		SmithMED00012		1	Medical Records: Mackey, Edward MD	Smith Medical Records
PX0073		SmithMED00013		1	Medical Records: McCombs, Paul MD	Smith Medical Records
PX0074		SmithMED00014		100	Medical Records: McCombs, Paul MD	Smith Medical Records
PX0075		000006-130DPM-0001	000006-130DPM-0073	73	Medical Records: McCombs, Paul MD Howell Allen Clinic	Smith Medical Records
PX0076		000006-92MOM-00006	000006-92MOM-00024	19	Medical Records: Medical Examiner's Report	Smith Medical Records
PX0077		000006-121MMS-00001	000006-121MMS-00015	15	Medical Records: MOHS Surgery & Dermatology	Smith Medical Records
PX0078		SmithMED00015		7	Medical Records: Neurological Surgeons	Smith Medical Records
PX0079		000006-77NEA-00001	000006-77NEA-00003	3	Medical Records: Neurosurgical Associates	Smith Medical Records
PX0080		000006-81NEA-00001	000006-81NEA-00004	4	Medical Records: Neurosurgical Associates	Smith Medical Records
PX0081		000006-63OAT-00004	000006-63OAT-00005	2	Medical Records: Otolaryngology Assoc of TN	Smith Medical Records
PX0082		000006-61OAT-00003		1	Medical Records: Otolaryngology Assoc of TN	Smith Medical Records
PX0083		000006-120POS-00001	000006-120POS-00010	10	Medical Records: Premier Orthopedics	Smith Medical Records
PX0084		000006-66SNUC-00070	000006-66SNUC-00078	9	Medical Records: Spalding & Nesbitt Urology Clinic	Smith Medical Records
PX0085		000006-62SNUC-00006	000006-62SNUC-00069	64	Medical Records: Spalding & Nesbitt Urology Clinic	Smith Medical Records
PX0086		SmithMED00016		10	Medical Records: Stasko, Thomas MD	Smith Medical Records
PX0087		000006-69AQC-00001	000006-69AQC-00144	144	Medical Records: TN Orthopedic Alliance Medical	Smith Medical Records
PX0088		SmithMED00017		48	Medical Records: University Medical Center	Smith Medical Records
PX0089		000006-37UMC-00095	000006-37UMC-00097	3	Medical Records: University Medical Center	Smith Medical Records
PX0090		000006-35UMC-00045	000006-35UMC-00094	50	Medical Records: University Medical Center	Smith Medical Records
PX0091		000006-113UAS-00001	000006-113UAS-00032	32	Medical Records: Urology Associates	Smith Medical Records
PX0092		000006-79VANPA-00001	000006-79VANPA-00004	4	Medical Records: Vanderbilt University Medical Center	Smith Medical Records
PX0093		000006-40VUM-00001	000006-40VUM-00013	13	Medical Records: Vanderbilt University Medical Center	Smith Medical Records
PX0094		SmithMED00005		56	Medical Records: Walgreens Pharmacy	Smith Medical Records
PX0095		000006-135WAG-00001	000006-135WAG-00002	2	Medical Records: Walgreens Pharmacy	Smith Medical Records
PX0096		000006-86CLW-00002	000006-86CLW-00009	8	Medical Records: Wood, Christopher DDS	Smith Medical Records
PX0097		000006-128CLW-00010	000006-128CLW-00023	14	Medical Records: Wood, Christopher DDS	Smith Medical Records
PX0100					Smith Family Photos	
PX0101		SmithMISC00018		1	Death Certificate	Smith Case Specific
PX0102		SmithMISC00019		29	Funeral Home Signature Book	Smith Case Specific
PX0103		000006-84RAT-00001	000006-84RAT-00061	61	Internal Revenue Service	Smith Case Specific

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX0104		SmithMISC00020		1	Letters Testamentary	Smith Case Specific
PX0105		SmithMISC00021		27	Nashville Office Machines	Smith Case Specific
PX0106		000006-91MNP-00002	000006-91MNP-00016	15	Nashville Police Dept Report	Smith Case Specific
PX0107		SmithMISC00022		2	Obituary	Smith Case Specific
PX0108					Smith Family DVD	Smith Case Specific
PX0109		SmithMISC00023		1	Suicide note	Smith Case Specific
PX0110					Call Notes	Smith Case Specific
PX0111					Call Notes	Smith Case Specific
PX0112					Samples	Smith Case Specific
PX0113					XLS of McCombs NDC data	Smith Case Specific
PX0114					Call Notes	Smith Case Specific
PX0115					Handwritten Notes on Medical Records by Smith	Smith Case Specific
PX0116					Handwritten Notes on Medical Records by Smith	Smith Case Specific
PX0117					Mackey CV	Smith Case Specific
PX0118					Mackey Smith Records	Smith Case Specific
PX0119					Mackey Call Notes	Smith Case Specific
PX0120					2004 Neurontin Label	Smith Case Specific
PX0121					Information	Smith Case Specific
PX0122					1992 Clinical Review	Smith Case Specific
PX0123					Affidavit of David Franklin	
PX0199		000006_96MNP_00010	000006_96MNP_00015	6	Metropolitan Police Department Homicide Unit Supplemental Report - Richard Smith	Depo Exhibit: Trimble, Michael 9/3/2008 EX:023
PX2000				40	Warner-Lambert guilty plea in United States v. Warner Lambert dated June 7, 2004	Pleading: Declaration of Andrew Finkelstein (OppMSJ1200.pdf) EX:0002
PX2001				15	Information in United States v. Warner Lambert, dated May 13, 2004	Pleading: Declaration of Andrew Finkelstein (OppMSJ1200.pdf) EX:0041
PX2002				54	Sentencing Memorandum of the United States	Depo Exhibit: Grabowski, Henry 1/21/2009 EX:009
PX2003		PFIZER_LALPHS_0084359	PFIZER_LALPHS_0084479	121	Division of Neuropharmacological Drug Products Combined Medical-Statistical Review NDA: 20-235, Indication: Adjunctive Medication in Refractory Partial Epilepsy	Depo Exhibit: Marino, John 7/3/2007 EX:029
PX2004		PFIZER_CPACELLA0009404	PFIZER_CPACELLA0009421	18	Behavioural Disturbance with Gabapentin, Professor Michael Trimble	Depo Exhibit: Trimble, Michael 10/19/2007 EX:024
PX2005		WLC_CBU_102999	WLC_CBU_103012	14	Michael Trimble, Psychosis with Gabapentin (1995);	Pleading: Declaration of Scott W. Slayer ESQ. (Su2D1160.pdf) EX:0029
PX2006	20031014	PFIZER_CTAYLOR_0015442	PFIZER_CTAYLOR_0015444	3	RE: GABA and PMDD	MISC

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX2007					FDA Advisory Committee meeting slide presentation by Dr. J Cramer on July 10, 2008	Expert Report: Gibbons002
PX2008					FDA. Joint Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee and the Psychopharmacologic Drugs Advisory Committee July 10,2008. Questions 2008-43 7b-01 -FDA-Katz.pdf At: http://www.fda.gov/ohrms/dockets/ac/O8/questions/2008-43	Expert Report: Weiss Smith001 - Materials Considered
PX2009				93	Background Package for July 10 Advisory Committee	Depo Exhibit: Gibbons, Robert 2/4/2009 EX:026
PX2010					Pfizer Lyrica & Neurontin slide presentation presented at FDA Advisory Committee meeting on July 10, 2008.	Expert Report: Gibbons002
PX2011					GlaxoSmithKline Lamictal slide presentation at FDA Advisory Committee Meeting on July 10, 2008	Expert Report: Gibbons002
PX2012					Katz R. Memorandum. Briefing Document for the July 10,2008 FDA Advisory Committee Meeting to Discuss Antiepileptic Drugs (AEDs) and Suicidality. June 12, 2008	Expert Report: Weiss Smith001 - Materials Considered
PX2014					Transcript of Joint Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee and the Psychopharmacologic Drugs Advisory Committee July 10, 2008.	Expert Report: Ruggieri001
PX2015					Video of July 10, 2008 Advisory Committee Hearing	MISC
PX2016					FDA Advisory Committee Meeting Briefing Documents dated July 10, 2008:Katz LetterLevenson, M. Statistical Review & Evaluation: Antiepileptic Drugs & SuicidalityMentari, E Clinical Review	Expert Report: Gibbons002
PX2017					FDA Alert May 5, 2009	MISC
PX2018				12	FDA Letter to Sponsors 12/2008	Depo Exhibit: Weiss-Smith, Sheila 12/22/2008 EX:026
PX2019					Neurontin Label April 2009	MISC
PX2020					Disclosure of Information By David Franklin (Exhibit 3)	MISC
PX2021					Crone Notice to Admit 11/29/2006	MISC
PX2022					Crone Defendant Responses to Notice to Admit 2/5/2007	MISC
PX2023					Crone Defendant Responses to Notice to Admit 7/31/2007	MISC
PX2024					Crone Defendant Responses to Notice to Admit 12/7/2007	MISC
PX2041				45	Curriculum Vitae of Dr. Michael Robert Trimble	Pleading: Declaration of Andrew Finkelstein (OppMIL1197.pdf) EX:0003
PX2046				27	label for Neurontin (gabapentin capsules, tablets and oral solution) distributed by Parke-Davis, Revised January 2007	Pleading: Declaration of Andrew Finkelstein (OppMIL1197.pdf) EX:0011
PX2054		PFIZER_LCASTRO_0075642	PFIZER_LCASTRO_0075643	2	excepts of David J. Rowbotham, Clinical Expert Report and Written Summary of Clinical Studies, Neuropathic Pain, Neurontin Capsules, 100 mg, Neurontin Capsules, 300 mg, Neurontin Capsules, 500 mg (June, 1999)	Pleading: Declaration of Andrew Finkelstein (OppMIL1197.pdf) EX:0022
PX2055		PFIZER_CTAYLOR_0005343	PFIZER_CTAYLOR_0005343	1	excepts from custodial file C. Taylor Gabapentin: Pharmacology Written Summary	Pleading: Declaration of Andrew Finkelstein (OppMIL1197.pdf) EX:0024
PX2061				9	Gabapentin Data Capture Aid	Pleading: Declaration of Andrew Finkelstein (OppMIL1197.pdf) EX:0032

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX2067				2	Zoloft web site About Zoloff – How Zoloff Works	Pleading: Declaration of Andrew Finkelstein (OppMIL1197.pdf) EX:0069
PX2073				16	excerpt of Food and Drug Administration, HHS, 21 CFR Ch. I (4-1-07 Edition) §201.57	Pleading: Declaration of Andrew Finkelstein (OppMIL1197.pdf) EX:0085
PX2078				2	Pfizer Global Research and Development Research Report No.: RR-REG 720-30134 (November 28, 2001)	Pleading: Declaration of Andrew Finkelstein (OppMIL1197.pdf) EX:0094
PX2079				1	Parke-Davis Pharmaceutical Research Division Memorandum from V. Trudeau to R. DeJong (May 8, 1990)	Pleading: Declaration of Andrew Finkelstein (OppMIL1197.pdf) EX:0095
PX2084		PFIZER_LCASTRO_0068012	PFIZER_LCASTRO_0068022	11	Defendant Lyrica Risk Management Committee Meeting, Power Point of Rachel E. Sobel, Epidemiology and Risk Management (September 17, 2004)	Pleading: Declaration of Andrew Finkelstein (OppMIL1197.pdf) EX:0105
PX2088				8	Curriculum Vitae of Cheryl D. Blume, Ph.D.	Pleading: Declaration of Andrew Finkelstein (OppMIL1197.pdf) EX:0116
PX2089				5	United States Patent No. 4,910,023 (March 20, 1990)	Pleading: Declaration of Andrew Finkelstein (OppMIL1197.pdf) EX:0118
PX2090				50	Declaration of Keith Altman (April 4, 2008)	Pleading: Declaration of Andrew Finkelstein (OppMIL1197.pdf) EX:0120
PX2093		PFIZER_LALPHS_0084480	PFIZER_LALPHS_0084498	19	Cynthia G. McCormick, M.D., Division of Neuropharmacological Drug Products, Review and Evaluation of Clinical Data (September 27, 1993)	Pleading: Declaration of Andrew Finkelstein (OppMIL1197.pdf) EX:0132
PX2103		PFIZER_LALPHS_0084627	PFIZER_LALPHS_0084703	77	FDA FOI Documents for Neurontin NDA Approval (July 28, 1994)	Pleading: Declaration of Andrew Finkelstein (OppMSJ1200.pdf) EX:0017
PX2105		NDA20235_SUB_001_0011	NDA20235_SUB_001_0011	1	page from the Neurontin NDA 20-235 which includes listing of patents	Pleading: Declaration of Andrew Finkelstein (OppMSJ1200.pdf) EX:0018
PX2106				11	portion of FDA's clinical review of Neurontin associated with the 2002 approval for post herpetic neuralgia (PHN) dated May 24, 2002. 23	Pleading: Declaration of Andrew Finkelstein (OppMSJ1200.pdf) EX:0020
PX2107		RR 720-04305		2	portion of the Gabapentin Pediatric Integrated Summary of Safety dated December 3, 1999	Pleading: Declaration of Andrew Finkelstein (OppMSJ1200.pdf) EX:0021
PX2109				11	Appendix C.55 of Pfizer's Integrated Summary of Safety for the Post Herpetic Neuralgia NDA dated August 6, 2001	Pleading: Declaration of Andrew Finkelstein (OppMSJ1200.pdf) EX:0023
PX2110				1	chart created under F.R.E 1006 entitled "Percentage of Serious Reports for Suicidal and Self Injurious Behaviors(HLT) By Indication Group."	Pleading: Declaration of Andrew Finkelstein (OppMSJ1200.pdf) EX:0024
PX2111		PFIZER_MPATEL_0036447	PFIZER_MPATEL_0036448	2	Pfizer correspondence From Manini Patel of Pfizer to Russell Katz of the FDA dated September 10, 2004	Pleading: Declaration of Andrew Finkelstein (OppMSJ1200.pdf) EX:0026
PX2114		PFIZER_MEVERTSZ_0109461	PFIZER_MEVERTSZ_0109463	3	FDA letter from Russell Katz to Mary Ann Evertsz dated May 3, 2006	Pleading: Declaration of Andrew Finkelstein (OppMSJ1200.pdf) EX:0030
PX2115		PFIZER_LKNAPP_0062000	PFIZER_LKNAPP_0062002	3	memorandum from Maribeth Lazzaro, Ph.D. to Tina Carriero, dated May 13, 2005	Pleading: Declaration of Andrew Finkelstein

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
						(OppMSJ1200.pdf) EX:0031
PX2118				3	pages from the transcript of the December 14, 1992 meeting of FDA's Peripheral and Central Nervous Systems Drugs Advisory Committee	Pleading: Declaration of Andrew Finkelstein (OppMSJ1200.pdf) EX:0034
PX2123				37	FDA Approval Letter dated May 24, 2002	Pleading: Declaration of Andrew Finkelstein (OppMSJ1200.pdf) EX:0039
PX2127		PFIZER_LCASTRO_0085939	PFIZER_LCASTRO_0085941	3	letter from Lisa Stockbridge of FDA to Andrea Garrity of Pfizer, dated June 29, 2001	Pleading: Declaration of Andrew Finkelstein (OppMSJ1200.pdf) EX:0043
PX2128				3	FDA alert concerning Gabitril dated February 18, 2005 printed from the FDA website, www.fda.gov	Pleading: Declaration of Andrew Finkelstein (OppMSJ1200.pdf) EX:0050
PX2129				2	portion of the product label for Avonex	Pleading: Declaration of Andrew Finkelstein (OppMSJ1200.pdf) EX:0051
PX2134		NDA21397_SUB1_002_0005	NDA21397_SUB1_002_0006	2	form 356h dated August 6, 2001 signed by Drusilla Scott	Pleading: Declaration of Andrew Finkelstein (OppMSJ1200.pdf) EX:0058
PX2135				1	chart created under F.R.E 1006 entitled "Cumulative Percentage Reports of Suicidal and Self Injurious behavior(HLT) for Neurontin vs. Background of All Other Drugs"	Pleading: Declaration of Andrew Finkelstein (OppMSJ1200.pdf) EX:0059
PX2136				2	chart created under F.R.E 1006 entitled "High Level Terms Greater than 1% of Serious Adverse Event Reports Through March 31, 2002	Pleading: Declaration of Andrew Finkelstein (OppMSJ1200.pdf) EX:0060
PX2138		PFIZER_DKARGMAN_0002911	PFIZER_DKARGMAN_0002911	10	e-mail from Dennis Kargman, dated March 6, 2006, with Gabapentin Data Capture Aid attached	Pleading: Declaration of Andrew Finkelstein (OppMSJ1200.pdf) EX:0063
PX2145		PFIZER_CTAYLOR_0010853	PFIZER_CTAYLOR_0010853	1	portion of a PowerPoint Presentation entitled "Clinical Development in the Slipstream of Gabapentin"	Pleading: Declaration of Andrew Finkelstein (OppMSJ1200.pdf) EX:0073
PX2146		WLC_CBU_115732	WLC_CBU_115732	1	portion of a document entitled "Neurontin Product Monograph."	Pleading: Declaration of Andrew Finkelstein (OppMSJ1200.pdf) EX:0075
PX2151				7	memorandum from Paul Leber of FDA to Robert Temple of FDA, dated December 13, 1993	Pleading: Declaration of Andrew Finkelstein (OppMSJ1200.pdf) EX:0082
PX2153		PFIZER_REGULATORY_000964	PFIZER_REGULATORY_000988	25	document entitled "Response to FDA Regarding Suicide and Suicide Attempts in Neurontin (Gabapentin) Clinical Trials – Phase I studies", dated November 16, 2004 authored by Bruce Parsons	Pleading: Declaration of Andrew Finkelstein (OppMSJ1200.pdf) EX:0087
PX2154				5	21. C.F.R. § 314.70. Ch. I (4-1-06 Edition)	Pleading: Declaration of Andrew Finkelstein (OppMSJ1200.pdf) EX:0088
PX2159				4	portion of Appendix C.3. of Parke-Davis Research Report 720-02957 entitled "Narrative Summaries and Tabular Data for Study Participants Who Withdrew Due To Adverse Events."	Pleading: Declaration of Andrew Finkelstein (OppMSJ1200.pdf) EX:0101
PX2160		NDA21397_MISC_007_0067		1	"Annotated Labeling" from NDA 21-397 Vol 001	Pleading: Declaration of Andrew Finkelstein (AGF_Su_Re.pdf) EX:0002
PX2169				8	FDA Manual of Policies and Procedures policy MAPP 6020.10 dated July 2, 2003 concerning "Dear Health Care Professional" letter	Pleading: Declaration of Andrew G. Finkelstein (AGF_Pre_SRe.pdf) EX:0001

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX2176		PFIZER_MEVERTSZ_0079951	PFIZER MEVERTSZ 0079969	18	Jeffrey Mohan, Gabapentin and Suicide (Mar. 14, 2006)	Pleading: Declaration of Mary Coronel (SuDo1159.pdf) EX:0003
PX2191		PFIZER_BPARSONS_0141815	PFIZER_BPARSONS_0141816	2	Record of FDA Contact regarding NDA 20-235 (Apr. 26, 2004)	Pleading: Declaration of Mary Coronel (MSJ1167.pdf) EX:0018
PX2193		PFIZER_REGULATORY_000001	PFIZER_REGULATORY_000001	1	Email from Courtney Calder, Center for Drug Evaluation and Research (FDA), to Molly Powers, Pfizer (Oct. 20,2005)	Pleading: Declaration of Mary Coronel (MSJ1167.pdf) EX:0021
PX2194		PFIZER_REGULATORY_000002	PFIZER_REGULATORY_000002	1	Email from Courtney Calder, Center for Drug Evaluation and Research (FDA), to Manini Patel, Pfizer (Oct. 27, 2005)	Pleading: Declaration of Mary Coronel (MSJ1167.pdf) EX:0022
PX2195		PFIZER_REGULATORY_000031	PFIZER_REGULATORY_000032	2	Email from Manini Patel, Pfizer, to Courtney Calder, Center for Drug Evaluation and Research (FDA) (Nov. 18,2005)	Pleading: Declaration of Mary Coronel (MSJ1167.pdf) EX:0023
PX2196		PFIZER_MEVERTSZ_0128892	PFIZER_MEVERTSZ_0128918	26	letter from Mary Ann C. Evertsz, Pfizer, to Russell Katz, M.D., Center for Drug Evaluation and Research (FDA) (with enclosed revised Neurontin labeling only) (Dec. 21,2005)	Pleading: Declaration of Mary Coronel (MSJ1167.pdf) EX:0025
PX2224		RR 720-02957			ECF 1761 Declaration of Ilyas Rona Exhibit 0002: 720-02957_ (Official)	Pleading: ECF 1761 Declaration of Ilyas Rona Exhibit EX:0002
PX2228					ECF 1761 Declaration of Ilyas Rona Exhibit 0007: 2008-4372b1-01-FDA	Pleading: ECF 1761 Declaration of Ilyas Rona Exhibit EX:0007
PX2243		RR 720-03392			ECF 1761 Declaration of Ilyas Rona Exhibit 0041: 720-03092_Investigators'_Brochure - Part 1	Pleading: ECF 1761 Declaration of Ilyas Rona Exhibit EX:0041
PX2247		WLC_FRANKLIN_0000199668			ECF 1761 Declaration of Ilyas Rona Exhibit 0048: WLC_FRANKLIN_0000199668	Pleading: ECF 1761 Declaration of Ilyas Rona Exhibit EX:0048
PX2324		RR 720-03908			ECF 1761 Declaration of Ilyas Rona Exhibit 0156: 720-03908	Pleading: ECF 1761 Declaration of Ilyas Rona Exhibit EX:0156
PX2329		RR 720-04130			ECF 1761 Declaration of Ilyas Rona Exhibit 0162: 720-04130	Pleading: ECF 1761 Declaration of Ilyas Rona Exhibit EX:0162
PX2332		RR 430-00125			ECF 1761 Declaration of Ilyas Rona Exhibit 0167: 430-00125	Pleading: ECF 1761 Declaration of Ilyas Rona Exhibit EX:0167
PX2342		PFIZER_LKNAPP_0050385			ECF 1761 Declaration of Ilyas Rona Exhibit 0178: PFIZER_LKNAPP_0050385	Pleading: ECF 1761 Declaration of Ilyas Rona Exhibit EX:0178
PX2366		PFIZER_LESLIETIVE_0020631			ECF 1761 Declaration of Ilyas Rona Exhibit 0218: PFIZER_LESLIETIVE_0020631	Pleading: ECF 1761 Declaration of Ilyas Rona Exhibit EX:0218
PX2475		RR 720-03675			ECF 1761 Declaration of Ilyas Rona Exhibit 0367: 720-03675_ (Official)	Pleading: ECF 1761 Declaration of Ilyas Rona Exhibit EX:0367
PX2476		RR 430-00124			ECF 1761 Declaration of Ilyas Rona Exhibit 0368: 430-00124	Pleading: ECF 1761 Declaration of Ilyas Rona Exhibit EX:0368
PX2477		RR 995-00070			ECF 1761 Declaration of Ilyas Rona Exhibit 0369: 995-00070_945-211_ (Part_I)	Pleading: ECF 1761 Declaration of Ilyas Rona Exhibit EX:0369
PX2487		RR 995-00057			ECF 1761 Declaration of Ilyas Rona Exhibit 0380: 995-00057_ (Official)	Pleading: ECF 1761 Declaration of Ilyas Rona Exhibit EX:0380
PX2502		PFIZER_LKNAPP_0023336			ECF 1761 Declaration of Ilyas Rona Exhibit 0397: PFIZER_LKNAPP_0023336	Pleading: ECF 1761 Declaration of Ilyas Rona Exhibit EX:0397
PX2535		RR 720-03779			ECF 1761 Declaration of Ilyas Rona Exhibit 0435: 720-03779	Pleading: ECF 1761 Declaration of Ilyas Rona Exhibit EX:0435
PX2543					ECF 1761 Declaration of Ilyas Rona Exhibit 0445: FDA Approved Labeling Text dated February 2005	Pleading: ECF 1761 Declaration of Ilyas Rona Exhibit EX:0445
PX2571		RR 4301-00066			ECF 1761 Declaration of Ilyas Rona Exhibit 0477: 4301-00066_ (Official)	Pleading: ECF 1761 Declaration of Ilyas Rona Exhibit EX:0477

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX2573		RR 995-00074			ECF 1761 Declaration of Ilyas Rona Exhibit 0479: 995-00074_(p1-366)	Pleading: ECF 1761 Declaration of Ilyas Rona Exhibit EX:0479
PX2574		RR 995-00085			ECF 1761 Declaration of Ilyas Rona Exhibit 0480: 995-00085	Pleading: ECF 1761 Declaration of Ilyas Rona Exhibit EX:0480
PX2743		RR 720-04378			ECF 1761 Declaration of Ilyas Rona Exhibit 0663: 720-04378	Pleading: ECF 1761 Declaration of Ilyas Rona Exhibit EX:0663
PX2744		RR 720-04483			ECF 1761 Declaration of Ilyas Rona Exhibit 0664: 720-04483_(Official)	Pleading: ECF 1761 Declaration of Ilyas Rona Exhibit EX:0664
PX2745		RR 720-04479			ECF 1761 Declaration of Ilyas Rona Exhibit 0665: 720-04479	Pleading: ECF 1761 Declaration of Ilyas Rona Exhibit EX:0665
PX2746		RR 720-04455			ECF 1761 Declaration of Ilyas Rona Exhibit 0666: 720-04455	Pleading: ECF 1761 Declaration of Ilyas Rona Exhibit EX:0666
PX2747		RR 720-04471			ECF 1761 Declaration of Ilyas Rona Exhibit 0667: 720-04471	Pleading: ECF 1761 Declaration of Ilyas Rona Exhibit EX:0667
PX2781		PFIZER_LESLIETIVE_0032603	PFIZER_LESLIETIVE_0032604	2	E-mail from Larry Alphas to John Marino re: National Public Radio-NEURONTIN Story to be aired TONIGHT	Depo Exhibit: Alphas, Larry 6/21/2007 EX:020
PX2784		FAL007604	FAL007604	2	E-mail from Christine Aschenbach to Allison Fannon, Larry Alphas, Angela Crespo, Steve Piron, Bruce Parsons, Ellen Dukes re: PSC Meeting Materials 1-15-03	Depo Exhibit: Alphas, Larry 6/21/2007 EX:039
PX2787		PFIZER_LESLIETIVE_0034178	PFIZER_LESLIETIVE_0034179	2	E-mail from Kirk Taylor to Leslie Tive & Timothy Hsu re: Professor Martin Koltzenburg question	Depo Exhibit: Alphas, Larry 6/22/2007 EX:047
PX2788		PFIZER_LESLIETIVE_0038763	PFIZER_LESLIETIVE_0038764	2	E-mail from Cathy Sigler to Leslie Tive re: Neurontin NPR Story-Med Info Q&A	Depo Exhibit: Alphas, Larry 6/22/2007 EX:050
PX2789				4	Presentation: Suicidality: The Problem and Emerging Solutions by Larry Alphas	Depo Exhibit: Alphas, Larry 6/22/2007 EX:051
PX2790		PFIZER_LESLIETIVE_0041008	PFIZER_LESLIETIVE_0041017	10	E-mail from Larry Alphas to Cathy Sigler & Leslie Tive re: Robert Siegel, host; my critique of the NPR report	Depo Exhibit: Alphas, Larry 6/22/2007 EX:B
PX2791				8	Division of Neuropharmacological Drug Products Review and Evaluation of Clinical Data, NDA 20-235	Depo Exhibit: Alphas, Larry 6/22/2007 EX:D
PX2798		UNREADABLE	UNREADABLE	59	Response to FDA Regarding Suicide and Suicide Attempt in Neurontin (gabapentin) Clinical Trials and Postmarketing Surveillance dated Sept .9, 2004	Depo Exhibit: Arrowsmith-Lowe, Janet 1/24/2008 EX:008
PX2799		PFIZER_LKNAPP_0022176	PFIZER_LKNAPP_0022177	2	E-mail from Atul Pande to Lloyd Knapp re: GBP in Bipolar Disorder	Depo Exhibit: Arrowsmith-Lowe, Janet 1/24/2008 EX:012
PX2806				12	Generic Dear Sponsor Letter re: new drug application	Depo Exhibit: Arrowsmith-Lowe, Janet 1/8/2009 EX:020
PX2808				45	Statistical Review and Evaluation Antiepileptic Drugs and Suicidality	Depo Exhibit: Arrowsmith-Lowe, Janet 1/8/2009 EX:024
PX2810				240	Finkelstein Neurontin November 12, 2007	Depo Exhibit: Blume, Cheryl 11/12/2007 EX:005
PX2812				23	Guidance for Industry, Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment March 2005	Depo Exhibit: Blume, Cheryl 11/12/2007 EX:009
PX2813				1	Chart of suicide and self-injurious behaviour	Depo Exhibit: Blume, Cheryl 11/12/2007 EX:010
PX2818				194	Gabapentin Capsules 8.6 Integrated Summary of Safety Information	Depo Exhibit: Blume, Cheryl 11/13/2007 EX:019
PX2819				143	5-29-92 Application to Market a New Drug for Human Use or an Antibiotic Drug for Human Use, Neurontin	Depo Exhibit: Blume, Cheryl 11/13/2007 EX:020
PX2828		PFIZER_REGULATORY_000003	PFIZER_REGULATORY_000003	1	E-mail from Courtney Calder to Manini Patel re: proceeding with minor labeling changes pertaining ro suicide-related events	Depo Exhibit: Blume, Cheryl 11/13/2007 EX:032
PX2866		AET019862	AET019881	20	Gabapentin for acute and chronic pain (Review) The Cochrane Collaboration	Depo Exhibit: Brodeur, Michael 7/1/2008 EX:024

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX2887		PFIZER_MBROWN_0001134	PFIZER_MBROWN_0001136	3	Rheumatology Orthopedic Neurology Team Challenges and Opportunities	Depo Exhibit: Brown, Mark 10/2/2007 EX:001
PX2898		PFIZER_CGLOVER_0002219	PFIZER_CGLOVER_0002220	2	E-mail from Tamela Martin to Louis Burke, Jefferson Campbell, Jeffrey Dodd, Craig Glover, Edwin McDaries, Daniel Morgan, Nicole Parker, Henry Schaefer & Derrick Surratt re: NEU-0063569 Neurontin Medical Letter Issue 1180	Depo Exhibit: Brown, Mark 10/2/2007 EX:012
PX2902		PFIZER_MBROWN_0000877	PFIZER_MBROWN_0000879	3	E-mail from Frederick Schmalberger to Stephen Sacchetti, Kurt Phillips and Mark Brown re: NEU-0183019 New Gabapentin Article in Med Letter April 2004	Depo Exhibit: Brown, Mark 10/2/2007 EX:016
PX2908		PFIZER_MBROWN_0000718	PFIZER_MBROWN_0000719	2	Agents of Change Journal Club Report, RON Specialty Representative: Sean Chase, Meeting Month: June 2002	Depo Exhibit: Brown, Mark 10/2/2007 EX:022
PX2910		PFIZER_MBROWN_0000615	PFIZER_MBROWN_0000615	1	Pfizer FYI only: Neurontin - Make it your #1 add on Therapy Start with Efficacy End with Efficacy	Depo Exhibit: Brown, Mark 10/2/2007 EX:024
PX2912		PFIZER_KBRETT_0002217	PFIZER_KBRETT_0002218	2	E-mail from Mark Brown re: phn notes, Summary notes from David Fantini's team	Depo Exhibit: Brown, Mark 10/2/2007 EX:026
PX2919		PFIZER_SDOFT_0034317	PFIZER_SDOFT_0034318	2	E-mail from Mark Brown to Daniel Linden, Suzanne Doft, Tamela Martin, Christopher Dowd and David Probert re: Topamax moving up with Neurologists	Depo Exhibit: Brown, Mark 10/2/2007 EX:033
PX2921		PFIZER_DPROBERT_0016709	PFIZER_DPROBERT_0016710	2	NTN 2003 Operating Plan	Depo Exhibit: Brown, Mark 10/2/2007 EX:035
PX2922		PFIZER_SDOFT_0010719	PFIZER_SDOFT_0010721	3	E-mail from Suzanne Doft to Shilpa Patel re: NEU-0020717 Neurontin Advisory Boards, first recommendation to the board	Depo Exhibit: Brown, Mark 10/2/2007 EX:036
PX2966		PFIZER_LKNAPP_0050019	PFIZER_LKNAPP_0050021	3	E-mail from Lloyd Knapp to Drusilla Scott, Atul Pande, Stephen Gracon, Byron Scott, Robert Michael Poole re: GDRC-Nerve Conduction Discussion	Depo Exhibit: Castro, Lucy 7/10/2007 EX:006
PX2970		PFIZER_LCASTRO_0004053	PFIZER_LCASTRO_0004054	2	E-mail from Marino Garcia to Angela Crespo, Michael Rowbotham, David Probert, John Marino, Joan Kaplan, Kenna Reehil, Valerie Flapan, Lucy Castro, Andrea Garrity, Meg Yoder, Leslie Tive, Robert Glanzman, John Krayacich, Nicky Towse, Steve Pomerantz re: Please read - Article: ""Emerging Therapies in Chronic Pain""	Depo Exhibit: Castro, Lucy 7/10/2007 EX:010
PX2971		PFIZER_LCASTRO_0007990	PFIZER_LCASTRO_0008004	15	E-mail from Meg Yoder to John Marino, Christine Grogan, Craig Glover, Suzanne Doft, Marino Garcia, Michael Rowbotham, David Probert, Allison Fannon, Steve Piron, Joan Kaplan, Angela Crespo, Leigh Anne Hemenway, Leslie Tive, Robert Glanzman, Elizabeth Mutisya, Lucy Castro, Valerie Flapan, John Krayacich re: 2002 Neurontin Team Goals	Depo Exhibit: Castro, Lucy 7/10/2007 EX:011
PX2972		PFIZER_LCASTRO_0016712	PFIZER_LCASTRO_0016717	6	E-mail from Nancy Mancini to Lucy Castro, Daphne Nugent Laiken, Manini Patel re: Neurontin sales information needed	Depo Exhibit: Castro, Lucy 7/10/2007 EX:012
PX2973		PFIZER_LCASTRO_0007518	PFIZER_LCASTRO_0007531	14	Presentation: Rationale for a Social Phobia Clinical Program with Neurontin, GDRC Meeting November 8, 2001	Depo Exhibit: Castro, Lucy 7/10/2007 EX:013
PX2982				4	Letter from Lisa Stockbridge, Ph.D, Regulatory Reviewer to Lucy Castro re: NDA #s 20-235, 20-882 Neurontin (gabapentin) MACMIS #10738, representations about Neurontin which are false or misleading	Depo Exhibit: Castro, Lucy 7/11/2007 EX:025
PX2983				14	Letter from Lisa Stockbridge, Ph.D, Regulatory Reviewer to Andrea Garrity re: NDA #s 20-235, 20-882 Neurontin (gabapentin) MACMIS #10174, a slim jim for Neurontin that is misleading and in violation of the Federal Food, Drug, and Cosmetic Act	Depo Exhibit: Castro, Lucy 7/11/2007 EX:026
PX2988		PFIZER_BPARSON_0155116	PFIZER_BPARSON_0155117	2	E-mail from Manini Patel to Rudolf Altevogt, Bruce Parsons, Lloyd Knapp, Ileen Roos, Larry Alphs, Lucy Castro, Claire Wohlhuter, Manfred Hauben, Paul Nitschmann, Robert Clark, Phyllis Christesen, Nicky Hall, Suzanne Doft, Stephen Cristo, Mary Kuskin re: FDA request for teleconference with Pfizer to discuss safety concerns with Neurontin	Depo Exhibit: Castro, Lucy 7/11/2007 EX:031

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX2994				20	Gabitril (tiagabine hydrochloride) Tablets, Feb. 2005 product labeling text	Depo Exhibit: Castro, Lucy 7/11/2007 EX:040
PX2998				16	Guidance for Industry, Adverse Reactions Section of Labeling for Human Prescription Drug and Biological Products - Content and Format, January 2006	Depo Exhibit: Castro, Lucy 7/11/2007 EX:046
PX3017		WLC_CBU_090238	WLC_CBU_090256	19	Memo from Epilepsy Marketing Team re: Situation Analysis for Neurontin, replace with attached 5/29/96	Depo Exhibit: Cavic, George 9/26/2007 EX:017
PX3022		WLC_FRANKLIN_0000069499	WLC_FRANKLIN_0000069549	51	Memo from Edda Guerrero re: Neurontin Tactics Planning Meeting	Depo Exhibit: Cavic, George 9/27/2007 EX:024
PX3023		WLC_FRANKLIN_0000056596	WLC_FRANKLIN_0000056615	20	1997 National Strategies and Tactics	Depo Exhibit: Cavic, George 9/27/2007 EX:025
PX3042		WLC_FRANKLIN_0000045531	WLC_FRANKLIN_0000045549	19	Neurontin War Games Summary Report, April 3, 1996	Depo Exhibit: Cheng, Clare 1/29/2008 EX:002
PX3049		WLC_FRANKLIN_0000173393	WLC_FRANKLIN_0000173450	58	Presentation: Toolbox Meeting, January 30, 1997	Depo Exhibit: Cheng, Clare 1/29/2008 EX:009
PX3051		WLC_FRANKLIN_0000047983	WLC_FRANKLIN_0000047984	2	Memo from Clare Cheng & Carla Dago to A. Crook, J. Knoop, J. Rizzo, L. Ciancio, M. Friedman, S. Miller, D. Saltel, T. Albright re: Notes - Telefocus Group, Telefocus Group with high AED deciled neurologists held on August 14, 1996	Depo Exhibit: Cheng, Clare 1/29/2008 EX:011
PX3056		WLC_FRANKLIN_0000055066	WLC_FRANKLIN_0000055096	31	Neurontin gabapentin capsules New Hire Training, October 14, 1997	Depo Exhibit: Cheng, Clare 1/29/2008 EX:016
PX3057		WLC_FRANKLIN_0000112859	WLC_FRANKLIN_0000112883	25	1998 Neurontin Tactics, Prepared 7/30/97 by Cline, Davis & Mann	Depo Exhibit: Cheng, Clare 1/29/2008 EX:017
PX3065		WLC_CBU_083783	WLC_CBU_083799	17	1999 Marketing Plan Neurontin	Depo Exhibit: Cheng, Clare 1/29/2008 EX:027
PX3068		MAC_E_0011587	MAC_E_0011629	43	Neurontin 2003 Publications Plan Review of Capabilities and Strategic Plan, September 2002	Depo Exhibit: Cooper, David 12/20/2007 EX:001
PX3071		PFIZER_LESLIETIVE_0014685	PFIZER_LESLIETIVE_0014689	5	E-mail from Robert Glantzman to David Cooper, Allison Fannon, Angela Crespo, Bruce Parsons, David Probert, Suzanne Doft, Erica Johansson-Neil, Jeremy Mierop, Larry Alphs, Leslie Tive re: Australian Analysis of Refractory NeP in pivotal trials	Depo Exhibit: Cooper, David 12/20/2007 EX:004
PX3091		MAC_0000084	MAC_0000086	3	E-mail from David Cooper to Angela Crespo, Robert Glanzman, Sue Huang re: Backonja, proposed use of the non-peer reviewed IASP poster that MAC ghost-wrote along with the Neurontin PSC for Dr. Backonja	Depo Exhibit: Cooper, David 12/20/2007 EX:025
PX3111		WLC_FRANKLIN_0000056368	WLC_FRANKLIN_0000056384	17	Neurontin Market Overview	Depo Exhibit: DeSimone, Christopher 10/1/2007 EX:008
PX3114		WLC_FRANKLIN_0000056218	WLC_FRANKLIN_0000056250	33	1998 Marketing Plan, Neurontin	Depo Exhibit: DeSimone, Christopher 10/2/2007 EX:013
PX3118		WLC_CBU_090682	WLC_CBU_090684	3	Handwritten Memo from Trevor Polischuk to Laura re: data useful for Neurontin in neuropathic pain	Depo Exhibit: DeSimone, Christopher 10/2/2007 EX:018
PX3120		WLC_CBU_092022	WLC_CBU_092025	4	Memo from Lynne Fredericks re: Anticonvulsant Market New Patient Starts - January 1999 Data	Depo Exhibit: DeSimone, Christopher 10/2/2007 EX:020
PX3121		WLC_CBU_079871	WLC_CBU_079874	4	Memo from Lynne Fredericks re: Anticonvulsant Market New Patient Starts - April 1999 Data	Depo Exhibit: DeSimone, Christopher 10/2/2007 EX:021
PX3122		MDL_VENDORS_007574	MDL_VENDORS_007577	4	Memo from Lynne Fredericks re: Anticonvulsant Market New Patient Starts - June 1999 Data	Depo Exhibit: DeSimone, Christopher 10/2/2007 EX:022
PX3123		MDL_VENDORS_007578	MDL_VENDORS_007594	17	New Prescriptions Chart	Depo Exhibit: DeSimone, Christopher 10/2/2007 EX:023
PX3124		MDL_VENDORS_007595	MDL_VENDORS_007624	30	Neurontin: 1999 Situation Analysis	Depo Exhibit: DeSimone, Christopher 10/2/2007 EX:024
PX3129		PFIZER_SDOFT_0010403	PFIZER_SDOFT_0010431	29	E-mail from Suzanne Doft to XTEC Media re: NEU-0020634 Employer Ad Bd Slides	Depo Exhibit: Doft, Suzanne 6/12/2007 EX:003

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX3133		PFIZER_SDOFT_0003454	PFIZER_SDOFT_0003459	6	Suzanne Doft, Individual Development Plan	Depo Exhibit: Doft, Suzanne 6/12/2007 EX:006
PX3134		PFIZER_SDOFT_0002465	PFIZER_SDOFT_0002527	63	Presentation: Incremental Market Potential With An FDA Approved Indication for Neuropathic Pain	Depo Exhibit: Doft, Suzanne 6/12/2007 EX:007
PX3135		PFIZER_SDOFT_0002862	PFIZER_SDOFT_0002962	101	Presentation: Neuropathic Pain Positioning Strategy Research-Final Results from the U.S.	Depo Exhibit: Doft, Suzanne 6/13/2007 EX:008
PX3136		PFIZER_SDOFT_0005463	PFIZER_SDOFT_0005466	4	Suzanne Doft, Neurontin Marketing Team Draft, 2002 Personal Goals	Depo Exhibit: Doft, Suzanne 6/13/2007 EX:009
PX3138		PFIZER_SDOFT_0052466	PFIZER_SDOFT_0052541	76	Neurontin, Neuropathic Pain Issues in the Workplace, Meeting Report	Depo Exhibit: Doft, Suzanne 6/13/2007 EX:013
PX3143		PFIZER_SDOFT_0067075	PFIZER_SDOFT_0067075	1	E-mail from John Marino re: NEU-0006528 OP2002 Review	Depo Exhibit: Doft, Suzanne 6/13/2007 EX:018
PX3145		PFIZER_SDOFT_0068277	PFIZER_SDOFT_0068322	46	Presentation: Neurontin/Pregabalin Strategic Priorities Discussion, June 10, 2003	Depo Exhibit: Doft, Suzanne 6/13/2007 EX:020
PX3153		PFIZER_SDOFT_0069755	PFIZER_SDOFT_0069759	5	E-mail from Clare Kennedy to Suzanne Doft, Joe Butera, David Probert, Avnish Mishra, Andrea Zeuschner re: Lost revenue in Top 3 PBM Mail order	Depo Exhibit: Doft, Suzanne 6/13/2007 EX:033
PX3156		PFIZER_SDOFT_0050578	PFIZER_SDOFT_0050591	15	Presentation: Neurontin, Performance, Market Overview, Opportunities/Strategies, Medical Platform, Finances	Depo Exhibit: Doft, Suzanne 6/13/2007 EX:037
PX3157		FAL007964	FAL007966	3	E-mail from Angela Crespo to Christine Aschenbach, Allison Fannon re: Reckless contact information	Depo Exhibit: Doft, Suzanne 6/13/2007 EX:038
PX3161		PFIZER_MPATEL_0131638	PFIZER_MPATEL_0131642	5	E-mail from Larry Alphs re: Neurontin in the WSJ and NY Times Today - December 20, 2002	Depo Exhibit: Dowd, Christopher 9/14/2007 EX:001
PX3165		PFIZER_CDOWD_0000043	PFIZER_CDOWD_0000098	56	E-mail from Timothy Hylan to Lois Fitton, Richard O'Sullivan, Steve Romano, Jim Sage, Christopher Dowd re: NEU-0085355 Some information on Neurontin, some discusses bipolar	Depo Exhibit: Dowd, Christopher 9/14/2007 EX:005
PX3166		PFIZER_LKNAPP_0071138	PFIZER_LKNAPP_0071147	10	E-mail from Claire Wohlhuter to Lloyd Knapp re: Q&A Backgrounder on suicide issue for distribution to PD2, Vista RX and Neurology	Depo Exhibit: Dowd, Christopher 9/14/2007 EX:006
PX3179		PFIZER_EDUKES_0022802	PFIZER_EDUKES_0022819	18	Draft: 2003 Unabridged Neurontin Medical Operating Plan, July 16, 2002	Depo Exhibit: Dukes, Ellen 6/28/2007 EX:014
PX3198		PFIZER_AFANNON_0002969	PFIZER_AFANNON_0003021_0003023	54	2003 Neurontin Strategic and Tactical Planning Meeting July 31, 2002	Depo Exhibit: Dukes, Ellen 6/29/2007 EX:036
PX3199		PFIZER_LESLIETIVE_0015410	PFIZER_LESLIETIVE_0015416	7	Memo from Cynthia de Luise re: Neurontin Product Maintenance and Pharmacovigilance (PMP) Team Meeting Minutes (17 January 2002)	Depo Exhibit: Dukes, Ellen 6/29/2007 EX:038
PX3209		PFIZER_RGLANZMAN_0090432	PFIZER_RGLANZMAN_0090570	139	Presentation: Neurontin 2001 U. S. Operating Plan, October 11, 2000	Depo Exhibit: Fannon, Allison 6/19/2007 EX:009
PX3210		PFIZER_LESLIETIVE_0003556	PFIZER_LESLIETIVE_0003573	18	Presentation: Neurontin Global Operating Plan 2001	Depo Exhibit: Fannon, Allison 6/19/2007 EX:010
PX3211		PFIZER_LKNAPP_0038962	PFIZER_LKNAPP_0038987	26	Neurontin Publication Planning Meeting July 12, 2001	Depo Exhibit: Fannon, Allison 6/19/2007 EX:011
PX3277				77	Parke-Davis Pharmaceutical Research Division Research Report No. RR-X 720-02455 Titled: Investigator's Brochure - Gabapentin (CI-945) Dated: 4/28/89	Depo Exhibit: Furberg, Curt Daniel 3/11/2009 EX:003
PX3278				104	Parke-Davis Pharmaceutical Research Division Research Report No. RR-X 720-03092 Titled: Investigator's Brochure - Gabapentin (CI-945) Dated: 5/21/92	Depo Exhibit: Furberg, Curt Daniel 3/11/2009 EX:004
PX3279				23	Parke-Davis Pharmaceutical Research Division Research Report No. RR-X 720-03362 Titled: Investigator's Brochure for Neurontin-Gabapentin (CI-945) For Studies Conducted in the United States Dated: 4/19/94	Depo Exhibit: Furberg, Curt Daniel 3/11/2009 EX:005
PX3280				39	Parke-Davis Pharmaceutical Research Division Research Report No. RR-X 720-03381 Titled: Investigator's Brochure for Neurontin-Gabapentin (CI-945) For Studies Conducted in the United States	Depo Exhibit: Furberg, Curt Daniel 3/11/2009 EX:006

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
					Dated: 5/31/94	
PX3294		PFIZER_AGARRITY_0000618	PFIZER_AGARRITY_0000619	2	E-mail from Andrea Garrity to Lucy Castro, Manini Patel re: Policy on reprints/Washington Legal Foundation Ruling	Depo Exhibit: Garrity, Andrea 6/19/2007 EX:015
PX3296		PFIZER_AGARRITY_0009938	PFIZER_AGARRITY_0009943	6	E-mail from Joe Feczko re: Neurontin, promotion and marketing	Depo Exhibit: Garrity, Andrea 6/19/2007 EX:017
PX3297		PFIZER_AGARRITY_0004556	PFIZER_AGARRITY_0004571	15	E-mail from John Marino re: DPC Neurontin - Final	Depo Exhibit: Garrity, Andrea 6/19/2007 EX:018
PX3303		PFIZER_AGARRITY_0002142	PFIZER_AGARRITY_0002142	1	E-mail from John Wolleben to Lucy Castro, Martha Brumfield, Andrew Clair, Andrea Garrity re: Neurontin NOV	Depo Exhibit: Garrity, Andrea 6/19/2007 EX:025
PX3304		PFIZER_AGARRITY_0002730	PFIZER_AGARRITY_0002741_0002745	6	Summary of Spontaneous Post-Marketing Reports for Gabapentin, as of December 31, 2000	Depo Exhibit: Garrity, Andrea 6/20/2007 EX:027
PX3309		PFIZER_AGARRITY_0001851	PFIZER_AGARRITY_0001913	63	E-mail from Lucy Castro to Valerie Flapan, Andrea Garrity re: Neurontin Major Markets Business Plan	Depo Exhibit: Garrity, Andrea 6/20/2007 EX:033
PX3316				38	Center for Drug Evaluation and Research, Application 21-397, 21-423, 21-424 Approval Letter	Depo Exhibit: George, Timothy 6/21/2007 EX:007
PX3343				31	Assessment of Suicide and Related Behaviors in Patients Treated with the -Ligands, Gabapentin and Pregabalin, April 29, 2008	Depo Exhibit: Gibbons, Robert 2/3/2009 EX:016
PX3344		PFIZER_REGULATORY_000510	PFIZER_REGULATORY_000936_000954	24	Letter from Mary Ann Coronel Evertsz,RPh to Russell Katz, MD re: Neurontin (gabapentin) capsules NDA 20-235, Neurontin (gabapentin) tablets NDA 20-882, Neurontin (gabapentin) oral solution NDA 21-129, Request for Information - Response to FDA suicidality	Depo Exhibit: Gibbons, Robert 2/3/2009 EX:017
PX3345				7	Letter from Molly Powers to Russell Katz re: NDA 21-446-Lyrica (pregabalin) Capsules C-V, Request for Information - Response to FDA Suicidality Request	Depo Exhibit: Gibbons, Robert 2/3/2009 EX:018
PX3347				21	The Relationship Between Antiepileptics and Suicide Attempts	Depo Exhibit: Gibbons, Robert 2/3/2009 EX:020
PX3351				3	Chart: Columns titled Trial, Eposure Days, etc.	Depo Exhibit: Gibbons, Robert 2/4/2009 EX:024
PX3352				21	Robert Gibbons invoices to Wheeler Trigg and Kenedy LLP	Depo Exhibit: Gibbons, Robert 2/4/2009 EX:025
PX3354				7	Chart: All Diags for Bipolar	Depo Exhibit: Gibbons, Robert 2/4/2009 EX:028
PX3373				4	SAS Output	Depo Exhibit: Gibbons, Robert 3/5/2009 EX:048
PX3385				56	Presentation: Statistical Issues in Drug Safety: The curious case of Antidepressants, Anticonvulsants,..., and Suicide	Depo Exhibit: Gibbons, Robert 3/5/2009 EX:059
PX3402		PFIZER_RGLANZMAN_0004287	PFIZER_RGLANZMAN_0004289	3	E-mail from Robert Glanzman re: Neurontin Product Profiles	Depo Exhibit: Glanzman, Robert 8/1/2007 EX:012
PX3404		PFIZER_RGLANZMAN_0035401	PFIZER_RGLANZMAN_0035422	22	Presentatin dated May 23, 2001	Depo Exhibit: Glanzman, Robert 8/1/2007 EX:015
PX3410		PFIZER_RGLANZMAN_0106496	PFIZER_RGLANZMAN_0106503	8	Presentation: Roles and Responsiblities for Manuscript Teams	Depo Exhibit: Glanzman, Robert 8/1/2007 EX:022
PX3412		PFIZER_RGLANZMAN_0170204	PFIZER_RGLANZMAN_0170214	11	Key Message Sign-Off Sheet - Neurontin Publication Plan Key Messages	Depo Exhibit: Glanzman, Robert 8/1/2007 EX:024
PX3436		PFIZER_RGLANZMAN_0065528	PFIZER_RGLANZMAN_0065528	1	E-mail from John Marino re: Neurontin Overdose Reported	Depo Exhibit: Glanzman, Robert 8/2/2007 EX:052
PX3437		PFIZER_RGLANZMAN_0071542	PFIZER_RGLANZMAN_0071544	3	E-mail from Robert Glanzman to John Marino re: Neurontin Overdose Reported	Depo Exhibit: Glanzman, Robert 8/2/2007 EX:053
PX3438		PFIZER_RGLANZMAN_0033743	PFIZER_RGLANZMAN_0033747	5	E-mail from Robert Glanzman re: Post Herpetic Neuralgia	Depo Exhibit: Glanzman, Robert 8/2/2007 EX:054
PX3439		PFIZER_RGLANZMAN_0023036	PFIZER_RGLANZMAN_0023036	1	E-mail from Robert Glanzman re: Neurontin News, the data in bipolar disease with gabapentin isn't very good	Depo Exhibit: Glanzman, Robert 8/2/2007 EX:055

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX3442		PFIZER_RGLANZMAN_0148233	PFIZER_RGLANZMAN_0148241	9	Mechanisms of action: A Guide for Sales Colleagues	Depo Exhibit: Glanzman, Robert 8/2/2007 EX:058
PX3450		PFIZER_RGLANZMAN_0141301	PFIZER_RGLANZMAN_0141303	3	NTN 2003 Operating Plan, Strategies and Tactics	Depo Exhibit: Glanzman, Robert 8/2/2007 EX:066
PX3461		PFIZER_RGLANZMAN_0141302	PFIZER_RGLANZMAN_0141303	3	NTN 2003 Operating Plan - Strategies and Tactics	Depo Exhibit: Grabowski, Henry 1/21/2009 EX:015
PX3462		PFIZER_JMARINO_0002350	PFIZER_JMARINO_0002379	30	Neurontin: 2001 Situation Analysis	Depo Exhibit: Grabowski, Henry 1/21/2009 EX:016
PX3463		WLC_CBU_057865	WLC_CBU_057873	9	Letter from Lesley Frank to William Merino re: Parke-Davis promoting Neurontin for ""off-label"" uses	Depo Exhibit: Grabowski, Henry 1/21/2009 EX:017
PX3469				11	FAX from Laura Governale to Robin Ditts re: Neurontin Meeting Minutes	Depo Exhibit: Grabowski, Henry 1/21/2009 EX:028
PX3470		PFIZER_CGROGAN_0027897	PFIZER_CGROGAN_0027920	24	Presentation: SE CBU 1T 2000	Depo Exhibit: Grogan, Christina 6/25/2007 EX:001
PX3484				42	Corporate Integrity Agreement between the Office of Inspector General of the Department of Health and Human Services and Pfizer	Depo Exhibit: Grogan, Christina 6/26/2007 EX:018
PX3520		MDL_VENDORS_059152	MDL_VENDORS_059161	10	Letter from Paula Trushin to James Jefferson re: article ""Benzodiazepines and Anticonvulsants for Social Anxiety Disorder (Social Phobia)""	Depo Exhibit: Gutierrez, Ruben 10/10/2007 EX:019
PX3521			MDL_VENDORS_058938	2	Letter from James Jefferson to Jane Byun re: ""Benzodiazepines and Anticonvulsants for Social Anxiety Disorder (Social Phobia)""	Depo Exhibit: Gutierrez, Ruben 10/10/2007 EX:020
PX3538				702	Neurontin U.S. Market Update November 2000	Depo Exhibit: Hartman, Raymond 6/26/2008 EX:007
PX3551				4	21 CRF (4-1-06 Edition), Change in ownership of an application	Depo Exhibit: Hauben, Manfred 7/13/2007 EX:006
PX3554				177	Periodic Safety Update Report for: Gabapentin, August 1, 1998 - January 31, 1999	Depo Exhibit: Hauben, Manfred 7/13/2007 EX:012
PX3556		PFIZER_REGULATORY_000484	PFIZER_REGULATORY_000485	2	request for additional trail-level information pertaining analysis of suicidal thoughts and behavior in anti-epileptic drugs	Depo Exhibit: Hauben, Manfred 7/13/2007 EX:014
PX3557		PFIZER_LALPHS_0084680	PFIZER_LALPHS_0084687	8	Division of Neuropharmacological Drug Products Combined Medical-Statistical Review, NDA: 20-235, Indication: Refractory Partial Epilepsy	Depo Exhibit: Hauben, Manfred 7/13/2007 EX:015
PX3594				13	Letter from Russell Katz to Robert Clark re: safety labeling changes	Depo Exhibit: Jacobs, Douglas 1/15/2009 EX:002
PX3608		PFIZER_LESLIETIVE_0001830	PFIZER_LESLIETIVE_0001878	49	Presentation: Neurontin by Leslie Tive	Depo Exhibit: Kerrick-Walker, Jill 7/10/2007 EX:014
PX3617		PFIZER_RGLANZMAN_0046614	PFIZER_RGLANZMAN_0046615	2	E-mail from Robert Glanzman to Jill Kerrick-Walker re: GBP and mood	Depo Exhibit: Kerrick-Walker, Jill 7/10/2007 EX:023
PX3637		PFIZER_LCASTRO_0015324	PFIZER_LCASTRO_0015330	7	Memo from Cynthia de Luise re: Neurontin PMP Team Meeting (09 May 2001) Minutes	Depo Exhibit: Knapp, Lloyd 6/27/2007 EX:006
PX3651		PFIZER_LCASTRO_0073451	PFIZER_LCASTRO_0073454	4	Fax from Lisa Stockbridge to Andrea Garrity re: NDA #21-129 Neurontin (gabapentin) Oral Solution, MACMIS #9821, comments on proposed launch promotional materials for the pediatric indication for Neurontin oral solution	Depo Exhibit: Knapp, Lloyd 6/28/2007 EX:030
PX3653		PFIZER_LKNAPP_0137046	PFIZER_LKNAPP_0137084	38	E-mail from Drusilla Scott re: Agency version of Neurontin Label (action date of 4/24/02 targeted) Emergency meeting of LSC	Depo Exhibit: Knapp, Lloyd 6/28/2007 EX:032
PX3678		WLC_FRANKLIN_0000112201	WLC_FRANKLIN_0000112230	30	E-mail from Clare Cheng to A. Crook re: Neurontin 1997 Tactical Plan	Depo Exhibit: Knoop, John 1/24/2008 EX:028
PX3683		WLC_CBU_092879	WLC_CBU_092934	56	Neurontin (gabapentin) Program Overview, Feb. 23, 1999	Depo Exhibit: Knoop, John 1/24/2008 EX:037
PX3724				3	Research Report titled: An Iterim Report on an Open-Label, Uncontrolled, Multicenter Study to Determine the Long Term Safety and Efficacy of Gabapentin (CI-945) Administered as Monotherapy or	Depo Exhibit: Kruszewski, Stefan 12/7/2007 EX:030

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
					in Combination with Other Antiepileptic Drugs in Patients with Medically Uncontrolled Partial or Generalized Epileptic Seizures	
PX3729				2	Research Report: Integrated Summary of Safety Information of Gabapentin Capsules (Item 8.6 of the gabapentin NDA)	Depo Exhibit: Kruszewski, Stefan 12/7/2007 EX:036
PX3747		PFIZER_LESLIETIVE_0013908	PFIZER_LESLIETIVE_0013937	30	Presentation: Neurontin OP Presentation Market Analytics Review, Nancy Mancini, May 1, 2001	Depo Exhibit: Mancini, Nancy 7/9/2007 EX:002
PX3748		PFIZER_LESLIETIVE_0015418	PFIZER_LESLIETIVE_0015424	7	Memo from Cynthia de Luise re: Draft: Neurontin PMP Team Meeting (09 May 2001) Minutes	Depo Exhibit: Mancini, Nancy 7/9/2007 EX:003
PX3750		PFIZER_NMANCINI_0006296	PFIZER_NMANCINI_0006297	2	E-mail from Nancy Mancini to Avanish Mishra re: Update request, NTN's uses by indication	Depo Exhibit: Mancini, Nancy 7/9/2007 EX:005
PX3764		PFIZER_NMANCINI_0003737	PFIZER_NMANCINI_0003780	44	Presentation: Market Analytic Update	Depo Exhibit: Mancini, Nancy 7/10/2007 EX:019
PX3769		PFIZER_JMARINO_0002486	PFIZER_JMARINO_0002543	58	Presentation: Quarterly Brand Review Neurontin 4/98	Depo Exhibit: Marino, John 7/2/2007 EX:005
PX3770		PFIZER_JMARINO_0004619	PFIZER_JMARINO_0004620	2	Neurontin Proposed Strategies and Tactics	Depo Exhibit: Marino, John 7/2/2007 EX:006
PX3772		PFIZER_JMARINO_0000533	PFIZER_JMARINO_0000535	3	Global Development Review Committee Meeting, September 19, 2001	Depo Exhibit: Marino, John 7/2/2007 EX:011
PX3773		PFIZER_JMARINO_0000159	PFIZER_JMARINO_0000175	17	Presentation: Rationale for an Expanded DPN Clinical Program with Neurontin	Depo Exhibit: Marino, John 7/2/2007 EX:012
PX3775		PFIZER_JMARINO_0000931	PFIZER_JMARINO_0000932	2	E-mail from John Marino to Stephen Graco, Lloyd Knapp, Atul Pande, Drusilla Scott, Byron Scott re: GDRC - Nerve Conduction Discussion	Depo Exhibit: Marino, John 7/2/2007 EX:015
PX3776		PFIZER_LESLIETIVE_0076417	PFIZER_LESLIETIVE_0076418	2	E-mail from Kirk Taylor re: My thoughts on the POPP Study Investigator meeting	Depo Exhibit: Marino, John 7/2/2007 EX:020
PX3777		PFIZER_JMARINO_0000941	PFIZER_JMARINO_0000944	4	John Marino 2001 Goals	Depo Exhibit: Marino, John 7/3/2007 EX:026
PX3778		PFIZER_LCASTRO_0010342	PFIZER_LCASTRO_0010345	4	John Marino OP2002 Goals	Depo Exhibit: Marino, John 7/3/2007 EX:027
PX3779		PFIZER_LESLIETIVE_0042066	PFIZER_LESLIETIVE_0042068	3	WW Neurontin Team 2003 Goals	Depo Exhibit: Marino, John 7/3/2007 EX:028
PX3780		WLC_FRANKLIN_0000209771	WLC_FRANKLIN_0000209771	1	Letter from Norm Phillips, Vice President Physicians' World Communications Group to John Marino re: contract with group in Morris Plains	Depo Exhibit: Marino, John 7/3/2007 EX:030
PX3783		PFIZER_JMARINO_0000950	PFIZER_JMARINO_0000950	1	E-mail from John Marino to Marino Garcia re: Neurontin in Bipolar Disorder	Depo Exhibit: Marino, John 7/3/2007 EX:033
PX3785		NDA20235_MISC_008_0113	NDA20235_MISC_008_0121	9	Letter from Lesley Frank, Department of Health & Human Services to William Merino re: Parke-Davis promoting Neurontin for ""off label"" use	Depo Exhibit: Marino, John 7/3/2007 EX:035
PX3787		PFIZER_AGARRITY_0002030	PFIZER_AGARRITY_0002037	8	Memo from Cynthia de Luise re: Draft: Neurontin PMP Team Meeting (09 May 2001) Minutes	Depo Exhibit: Marino, John 7/3/2007 EX:038
PX3788		PFIZER_CTAYLOR_0011179	PFIZER_CTAYLOR_0011179	1	Slide titled: Neurontin (drug uses)	Depo Exhibit: Marino, John 7/3/2007 EX:039
PX3790		PFIZER_LTIVE_0006484	PFIZER_LTIVE_0006497	14	Slides: US Neurontin Use Data	Depo Exhibit: Marino, John 7/3/2007 EX:042
PX3791		PFIZER_CGROGAN_0021032	PFIZER_CGROGAN_0021035	4	Letter from Lisa Stockbridge to Lucy Castro re: a model for Neurontin that is in violation of the Federal Food, Drug, and Cosmetic Act	Depo Exhibit: Marino, John 7/3/2007 EX:044
PX3799				54	CV of Ronald W. Maris, PhD	Depo Exhibit: Maris, Ronald 10/20/2008 EX:050
PX3803				26	Presentation: Suicide and SSRIs, Ronald Wm Maris, PhD, A.A.F.S. Annual Conference, February 20, 2007	Depo Exhibit: Maris, Ronald 10/20/2008 EX:057
PX3816		WLC_CBU_166600	WLC_CBU_166628	29	Presentation: SE CBU 3T99 Sales and Marketing Plan	Depo Exhibit: Martin, Tamela 10/4/2007 EX:009

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX3823		PFIZER_TMARTIN_0000562	PFIZER_TMARTIN_0000629	68	Presentation: Neurontin Market Assessment Meeting	Depo Exhibit: Martin, Tamela 10/5/2007 EX:018
PX3849				3	FDA Alert: Information for Healthcare Professionals Suicidality and Antiepileptic Drugs	Depo Exhibit: McCormick, Cynthia 2/14/2008 EX:003
PX3850				4	FDA Alert: Information for Healthcare Professionals Suicidality and Antiepileptic Drugs	Depo Exhibit: McCormick, Cynthia 2/14/2008 EX:003A
PX3851		WLC_JTURNER_000459	WLC_JTURNER_000461	3	Record of FDA Contact, Report Outcome of FDA Gabapentin NDA acceptability to file review meeting of 3/11/92	Depo Exhibit: McCormick, Cynthia 2/14/2008 EX:004
PX3852				1	Memo from V. Trudeau to R. DeLong re: Follow-up Adverse Event Report	Depo Exhibit: McCormick, Cynthia 2/14/2008 EX:006
PX3853				15	Presentation: Suicidality and Anti-Epileptic Drugs: Status of Clinical Trial Data Analysis by Evelyn Mentari MD	Depo Exhibit: McCormick, Cynthia 2/14/2008 EX:007
PX3854				27	Affidavit of David Franklin PhD	Depo Exhibit: McCormick, Cynthia 2/14/2008 EX:008A
PX3855				1	Client Register, Shook, Hardy & Bacon LLP	Depo Exhibit: McCormick, Cynthia 2/14/2008 EX:010
PX3856				6	McCormick Consultation, LLC invoices to Shook, Hardy & Bacon	Depo Exhibit: McCormick, Cynthia 2/14/2008 EX:011
PX3857				4	Letter from Andrew Finkelstein to Russell Katz re: 258 MedWatch forms, each represents a suicide of an American who was on Neurontin	Depo Exhibit: McCormick, Cynthia 2/14/2008 EX:012
PX3862				38	Letter from Robert Temple to Janeth Turner re: NDA 20-235, new drug application dated January 15, 1992	Depo Exhibit: McCormick, Cynthia 2/14/2008 EX:019
PX3865		WLC_JTURNER_002615	WLC_JTURNER_002616	2	Record of FDA Contact - Request clarification from the gabapentin NDA	Depo Exhibit: McCormick, Cynthia 2/14/2008 EX:022
PX3867				2	Appendix C.3 Narrative Summaries and Tabular Data for Study Participants Who Withdrew Due to Adverse Events	Depo Exhibit: McCormick, Cynthia 2/14/2008 EX:025
PX3868				5	Gabapentin Open Label-Treatment Forms	Depo Exhibit: McCormick, Cynthia 2/14/2008 EX:026
PX3901		PFIZER_SPIRON_0022692	PFIZER_SPIRON_0022813	122	Presentation: The Neurontin and Pregabalin Positioning Study, May 2001	Depo Exhibit: Milan, Janet 11/29/2007 EX:003
PX3982		PFIZER_SPIRON_0011527	PFIZER_SPIRON_0011629	103	Presentation: Neurontin 2004 Operating Plan, September 30, 2003	Depo Exhibit: Mishra, Avanish 6/14/2007 EX:006
PX3986		PFIZER_SDOFT_0065713	PFIZER_SDOFT_0065715	3	Email from Suzanne Doft to Avanish Mishra re: NEU-0019169 Article: Change in Opioid use after the initiation of gabapentin therapy in patients with postherpetic neuralgia	Depo Exhibit: Mishra, Avanish 6/14/2007 EX:010
PX3989		PFIZER_AMISHRA_0000594	PFIZER_AMISHRA_0000602	9	Presentation: Neurontin Business in 2H 2004	Depo Exhibit: Mishra, Avanish 6/14/2007 EX:014
PX3996		PFIZER_SDOFT_0067568	PFIZER_SDOFT_0067572	5	US Neurontin Marketing Team 2004 Goals	Depo Exhibit: Mishra, Avanish 6/15/2007 EX:021
PX4034		PFIZER_LCASTRO_0005596	PFIZER_LCASTRO_0005602	7	Memo from Cynthia de Luise re: Draft: Neurontin PMP Team Meeting (09 May 2001) Minutes	Depo Exhibit: Pacella, Christopher 10/2/2007 EX:001
PX4038		PFIZER_CPACELLA_0050918	PFIZER_CPACELLA_0001589_0001592	20	Pfizer Drug Safety (Ann Arbor) Product Reference Guide Gabapentin CI #0945, NDA #20-235, International Birth Date Feb. 5, 1993	Depo Exhibit: Pacella, Christopher 10/2/2007 EX:005
PX4040		PFIZER_LTIVE_0031886	PFIZER_LTIVE_0031886	1	Email from Michael Campbell to Cathy Sigler, Cynthia de Luise, Christopher Pacella, Larry Alphs, Leslie Tive, Rudolf Altevogt, Manfred Hauben re: Gabapentin literature cases, overdose/suicide	Depo Exhibit: Pacella, Christopher 10/2/2007 EX:007
PX4042		PFIZER_CPACELLA_0015537	PFIZER_CPACELLA_0015537	1	Appendix, Second Safety Update Summary of Adverse Events	Depo Exhibit: Pacella, Christopher 10/2/2007 EX:010
PX4045		PFIZER_CPACELLA_0022701	PFIZER_CPACELLA_0022726	26	Summary of Spontaneous Post-Marketing Reports for Gabapentin, as of March 31, 2002 All Cases	Depo Exhibit: Pacella, Christopher 10/2/2007 EX:013
PX4046		PFIZER_CPACELLA_0061231	PFIZER_CPACELLA_0061257	27	Email from Christopher Pacella to Philip Arena, Lisa Cortina, Robert Glanzman, Alan Hassell, Manfred Hauben, Manini Patel, Alvaro Quintana, Tina Zhang re: Gabapentin Core Working Group Meeting	Depo Exhibit: Pacella, Christopher 10/2/2007 EX:014

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
					scheduled for July 25, 2002	
PX4047		PFIZER_CPACELLA_0029393	PFIZER_CPACELLA_0029396	4	Memo from Christopher Pacella re: Gabapentin Product Maintenance and Pharmacovigilance Labeling Core Working Group, July 25, 2002	Depo Exhibit: Pacella, Christopher 10/2/2007 EX:015
PX4048		PFIZER_CPACELLA_MULTIPLE	PFIZER_MPATEL_MULTIPLE	139	Angina Pectoris/Chest Pain/Chest Pain Substernal/Pain Chest and Gabapentin (Draft)	Depo Exhibit: Pacella, Christopher 10/2/2007 EX:016
PX4049		PFIZER_CPACELLA_0061978	PFIZER_CPACELLA_0061981	4	Memo from Christopher Pacella re: Gabapentin Product Maintenance and Pharmacovigilance Labeling Core Working Group, October 14, 2002	Depo Exhibit: Pacella, Christopher 10/2/2007 EX:017
PX4050		PFIZER_CPACELLA_0061982	PFIZER_CPACELLA_0061984	3	Memo from Christopher Pacella re: Gabapentin Product Maintenance and Pharmacovigilance Labeling Core Working Group, October 23, 2002	Depo Exhibit: Pacella, Christopher 10/2/2007 EX:018
PX4051		PFIZER_CPACELLA_0030209	PFIZER_CPACELLA_0030220	12	Pfizer Pharmaceutical Group (Private) Core Data Sheet, Product Document title: Gabapentin, January 30, 2003	Depo Exhibit: Pacella, Christopher 10/2/2007 EX:019
PX4053		WLC_FRANKLIN_0000088763	WLC_FRANKLIN_0000088763	1	Memo from Alan Walker to Dr. Klaus Laesecke, Dr. Mark Pierce, Ms. Lene Ulrich re: \$500 Million	Depo Exhibit: Pande, Atul 9/19/2007 EX:004
PX4056		WLC_FRANKLIN_0000134638	WLC_FRANKLIN_0000134638	1	Memo from Atul Pande to John Boris re: Gabapentin approvals	Depo Exhibit: Pande, Atul 9/19/2007 EX:007
PX4062		WLC_CBU_108865	WLC_CBU_108894	30	Marketing Assessment Neurontin in Neuropathic Pain and Spasticity	Depo Exhibit: Pande, Atul 9/19/2007 EX:014
PX4069		PFIZER_LKNAPP_0071019	PFIZER_LKNAPP_0071021	3	Email from Lloyd Knapp to Timothy Hsu re: Gabapentin in bipolar disorder: randomized controlled trials	Depo Exhibit: Pande, Atul 9/20/2007 EX:025
PX4077				1	Table 15: Summary of All Adverse Events in >1% of Patients in Placebo-Controlled Studies, by Body System and Treatment Group	Depo Exhibit: Pande, Atul 9/20/2007 EX:034
PX4078				4	Narrative Summaries and Tabular Data for Study Participants Who Withdrew Due to Adverse Events	Depo Exhibit: Pande, Atul 9/20/2007 EX:035
PX4081				231	Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company Research Report Title: Gabapentin Adjunctive Treatment in Patients with Bipolar Disorder	Depo Exhibit: Pande, Atul 9/20/2007 EX:038
PX4082		PFIZER_TMF_CRF_087451	PFIZER_TMF_CRF_087506	56	Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company Research Report Title: Investigators' Brochure - Neurontin (Gabapentin, CI-945)	Depo Exhibit: Pande, Atul 9/20/2007 EX:039
PX4087				8	Chart: AER ID/ AER NO/SEQ REACT/NAME/PF_NAME/HIT NAME/HLGT NAME/SOC NAME/DATE REPORTED/YQ/SENOUS REPORT/CLINICAL TRIAL	Depo Exhibit: Pande, Atul 9/20/2007 EX:048
PX4132				2	MedWatch report	Depo Exhibit: Ruggieri, Alexander 1/17/2008 EX:008
PX4133				1	Case details	Depo Exhibit: Ruggieri, Alexander 1/17/2008 EX:009
PX4143				2	Memo to Mary Parks from Kate Gelperin, Lanh Green re: Thiazolidinediones and Cardiovascular Adverse Effects	Depo Exhibit: Ruggieri, Alexander 12/5/2008 EX:021
PX4144				1	Graph: Percentage of Cardiac SOC Reports for Various Anti-Diabetic Drugs	Depo Exhibit: Ruggieri, Alexander 12/5/2008 EX:022
PX4147				103	Declaration of Cheryl Blume, PhD	Depo Exhibit: Ruggieri, Alexander 2/14/2009 EX:023
PX4148				9	Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company Gabapentin Open-Label Treatment Forms	Depo Exhibit: Ruggieri, Alexander 2/14/2009 EX:024
PX4149				4	Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company Gabapentin Open-Label Treatment Forms	Depo Exhibit: Ruggieri, Alexander 2/14/2009 EX:025
PX4157				60	Assessment of Suicide and Related Behaviors in Patients Treated with the -Ligands, Gabapentin and Pregabalin, April 29, 2008	Depo Exhibit: Ruggieri, Alexander 2/14/2009 EX:034
PX4159				52	Declaration of Keith Altman	Depo Exhibit: Ruggieri, Alexander 2/14/2009 EX:036

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX4160		PFIZER_CGROGAN_0005992	PFIZER_CGROGAN_0006002	11	Pfizer Neuropathic Pain PBM Advisory Board Executive Summary, March 3-4, 2002	Depo Exhibit: Samuels, Jennifer 10/9/2007 EX:001
PX4207				1	Gabapentin Mechanism Work Group - Team Charter, September 5, 2000	Depo Exhibit: Scott, Druscilla 12/12/2007 EX:017
PX4208				4	Email from John Marino re: Neurontin Labeling - Ground Rules and Agenda - Meeting May 22	Depo Exhibit: Scott, Druscilla 12/12/2007 EX:018
PX4209				4	Email from Druscilla Scott re: Neurontin PHN sNDA; status and labeling	Depo Exhibit: Scott, Druscilla 12/12/2007 EX:019
PX4212				4	Letter from Lisa Stockbridge to Lucy Castro re: a model for Neurontin that is in violation of the Federal Food, Drug, and Cosmetic Act	Depo Exhibit: Scott, Druscilla 12/12/2007 EX:022
PX4235				2	Lidoderm Label	Depo Exhibit: Scott, Druscilla 12/13/2007 EX:047
PX4253				3	Description of gabapentin	Depo Exhibit: Su, Julia 6/28/2007 EX:001
PX4254				5	Summary of gabapentin	Depo Exhibit: Su, Julia 6/28/2007 EX:002
PX4256				5	Summary of neurontin	Depo Exhibit: Su, Julia 6/28/2007 EX:004
PX4265		PFIZER_JSU_0031998	PFIZER_JSU_0032003	6	Email from John Marino re: National Public Radio - Neurontin Story to be Aired Tonight	Depo Exhibit: Su, Julia 8/16/2007 EX:013
PX4273				68	Pfizer Global Research & Development Research Report titled: Summary of Preclinical Pharmacological Studies with Gabapentin (CI-0945, PD 0087842-0000) In Vitro and in Laboratory Animals	Depo Exhibit: Taylor, Charles Jr 6/4/2007 EX:003
PX4274		PFIZER_JSU_0018966	PFIZER_JSU_0018981	16	Mechanisms of action - A guide for sales colleagues	Depo Exhibit: Taylor, Charles Jr 6/4/2007 EX:004
PX4285				9	Letter from Lesley Frank to William Merino re: Parke-Davis promoting Neurontin for "off-label" uses	Depo Exhibit: Teicher, Martin 7/7/2006 EX:001
PX4286				115	Review and Evaluation of Clinical Data, NDA 20-235 Indication: Refractory Epilepsy, January 31, 1992	Depo Exhibit: Teicher, Martin 7/7/2006 EX:002
PX4287				14	Letter from Lisa Stockbridge to Andrea Garrity re: a slim jim for Neurontin that is misleading and in violation of the Federal Food, Drug, and Cosmetic Act and applicable regulations	Depo Exhibit: Teicher, Martin 7/7/2006 EX:003
PX4288				4	Letter from Lisa Stockbridge to Lucy Castro re: a model for Neurontin that is in violation of the Federal Food, Drug, and Cosmetic Act	Depo Exhibit: Teicher, Martin 7/7/2006 EX:004
PX4289				76	Settlement Agreement and Release between the United States of America and Pfizer and Warner-Lambert	Depo Exhibit: Teicher, Martin 7/7/2006 EX:005
PX4290				15	United States of America v Warner Lambert Company General Allegations	Depo Exhibit: Teicher, Martin 7/7/2006 EX:007
PX4291		V084264	V084294	31	Neurontin: 1998 Situation Analysis	Depo Exhibit: Teicher, Martin 7/7/2006 EX:009
PX4292		PFIZER_LCASTRO_0002807	PFIZER_LCASTRO_0002814	8	Email from Elaine Vennard to The Hallelujah Core Team re: Hallelujah Core Team Meeting Minutes - 2/27/01	Depo Exhibit: Teicher, Martin 7/7/2006 EX:010
PX4293		PFIZER_LCASTRO_0068393	PFIZER_LCASTRO_0068399	7	Development Request, Category: Sleep (New), Type of Project: Rx to OTC Switch, Date: March 31, 2003	Depo Exhibit: Teicher, Martin 7/7/2006 EX:011
PX4294		PFIZER_LTIVE_0008553	PFIZER_LTIVE_0008559	7	Neurontin: 2001 Operating Plan Executive Summary	Depo Exhibit: Teicher, Martin 7/7/2006 EX:012
PX4295		V054146	V054149	4	Memo from Mi Dong to Neurontin (Anticonvulsant) Development Team re: Minutes - May 22, 1997, Neurontin Development Team Meeting	Depo Exhibit: Teicher, Martin 7/7/2006 EX:013
PX4296		PFIZER_LTIVE_0027352	PFIZER_LTIVE_0027353	2	Medical Director - Neurontin	Depo Exhibit: Tive, Leslie 7/19/2006 EX:017
PX4301		PFIZER_LTIVE_0005484	PFIZER_LTIVE_0005491	8	Memo from Cynthia De Luise re: Neurontin Product Maintenance and Pharmacovigilance (PMP) Team Meeting (18 October 2001) Minutes	Depo Exhibit: Tive, Leslie 7/19/2006 EX:022

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX4315		PFIZER_LTIVE_0042546	PFIZER_LTIVE_0042663	118	Presentation: Neurology Group 2003 Global Operating Plan, July 26, 2002	Depo Exhibit: Tive, Leslie 7/19/2006 EX:044
PX4323				2	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Humane Use	Depo Exhibit: Tive, Leslie 7/11/2007 EX:053
PX4324		PFIZER_LTIVE_0008005	PFIZER_LTIVE_0008008	4	Pfizer Consultants Meeting September 6, 2001	Depo Exhibit: Tive, Leslie 7/11/2007 EX:054
PX4336				53	Declaration of Michael Trimble, MD in Relation to Neurontin Causing Negative Mood and Behavioural Alterations, Including Suicidal Behavior, in Treated Patients	Depo Exhibit: Trimble, Michael 10/18/2007 EX:003
PX4360				593	NDA Reviewer's Guide Content and Format	Depo Exhibit: Turner, Janeth 10/11/2007 EX:002
PX4364		WLC_JTURNER_000583	WLC_JTURNER_000602	20	Gabapentin NDA/FDA Questions & Requests	Depo Exhibit: Turner, Janeth 10/11/2007 EX:006
PX4365		PFIZER_LALPHS_0082420	PFIZER_LALPHS_0082908	490	Gabapentin NDA FDA Questions/Requests Responses to FDA Requests Book 1	Depo Exhibit: Turner, Janeth 10/11/2007 EX:007
PX4366		PFIZER_LALPHS_0082979	PFIZER_LALPHS_0083398	418	Gabapentin NDA FDA Questions/Requests Responses to FDA Requests Book 2	Depo Exhibit: Turner, Janeth 10/11/2007 EX:008
PX4368		PFIZER_LALPHS_0087185	PFIZER_LALPHS_0087186	2	Record of FDA Contact: Review SBA and revised package insert	Depo Exhibit: Turner, Janeth 10/11/2007 EX:010
PX4376				37	Letter from Robert Temple to Janeth Turner re: NDA 20-235, new drug application dated January 15, 1992	Depo Exhibit: Turner, Janeth 10/11/2007 EX:022
PX4379		WLC_JTURNER_000698	WLC_JTURNER_000701	4	Record of FDA Contact: Discuss December 15, 1992 Advisory Committee Meeting to review the gabapentin NDA	Depo Exhibit: Turner, Janeth 10/11/2007 EX:029
PX4380		NDA20235_MISC_001_0270	NDA20235_MISC_001_0271	2	Record of FDA Contact: Confirm that Parke-Davis does not plan to make formal presentations at the Advisory Committee Meeting	Depo Exhibit: Turner, Janeth 10/11/2007 EX:030
PX4381		NDA20235_MISC_001_0102	NDA20235_MISC_001_01236	150	Record of FDA Contact: Obtain copy of FDA gabapentin Advisory Committee Briefing Document	Depo Exhibit: Turner, Janeth 10/11/2007 EX:031
PX4382		WLC_JTURNER_003660	WLC_JTURNER_003661	2	Application to Market a New Drug for Human Use or an Antibiotic Drug for Human Use - Neurontin	Depo Exhibit: Turner, Janeth 10/11/2007 EX:033
PX4383		NDA20235_MISC_001_0096	NDA20235_MISC_001_0098	3	Record of FDA Contact: Request clarification from FDA briefing document	Depo Exhibit: Turner, Janeth 10/12/2007 EX:035
PX4384		WLC_JMARINO_0001274	WLC_JMARINO_0001316	43	Memo from O. Brandicourt re: Neurontin Marketing Assessment	Depo Exhibit: Turner, Janeth 10/12/2007 EX:036
PX4385		WLC_FRANKLIN_0000134389	WLC_FRANKLIN_0000134390	2	Memo from Mi Dong to Neurontin (Anticonvulsant) Development Team re: Minutes, November 9, 1994, Neurontin Development Strategy Meeting	Depo Exhibit: Turner, Janeth 10/12/2007 EX:038
PX4386				6	Memo from Mi Dong to Neurontin (Anticonvulsant) Development Team re: Minutes, March 14, 1995 Neurontin Development Strategy Meeting	Depo Exhibit: Turner, Janeth 10/12/2007 EX:039
PX4388		WLC_FRANKLIN_0000090128	WLC_FRANKLIN_0000090130	3	Letter from Paul Leber to Janeth Turner re: supplemental new drug application dated September 13, 1996	Depo Exhibit: Turner, Janeth 10/12/2007 EX:043
PX4394		PFIZER_LKNAPP_0035987	PFIZER_LKNAPP_0035989	3	Email from Marino Garcia re: Key Messages	Depo Exhibit: Valerio, Stephen 11/28/2007 EX:003
PX4396		PFIZER_LKNAPP_0039256	PFIZER_LKNAPP_0039282	27	MAC Publications Plan Template	Depo Exhibit: Valerio, Stephen 11/28/2007 EX:005
PX4397		PFIZER_RGLANZMAN_0082261	PFIZER_RGLANZMAN_0082317	57	Presentation: Neurontin Publications Subcommittee Current Status and 2002 Plans	Depo Exhibit: Valerio, Stephen 11/28/2007 EX:006
PX4416				138	Parke-Davis Pharmaceutical Research, titled: A Double-Blind Placebo-Controlled Trial with 3 Doses of Gabapentin for Treatment of Painful Diabetic Neuropathy	Depo Exhibit: Vega, Adrian 6/13/2007 EX:008
PX4418		PFIZER_LCASTRO_0043325	PFIZER_LCASTRO_0043398	74	Gabapentin vs. Placebo in Patients with Neuropathic Pain. A Randomized, Double-Blind, Cross-Over, Multi-Center Study in the Nordic Area - Final Report	Depo Exhibit: Vega, Adrian 6/13/2007 EX:010

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX4422				7	Parke-Davis Pharmaceutical Research, titled: Gabapentin Adjunctive Treatment in Patients with Bipolar Disorder	Depo Exhibit: Vega, Adrian 6/13/2007 EX:016
PX4425				62	Goadecke AG - Research and Development Report titled: A Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of the Safety and Efficacy of Gabapentin (CI-945) as a Prophylactic Interval Therapy in Patients with Common Migraine	Depo Exhibit: Vega, Adrian 6/13/2007 EX:021
PX4429				2	Summary: Neurontin is not approved by the FDA for perioperative treatment of pain	Depo Exhibit: Vega, Adrian 6/13/2007 EX:025
PX4430				50	Parke-Davis Pharmaceutical Research Report titled: A Single-Dose, Double-Blind, Placebo-Controlled, Comparative Efficacy Study of Gabapentin and Hydrocodone, Alone or in Combination, in Patients with Postoperative Dental Pain	Depo Exhibit: Vega, Adrian 6/13/2007 EX:026
PX4440				5	Summary of Neurontin, Clinical Data	Depo Exhibit: Vega, Adrian 6/14/2007 EX:036
PX4441				6	Parke-Davis Pharmaceutical Research Division Report titled: Integrated Summary of Safety Information of Gabapentin Capsules	Depo Exhibit: Vega, Adrian 6/14/2007 EX:037
PX4474				3	Isotretinoin (marketed as Accutane)	Depo Exhibit: Weiss-Smith, Sheila 1/9/2008 EX:009
PX4476		PFIZER_THO_0074421	PFIZER_THO_0074422	2	MedWatch report	Depo Exhibit: Weiss-Smith, Sheila 1/9/2008 EX:011
PX4487		PFIZER_THO_0000792	PFIZER_THO_0000809	17	Serious Adverse Events, Gabapentin Related Clinical Study Cases 01/01/1980-31/12/2003	Depo Exhibit: Weiss-Smith, Sheila 12/22/2008 EX:022
PX4496		WLC_FRANKLIN_0000097442	WLC_FRANKLIN_0000097442	1	Slide titled: Top 10 Uses of Neurontin	Depo Exhibit: Windom, Timothy 12/6/2007 EX:002
PX4527		PFIZER_SDOFT_0026365	PFIZER_SDOFT_0026340		Page from 01/09/2002 Neurontin Publications Subcommittee Plans	Expert Report: 2 King B Report REF MATERIALS
PX4528		X028957	X028962		Parke-Davis Memorandum: Meeting Minutes, March 14, 1995, Neurontin Development Team Meeting	Expert Report: 2 King B Report REF MATERIALS
PX4529		V090836	V090877		Marketing Assessment: Neurontin in Psychiatric Disorders	Expert Report: 2 King B Report REF MATERIALS
PX4530		V091389			Parke-Davis Memorandum: Neurontin Verbatims	Expert Report: 2 King B Report REF MATERIALS
PX4531		W003095	W003109		Neurontin 1996 SE CBU Plan	Expert Report: 2 King B Report REF MATERIALS
PX4532		WL 07520	WL 07547		Neurontin Marketing Assessments	Expert Report: 2 King B Report REF MATERIALS
PX4533		X001884	X001900		Neurontin Northeast CBU 1997	Expert Report: 2 King B Report REF MATERIALS
PX4534		X003630	X003658		T196 Neurontin/Pharmaceutical Sector 1996 Operating Plan	Expert Report: 2 King B Report REF MATERIALS
PX4535		X005102	X005110		Letter to Phil Magistro from Jacki Gordon	Expert Report: 2 King B Report REF MATERIALS
PX4536		X005384	X005386		Parke-Davis Memorandum: Selected Physician Titration Update	Expert Report: 2 King B Report REF MATERIALS
PX4537		V086787	V086792		Parke-Davis Marketing Planning: Meeting Minutes/Action Items from Marketing Council Meeting Feb 28-March 2, 1995, Lyon, France	Expert Report: 2 King B Report REF MATERIALS
PX4538		X028920	X028924		Parke-Davis Memorandum: Minutes, November 14, 1995, Neurontin Development Team Meeting	Expert Report: 2 King B Report REF MATERIALS
PX4539		V084073			1998 Strategic Plan and A and P Allocation Grid	Expert Report: 2 King B Report REF MATERIALS
PX4540					Rx List website, "Seldane," http://www.rxlist.com/cgi/generic/terfen.htm , accessed October 22, 2007.	Expert Report: 2 King B Report REF MATERIALS

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX4541					MediceNet.com website, "Definition of Placebo Effect," http://www.medterms.com/script/main/art.asp?articlekey=31481 , accessed October 22, 2007.	Expert Report: 2 King B Report REF MATERIALS
PX4542					Mayo Clinic website, http://www.mayoclinic.com/health/postherpeticneuralgia/DS00277 , accessed October 22, 2007.	Expert Report: 2 King B Report REF MATERIALS
PX4543					King, C., Statement Before the Committee on Governmental Affairs, Subcommittee on Oversight of Government Management, Restructuring and the District of Columbia, United States Senate, May 14, 2002 (available at < http://hsgac.senate.gov/051302king.pdf > as	Expert Report: 2 King B Report REF MATERIALS
PX4544					Drugs.com website, http://www.drugs.com/top200_2003.html , accessed October 22, 2007.	Expert Report: 2 King B Report REF MATERIALS
PX4545					21 CFR 202.1.	Expert Report: 2 King B Report REF MATERIALS
PX4546		X029226	X029227		Interoffice Memorandum from Atul Pande: Gabapentin Psychiatric Studies	Expert Report: 2 King B Report REF MATERIALS
PX4547		X029017	X029025		Parke-Davis Memorandum: Meeting Minutes, October 18, 1994, Neurontin Development Team Meeting	Expert Report: 2 King B Report REF MATERIALS
PX4548		X028974	X028975		Parke-Davis Memorandum: Meeting Minutes, January 17, 1995, Neurontin Development Team Meeting	Expert Report: 2 King B Report REF MATERIALS
PX4549		X028965	X028969		Parke-Davis Memorandum: Meeting Minutes, February 21, 1995, Neurontin Development Team Meeting	Expert Report: 2 King B Report REF MATERIALS
PX4550		X005926	X005950		1998 Neurontin Tactics	Expert Report: 2 King B Report REF MATERIALS
PX4551		PFIZER_AFANNON_0002934			Neurontin Publication Planning 2003 by Allison Fannon	Expert Report: 2 King B Report REF MATERIALS
PX4552		V082736	V 082736 – 082761		V082761	Expert Report: 2 King B Report REF MATERIALS
PX4553		V042352	V042363		Parke-Davis Product Planning	Expert Report: 2 King B Report REF MATERIALS
PX4554		V047116	V047129		Neurontin Core Marketing Team Meeting, New York, NY	Expert Report: 2 King B Report REF MATERIALS
PX4555		V049269	V049274		Parke-Davis Memorandum: Meeting Minutes from August 29, 1995, Neurontin Indications Decision Analysis Group Meeting	Expert Report: 2 King B Report REF MATERIALS
PX4556		V053877			Neurontin (CI-945) Indication Publications Decision Analysis	Expert Report: 2 King B Report REF MATERIALS
PX4557		V057651			Emerging Applications in the Uses of AEDs_An Educational Proposal	Expert Report: 2 King B Report REF MATERIALS
PX4558		V058083			Northeast CBU 1997 Situation Analysis	Expert Report: 2 King B Report REF MATERIALS
PX4560		V090268			Parke-Davis Fax from Alan Walker	Expert Report: 2 King B Report REF MATERIALS
PX4562					US Department of Justice, "Warner-Lambert to Pay \$430 Million to Resolve Criminal & Civil Health Care Liability Relating to Off-Label Promotion," available at http://www.usdoj.gov/opa/pr/2004/May/04_civ_322.htm , accessed October 14, 2007.	Expert Report: 2 King B Report REF MATERIALS
PX4563		PFIZER_JMARINO_0001272			Fax including the Exploratory Development Plan for Psychiatric Indications for Gabapentin	Expert Report: 2 King B Report REF MATERIALS
PX4564		PFIZER_LTIVE_0008259			Neurontin 2002 Operating Plan	Expert Report: 2 King B Report REF MATERIALS
PX4565		PFIZER_LTIVE_0008284			Neurontin US Field Force Allocation	Expert Report: 2 King B Report REF MATERIALS

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX4566		PFIZER_RGLANZMAN_00000677	PFIZER_RGLANZMAN_00000677		2001 Key Issues and Strategies	Expert Report: 2 King B Report REF MATERIALS
PX4567		PFIZER_RGLANZMAN_0000669	PFIZER_RGLANZMAN_0000669		Share of Voice Data	Expert Report: 2 King B Report REF MATERIALS
PX4568		PFIZER_SDOFT_0026340	PFIZER_SDOFT_0026340		Page from 01/09/2002 Neurontin Publications Subcommittee Plans	Expert Report: 2 King B Report REF MATERIALS
PX4569		V069673	V069676		Neurontin Article Series	Expert Report: 2 King B Report REF MATERIALS
PX4570		PFIZER_SDOFT_0026346	PFIZER_SDOFT_0026340		Page from 01/09/2002 Neurontin Publications Subcommittee Plans	Expert Report: 2 King B Report REF MATERIALS
PX4571		PFIZER_SDOFT_0026347	PFIZER_SDOFT_0026349		Page from 01/09/2002 Neurontin Publications Subcommittee Plans	Expert Report: 2 King B Report REF MATERIALS
PX4572		V082736	V082761		Parke-Davis Memorandum: Neurontin Marketing Assessment	Expert Report: 2 King B Report REF MATERIALS
PX4574					Greenland re: gabapentin	Expert Report: 3 Greenland B Report REF MATERIALS
PX4575		PFIZER_LTIVE_0007563	PFIZER_LTIVE_0007580		RR-REG 740-03550, Pfizer. 3.2 Studies With Gabapentin Directed at Mechanism of Action. Confidential Pfizer Documents. DM_FILE/CI-0945 (JMF08901a).	Expert Report: 6 Kruszewski B Report REF MATERIALS 21
PX4576		IND_28454_SUB_004_0_101			Research Report	Expert Report: 6 Kruszewski B Report REF MATERIALS 42
PX4577					Blunberg, Alan. (March 30, 1992) Memo to Distribution: Gabapentin MAA - Product Profile. International Regulatory Affairs, Parke-Davis Pharmaceutical Research Division, Warner-Davis Company.p. 3.	Expert Report: 6 Kruszewski B Report REF MATERIALS 61
PX4578		PFIZER_LALPHS_0084360			Page from FDA FOI Documents for Neurontin NDA Approval	Expert Report: 6 Kruszewski B Report REF MATERIALS 94
PX4579					Warner-Lambert. (7/20/1987) Gabapentin versus placebo in Patients with Partial Seizures, Patient CD #205, Protocol #945-5-010. Warner-Lambert International. 1-2, 88, 96, 108-109.	Expert Report: 6 Kruszewski B Report REF MATERIALS 103
PX4580					Warner-Lambert. (4/8/1988) Gabapentin versus placebo in Patients with Partial Seizures, Patient CKS #213, Protocol #945-5---1. Warner-Lambert International. 154-155, 349, 352, 363.	Expert Report: 6 Kruszewski B Report REF MATERIALS 104
PX4581					Official research report from 945-15 Warner-Lambert. (5/8/1990) Adverse Event Information, Patient 945-15-01 #001 RWB. Parke-Davis Pharmaceutical Research Division, Warner-Lamber Company. 101-103, 118, 121, 127.	Expert Report: 6 Kruszewski B Report REF MATERIALS 111
PX4582					193	Expert Report: 6 Kruszewski B Report REF MATERIALS 124
PX4583		PFIZER_L_CASTRO_0011361			Pfizer (alpha-2-gamma) Compounds in Development, January 2002	Expert Report: 6 Kruszewski B Report REF MATERIALS 5
PX4584					Parke-Davis. (Aug 2003) Neurontin (Gabapentin) Capsules: Neurontin (Gabapentin) Tablets: Neurontin (Gabapentin) Oral Solution. Lori Murray, Senior Ed. PDR: 58 Edition: 2004: Physicians Desk Reference. Thompson PDR. Montvale, NJ. 2004. 2559.	Expert Report: 6 Kruszewski B Report REF MATERIALS 1
PX4587		PFIZER_CTAYLOR_0010782	PFIZER_CTAYLOR_0010807		Investigator's Brochure Neurontin (gabapentin) October 2001	Expert Report: 8 Roth Supplemental Expert Disclosure List REF MATERIALS
PX4590		PFIZER_RGLANZMAN_0125468	PFIZER_RGLANZMAN_0127300		NeP ISS	Expert Report: Arrowsmith-Lowe001
PX4592		PFIZER_MPATEL_0088542	PFIZER_MPATEL_0088860		RR-MEMO 720-03847 (Safety Info for Study 945-177)	Expert Report: Arrowsmith-Lowe001
PX4593		PFIZER_MEVERTSZ_0034364	PFIZER_MEVERTSZ_0034693		Monotherapy ISS	Expert Report: Arrowsmith-Lowe001

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX4594		PFIZER_LCASTRO_0057483	PFIZER_LCASTRO_0058337		Research Report for Study 945-077	Expert Report: Arrowsmith-Lowe001
PX4595		PFIZER_LCASTRO_0021988	PFIZER_LCASTRO_0023071		Research Report for Study 945-092	Expert Report: Arrowsmith-Lowe001
PX4596		PFIZER_AGARRITY_0007313	PFIZER_AGARRITY_0009693		PHN ISS	Expert Report: Arrowsmith-Lowe001
PX4599		WLC_CBU_061841	WLC_CBU_062079		Pediatric ISS	Expert Report: Arrowsmith-Lowe001
PX4600		PFIZER_REGULATORY_000260			Appendix 5, Pfizer Safety and Risk Management Literature Review: Gabapentin Use Among Persons with a History of Psychotic Disorder (December 1, 2005) .	Expert Report: Arrowsmith-Lowe002
PX4609		PFIZER_LKNAPP_0062278			Letter from Dr. Russell Katz, Director, FDA Division of Neuropharmacology to Pfizer (March 16, 2005) .	Expert Report: Arrowsmith-Lowe002
PX4611		PFIZER_JMOHAN_0000479			Appendix 4, Pfizer Response to EMEA, (December 14, 2005) Pfizer_JMohan_0000479.	Expert Report: Arrowsmith-Lowe002
PX4620		RR 720-03236			RR-Reg 720-03236, NDA 20-235, Appendix B.3 (May 12, 1993)	Expert Report: Arrowsmith-Lowe002
PX4664		RR 720-03315			RR-Reg 720-03315, NDA 20-235, Fourth Safety Update (December 15, 1992), including appendices.	Expert Report: Arrowsmith-Lowe002
PX4678		RR-X 720-02455			Investigator Brochure RR-X 720-02455 dated 05/21/1992	Expert Report: Barkin supp expert report doc 1503-2 REF MATERIALS 25
PX4688		WLC_FRANKLIN_0000127967	WLC_FRANKLIN_0000127971	4	Neurontin Studies	Expert Report: Blume, Cheryl 10/22/2007 p90 fn56
PX4689		WLC_FRANKLIN_0000041507	WLC_FRANKLIN_0000041510	4	Letter to James Parker re: NDA# 20-235 Neurontin (gabapentin capsules) MACMIS ID# 3323	Expert Report: Blume, Cheryl 10/22/2007 p90 fn56
PX4690		WLC_FRANKLIN_0000046767	WLC_FRANKLIN_0000046772	6	Parke-Davis Memorandum: Meeting Minutes-February 25, 1997, Neurontin Development Team Meeting	Expert Report: Blume, Cheryl 10/22/2007 p2 fn3
PX4691		WLC_FRANKLIN_0000052952	WLC_FRANKLIN_0000052957	6	Parke-Davis Memorandum: Minutes-April 22, 1997, Neurontin Development Team Meeting	Expert Report: Blume, Cheryl 10/22/2007 p2 fn3
PX4692		WLC_FRANKLIN_0000053292	WLC_FRANKLIN_0000053300	9	Letter to William Marino re: NDA 20-235 Neurontin (gabapentin capsules) MACMIS File ID# 4162	Expert Report: Blume, Cheryl 10/22/2007 p3 fn7; p90 fn56; p176 fn119
PX4693		WLC_FRANKLIN_0000053306	WLC_FRANKLIN_0000053309	4	Letter to Joan Hankin re: Advertizing MACMIS ID# 3424	Expert Report: Blume, Cheryl 10/22/2007 p90 fn56
PX4694		WLC_FRANKLIN_0000087284	WLC_FRANKLIN_0000087293	10	Fax to B. Garofalo from L. Hayes re: Gabapentin for Treatment of Pain Consultants Meeting, September 28, 1995; Boston, MA	Expert Report: Blume, Cheryl 10/22/2007 p85 fn50
PX4695		WLC_FRANKLIN_0000127963	WLC_FRANKLIN_0000127966	4	Warner-Lambert Company Responses to Questions 1-7 and Specifications 12, 13 and 14	Expert Report: Blume, Cheryl 10/22/2007 p90 fn56
PX4696		WLC_JTURNER_000230	WLC_JTURNER_000231	2	Summary of teleconference	Expert Report: Blume, Cheryl 10/22/2007 p148 fn65
PX4697		RR 720-02480			RR 720-02480	Expert Report: Blume, Cheryl 10/22/2007 059
PX4698		RR 720-03991			Research Report_No:RR-MEMO 720-03991	Expert Report: Blume, Cheryl 10/22/2007 p77 para121
PX4699		WLC_FRANKLIN_0000041500	WLC_FRANKLIN_0000041506	7	Letter to James Parker re: NDA# 20-235 Neurontin (gabapentin capsules) MACMIS ID# 3323	Expert Report: Blume, Cheryl 10/22/2007 p90 fn56
PX4700		IND28454_MISC_005_0026	IND28454_MISC_005_0030	5	Pre-NDA Meeting Summary	Expert Report: Blume, Cheryl 10/22/2007 p8 fn23
PX4701		WLC_FRANKLIN_0000127961	WLC_FRANKLIN_0000127962	2	Letter to Lesley Frank re: MACMIS File ID #4162 NDA-20-235, Neurontin (gabapentin capsules)	Expert Report: Blume, Cheryl 10/22/2007 p90 fn56
PX4702		PFIZER_JSU_0027004	PFIZER_JSU_0027008	5	Executive Summary- Suicide Rates in Neurontin-treated Population Groups	Expert Report: Blume, Cheryl 10/22/2007 p152 para214

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX4703		PFIZER_LLAMOREAUX_0018652	PFIZER_LLAMOREAUX_0018673	22	Research Study report: An open-label multicenter study of the safety and efficacy of gabapentin as monotherapy or add-on therapy in the long-term treatment of epileptic seizures	Expert Report: Blume, Cheryl 10/22/2007 p13 fn37
PX4704					JONCA BULL STATEMENT	Expert Report: Blume, Cheryl 10/22/2007 121
PX4705					WARNER-LAMBERT TO PAY \$430 MILLION	Expert Report: Blume, Cheryl 10/22/2007 001
PX4706		WLC_JTURNER_000284			WLC_JTURNER_000284	Expert Report: Blume, Cheryl 10/22/2007 188
PX4707		PFIZER_CTAYLOR_0001913	PFIZER_CTAYLOR_0001962	50	Antiepileptic Drugs for Treatment of Neuropathic Pain	Expert Report: Blume, Cheryl 10/22/2007 p185 fn138
PX4708		PFIZER_JSU_0023289	PFIZER_JSU_0023314	26	Charles Dellinger vs. Pfizer, Summons to Proceed before a Magistrate Judge	Expert Report: Blume, Cheryl 10/22/2007 p85 fn52, fn53
PX4709		IND60622_MISC_002_0011			IND60622_MISC_002_0011	Expert Report: Blume, Cheryl 10/22/2007 101
PX4710		PFIZER_JSU_0026538	PFIZER_JSU_0026542	5	Suicide Clinical Communications Letter	Expert Report: Blume, Cheryl 10/22/2007 p153 fn73, fn74, fn75
PX4711		NDA20235_MISC_002_0080			NDA20235_MISC_002_0080	Expert Report: Blume, Cheryl 10/22/2007 129
PX4712		PFIZER_LALPHS_0084338	PFIZER_LALPHS_0084703	366	FDA FOI Documents for Neurontin NDA Approval	Expert Report: Blume, Cheryl 10/22/2007 p11 fn31, fn32
PX4713		PFIZER_LCASTRO_0026268	PFIZER_LCASTRO_0026269	2	FDA Contact Report	Expert Report: Blume, Cheryl 10/22/2007 p154 fn78
PX4714		PFIZER_LCASTRO_0039757	PFIZER_LCASTRO_0039759	3	Letter to Andrea Garrity re: NDA #s 20-235, 20-882 Neurontin (gabapentin) MACMIS # 10174	Expert Report: Blume, Cheryl 10/22/2007 p149 fn71
PX4715		PFIZER_LCASTRO_0065672	PFIZER_LCASTRO_0065681	10	Potential for Drug Abuse with Gabapentin: A Post-Marketing Safety Analysis	Expert Report: Blume, Cheryl 10/22/2007 p160 fn106
PX4716		PFIZER_LCASTRO_0068931	PFIZER_LCASTRO_0068945	15	Response to FDA regarding suicide and suicide attempt in Neurontin (gabapentin) clinical trials-Phase 1 Studies	Expert Report: Blume, Cheryl 10/22/2007 p156 fn88
PX4717		PFIZER_LCASTRO_0073127	PFIZER_LCASTRO_0073132	6	Fax transmittal of letter to Lucy Castro re: Neurontin	Expert Report: Blume, Cheryl 10/22/2007 p160 fn104, fn105
PX4718		RR 720-04229			Research Report No:RR 720-04229	Expert Report: Blume, Cheryl 10/22/2007 p24 fn39
PX4719		PFIZER_JSU_0026537	PFIZER_JSU_0026537	1	Email from Michelle Clausen re: Neurontin-med info letter	Expert Report: Blume, Cheryl 10/22/2007 p153 fn73, fn74, fn75
PX4720		NDA21397_MISC_008_0085			NDA21397_MISC_008_0085	Expert Report: Blume, Cheryl 10/22/2007 066
PX4721		RR 720-03856			RR 720-03856	Expert Report: Blume, Cheryl 10/22/2007 128
PX4722		WLC_FRANKLIN_0000041293	WLC_FRANKLIN_0000041296	4	Letter to Sherry Danese re: Advertising and Promotion	Expert Report: Blume, Cheryl 10/22/2007 p90 fn56
PX4723		AER_SOURCE_0145583			AER_SOURCE_0145583	Expert Report: Blume, Cheryl 10/22/2007 008
PX4724		IND60622_MISC_002_0011_24	IND60622_MISC_002_0011_24	1	Pfizer Meeting Minutes Summary	Expert Report: Blume, Cheryl 10/22/2007 p160 fn101, fn102, fn103
PX4725		MAA_MISC_030_0075	MAA_MISC_030_0077	3	Parke-Davis Memorandum: Gabapentin MAA-Product Profile	Expert Report: Blume, Cheryl 10/22/2007 p187 fn150
PX4726		NDA20235_MISC_002_080			Parke-Davis Worldwide Regulatory Affairs FDA Contact	Expert Report: Blume, Cheryl 10/22/2007 p178 fn129

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX4727					JANET WOODCOCK STATEMENT	Expert Report: Blume, Cheryl 10/22/2007 122
PX4728		PFIZER_CPACELLA_0050918	PFIZER_CPACELLA_0050933	16	Pfizer Drug Safety (Ann Arbor) Product Reference Guide Gabapentin CI#0945 NDA#20-235 International Birth Date (IBD) February 5, 1993	Expert Report: Blume, Cheryl 10/22/2007 p36 fn41
PX4729		PFIZER_MEVERTSZ_0079431	PFIZER_MEVERTSZ_0079435	5	Letter to Russell Katz re: Request for Information-Response to FDA suicidality request	Expert Report: Blume, Cheryl 10/22/2007 p158 fn99
PX4730					GABITRIL PUBLIC HEALTH ADVISORY	Expert Report: Blume, Cheryl 10/22/2007 058
PX4731					DAVID FRANKLIN AFIDAVIT - MAY 19, 2003	Expert Report: Blume, Cheryl 10/22/2007 053
PX4732		PFIZER_PSUR_0002058			PFIZER_PSUR_0002058	Expert Report: Blume, Cheryl 10/22/2007 049
PX4733		PFIZER_PSUR_0002049			PFIZER_PSUR_0002049	Expert Report: Blume, Cheryl 10/22/2007 048
PX4734					DEAR DR. LETTER - ELDEPRYL	Expert Report: Blume, Cheryl 10/22/2007 021
PX4735					ISOTRETINOINHCP	Expert Report: Blume, Cheryl 10/22/2007 018
PX4736					LYRICA_2005	Expert Report: Blume, Cheryl 10/22/2007 161
PX4737		NDA21397_MISC_007_0051	NDA21397_MISC_007_0067	17	Section 3.1 (Background) for NDA 21-397	Expert Report: Blume, Cheryl 10/22/2007 p187 fn151
PX4738		RR 740-03075			Research Report No: RR 740-03075	Expert Report: Blume, Cheryl 10/22/2007 p17 para59
PX4739		PFIZER_LCASTRO_0073452	PFIZER_LCASTRO_0073452	1	Neurontin Warning Label	Expert Report: Blume, Cheryl 10/22/2007 p149 fn69, fn70
PX4740					AGITATION	Expert Report: Blume, Cheryl 10/22/2007 193
PX4741		RR 720-04174			Research Report No: RR 720-04174	Expert Report: Blume, Cheryl 10/22/2007 p42 fn43
PX4742					1-10% AES REPORTED	Expert Report: Blume, Cheryl 10/22/2007 027
PX4743		RR 720-04231			Research Report No: RR 720-04231	Expert Report: Blume, Cheryl 10/22/2007 p37 fn42
PX4744		RR 720-04232			Research Report No: RR 720-04232	Expert Report: Blume, Cheryl 10/22/2007 p179 para274
PX4745		RR 720-03893			Research Report No: RR 720-03893	Expert Report: Blume, Cheryl 10/22/2007 p179 para274
PX4746		RR 720-30135			Research Report No: RR-REG 720-30135	Expert Report: Blume, Cheryl 10/22/2007 p94 fn60
PX4747		RR 720-03891****0389			Research Report No: RR 720-03891	Expert Report: Blume, Cheryl 10/22/2007 p179 para274
PX4748		RR 740-03253			Research Report No: RR 740-03253	Expert Report: Blume, Cheryl 10/22/2007 p84 para133
PX4749		RR 744-00238			Research Report No: RR 744-00238	Expert Report: Blume, Cheryl 10/22/2007 p85 fn54
PX4750		RR 720-03362			Research Report No: RR-X 720-03362	Expert Report: Blume, Cheryl 10/22/2007 p79 para124
PX4751		RR 720-03381			Research Report No: RR-X 720-03381	Expert Report: Blume, Cheryl 10/22/2007 p79 para124
PX4752		RR 720-03480			Research Report No: RR-X 720-03480	Expert Report: Blume, Cheryl 10/22/2007 p79 para127

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX4753		WLC_CBU_000836	WLC_CBU_000874	39	Dear Healthcare Professional Letter from Bill Sigmund	Expert Report: Blume, Cheryl 10/22/2007 p42 fn44; p43 fn45
PX4754		WLC_FRANKLIN_0000038943	WLC_FRANKLIN_0000038945	3	Fax sent to James Parker re: NDA#20-235 Neurontin (gabapentin) capsules MACMIS ID# 3224	Expert Report: Blume, Cheryl 10/22/2007 p90 fn56
PX4755		RR 720-04363			Research Report No: RR 720-04363	Expert Report: Blume, Cheryl 10/22/2007 p179 para274
PX4756		RR 770-00286			Parke-Davis Memorandum: Gabapentin Analgesia Studies	Expert Report: Blume, Cheryl 10/22/2007 p84 para132
PX4757		PFIZER_MPATEL_0039110	PFIZER_MPATEL_0039168	59	Response to FDA regarding suicide and suicide attempt in Neurontin (gabapentin) clinical trials and postmarketing surveillance	Expert Report: Blume, Cheryl 10/22/2007 p156 fn87, fn91, fn92
PX4758		PFIZER_PSUR_0002015	PFIZER_PSUR_0002193	179	Postmarketing Experience Report according to CIOMS II April 1993 to May 22, 1995	Expert Report: Blume, Cheryl 10/22/2007 p62 fn48, fn49
PX4759		PFIZER_PSUR_0003596	PFIZER_PSUR_0004595	101	Periodic Safety Update Report Gabapentin February 1, 2003 through January 31, 2004	Expert Report: Blume, Cheryl 10/22/2007 p164 fn111
PX4760		PFIZER_THO_0001538	PFIZER_THO_0001541	4	Email from Manini Patel to Tina Ho re: Neurontin	Expert Report: Blume, Cheryl 10/22/2007 p171 fn114; p172 fn115
PX4761		PFIZER_THO_0004955	PFIZER_THO_0004956	2	Email from Tina Ho to Steve Baldwin re: Neurontin and Suicide	Expert Report: Blume, Cheryl 10/22/2007 p153 fn72
PX4762		PFIZER_THO_0005262	PFIZER_THO_0005273	12	Report on Gabapentin and Suicide	Expert Report: Blume, Cheryl 10/22/2007 p155 fn81, fn83, fn85, fn86
PX4763		RR 720-03894			Research Report No: RR 720-03894	Expert Report: Blume, Cheryl 10/22/2007 p179 para274
PX4764		RR 740-02959			Research Report No: RR 740-02959	Expert Report: Blume, Cheryl 10/22/2007 p84 para130
PX4765		RR 4192-0166			Research Report No: RR 4192-0166	Expert Report: Blume, Cheryl 10/22/2007 p185 fn139
PX4766		RR 4301-0124			Research Report No: RR 4301-00124	Expert Report: Blume, Cheryl 10/22/2007 p14 paraB
PX4767		RR 720-02816			Research Report No: RR 720-02816	Expert Report: Blume, Cheryl 10/22/2007 p14 paraC
PX4768		RR 720-02837			Research Report No: RR 720-02837	Expert Report: Blume, Cheryl 10/22/2007 p13 fn37; p15 paraD; p179
PX4769		RR 720-02883			Research Report No: RR 720-02883	Expert Report: Blume, Cheryl 10/22/2007 p16 paraE, paraF
PX4770		RR 720-02993			Research Report No: RR 720-02993	Expert Report: Blume, Cheryl 10/22/2007 p17 paraG
PX4771		RR 720-03498			Research Report No: RR 720-03498	Expert Report: Blume, Cheryl 10/22/2007 p179 para274
PX4772		RR 720-03732			Research Report No: RR-REG 720-03732	Expert Report: Blume, Cheryl 10/22/2007 p79 para123
PX4773		PFIZER_THO_0005335	PFIZER_THO_0005395	61	Response to FDA regarding suicide and suicide attempt in Neurontin (gabapentin) clinical trials and postmarketing surveillance	Expert Report: Blume, Cheryl 10/22/2007 p155 fn84
PX4812		RR 720-02957			720-02957.pdf (Integrated Summary of Safety of Gabapentin)	Expert Report: Furberg supp expert report doc 1503-3 REF MATERIALS 1
PX4844					FDA Amicus Brief regarding Neurontin and Suicidality dated July 1, 2008	Expert Report: Gibbons002
PX4846					Pfizer Slide presentation to Columbia University Antiepileptic Drug Meeting dated June 2, 2008	Expert Report: Gibbons002

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX4848		PFIZER_JMARINO_0000703	PFIZER_JMARINO_0000704	2	Email sent to Elizabeth Mutisya from John Marino re: POPP Study	Expert Report: King III, Charles 10/22/07 p37 fn140
PX4849		WLC_CBU_038946	WLC_CBU_038948	3	Neurontin 1996 SE CBU Plan	Expert Report: King III, Charles 10/22/07 p32 fn104
PX4850		WLC_FRANKLIN_0000052548	WLC_FRANKLIN_0000052548	1	Parke-Davis Memorandum: Reporting of Neurontin Indication Publications Analysis	Expert Report: King III, Charles 10/22/07 p12 fn34; p31 fn100
PX4851		PFIZER_LTIVE_0008275	PFIZER_LTIVE_0008292	18	8/2/2001 Neurontin Field Force Allocation	Expert Report: King III, Charles 10/22/07 p43 fn164, fn165; p47 fn177, fn178
PX4852		PFIZER_LTIVE_0009300	PFIZER_LTIVE_0009327	28	Email sent to Michelle Mays from Leslie Tive re: April PSC meeting action report	Expert Report: King III, Charles 10/22/07 p38 fn146
PX4853		PFIZER_RGLANZMAN_0000650	PFIZER_RGLANZMAN_0000776	127	Neurontin 2001 US Operating Plan	Expert Report: King III, Charles 10/22/07 p36 fn137; p37 fn139
PX4854		PFIZER_RGLANZMAN_0054596	PFIZER_RGLANZMAN_0054609	14	Letter to Andrea Garrity re: NDA #s 20-235, 20-882 Neurontin (gabapentin) MACMIS # 10174	Expert Report: King III, Charles 10/22/07 p38 fn155
PX4855		PFIZER_LKNAPP_0091179	PFIZER_LKNAPP_0091182	4	Email sent from John Marino re: Neurontin, Boston Globe Report, November 25, 2002	Expert Report: King III, Charles 10/22/07 p32 fn102
PX4856		PFIZER_SDOFT_0026331	PFIZER_SDOFT_0026387	57	Neurontin Publications Subcommittee Current Status and 2002 Plans	Expert Report: King III, Charles 10/22/07 p37 fn143; p38 fn146, fn147
PX4857		PFIZER_LKNAPP_0070556	PFIZER_LKNAPP_0070558	3	Email sent from Larry Alphs re: Minutes from NeP expert panel	Expert Report: King III, Charles 10/22/07 p38 fn152
PX4858		WLC_FRANKLIN_0000041005	WLC_FRANKLIN_0000041005	1	Fax including a copy of the Meeting Minutes of the Core Marketing Team Meeting with conclusions and action items	Expert Report: King III, Charles 10/22/07 p30 fn89
PX4859		WLC_FRANKLIN_0000041006	WLC_FRANKLIN_0000041016	11	Conclusions and Action Items: Neurontin	Expert Report: King III, Charles 10/22/07 p30 fn89
PX4860		WLC_FRANKLIN_0000045772	WLC_FRANKLIN_0000046077	306	Neurontin Core Marketing Team Meeting in New York, NY	Expert Report: King III, Charles 10/22/07 p30 fn89
PX4861		WLC_FRANKLIN_0000047966	WLC_FRANKLIN_0000047971	6	Parke-Davis Memorandum: Meeting Minutes from August 29, 1995 Neurontin Indications Decision Analysis Group Meeting	Expert Report: King III, Charles 10/22/07 p31 fn100
PX4862		WLC_FRANKLIN_0000052547	WLC_FRANKLIN_0000052547	1	Email sent from Francie Kivel re: Neurontin Indication Publications Analysis Report (includes Appendices)	Expert Report: King III, Charles 10/22/07 p12 fn34; p31 fn100
PX4863		PFIZER_JMARINO_0001268	PFIZER_JMARINO_0001273	6	Fax transmittle of Exploratory Development Plan for Psychiatric Indications for Gabapentin	Expert Report: King III, Charles 10/22/07 p12 fn35
PX4864		PFIZER_RGLANZMAN_0134501	PFIZER_RGLANZMAN_0134503	3	Email sent from Elizabeth Mutisya re: GBP-post amputation pain	Expert Report: King III, Charles 10/22/07 p37 fn140
PX4865		PFIZER_JMARINO_0000367	PFIZER_JMARINO_0000367	1	Email sent from John Marino re: Neurontin GDRC Presentation	Expert Report: King III, Charles 10/22/07 p38 fn151
PX4866		0008597	0008608		AED Advisory Board Presentations by Mike Valentino	Expert Report: King III, Charles 10/22/07 p30 fn87
PX4867		PFIZER_AFANNON_0002912	PFIZER_AFANNON_0002967	56	Neurontin Publication Planning 2003 by Allison Fannon	Expert Report: King III, Charles 10/22/07 p38 fn144, fn145
PX4868		PFIZER_APANDE_0000544	PFIZER_APANDE_0000548	5	USPTO Patent Full-Text and Image Database	Expert Report: King III, Charles 10/22/07 p9 fn23
PX4869		PFIZER_CTAYLOR_0000412	PFIZER_CTAYLOR_0000451	40	Gabapentin PPT slides	Expert Report: King III, Charles 10/22/07 p17 fn39
PX4870		PFIZER_JMARINO_0000153	PFIZER_JMARINO_0000154	2	Email sent to John Marino from Steve Piron re: GDRC Meeting Minutes for September 19, 2001	Expert Report: King III, Charles 10/22/07 p38 fn151, fn152, fn153
PX4871		PFIZER_LTIVE_0008228	PFIZER_LTIVE_0008260	33	Neurontin 2002 Operating Plan PPT Slides	Expert Report: King III, Charles 10/22/07 p36 fn137
PX4872		PFIZER_JMARINO_0000363	PFIZER_JMARINO_0000366	4	Neurontin PPT slides	Expert Report: King III, Charles 10/22/07 p38 fn151

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX4873		WLC_FRANKLIN_0000052549	WLC_FRANKLIN_0000052576	1	Neurontin (CI-945) Indication Publications Decision Analysis	Expert Report: King III, Charles 10/22/07 p12 fn34; p31 fn100
PX4874		PFIZER_JMARINO_0000809	PFIZER_JMARINO_0000809	1	Email sent from John Marino to Elizabeth Mutisya re: POPP Study	Expert Report: King III, Charles 10/22/07 p37 fn140, fn141; p38 fn149, fn151
PX4875		PFIZER_LCASTRO_0002678	PFIZER_LCASTRO_0002682	5	Email sent from David Probert re: Publication of Key Studies	Expert Report: King III, Charles 10/22/07 p37 fn141; p38 fn149
PX4876		PFIZER_LESLIETIVE_0020985	PFIZER_LESLIETIVE_0020986	2	Email sent from Judy Brown re: 25 and 26 Studies	Expert Report: King III, Charles 10/22/07 p37 fn141, fn142; p38 fn149
PX4877		PFIZER_LESLIETIVE_0080783	PFIZER_LESLIETIVE_0080784	2	Email sent to Leslie Tive from John Marino re: 224 Study	Expert Report: King III, Charles 10/22/07 p37 fn141
PX4878		PFIZER_LKNAPP_0009569	PFIZER_LKNAPP_0009573	5	Pfizer Consultants Meeting	Expert Report: King III, Charles 10/22/07 p38 fn151
PX4879		PFIZER_LKNAPP_0070537	PFIZER_LKNAPP_0070544	8	Expert Meeting Report: development of compounds for neuropathic pain	Expert Report: King III, Charles 10/22/07 p46 fn175
PX4880		PFIZER_JMARINO_0000155	PFIZER_JMARINO_0000157		Global Development Review Committee Meeting Minutes	Expert Report: King III, Charles 10/22/07 p38 fn151, fn152, fn153
PX4881		WLC_FRANKLIN_0000111299	WLC_FRANKLIN_0000111302	4	Letter to Phil Magistro from Jacki Gordon	Expert Report: King III, Charles 10/22/07 p32 fn102
PX4882		WLC_FRANKLIN_0000166608	WLC_FRANKLIN_0000166635	28	Parke-Davis Memorandum: Neurontin Marketing Assessments	Expert Report: King III, Charles 10/22/07 p11 fn33; p12 fn34; p29 fn85
PX4883		WLC_FRANKLIN_0000134637	WLC_FRANKLIN_0000134637	1	Interoffice Memorandum from Atul Pande: Gabapentin Psychiatric Studies	Expert Report: King III, Charles 10/22/07 p12 fn34; p29 fn85
PX4884		WLC_FRANKLIN_0000134428	WLC_FRANKLIN_0000134436	9	Parke-Davis Memorandum: Meeting Minutes, October 18, 1994, Neurontin Development Team Meeting	Expert Report: King III, Charles 10/22/07 p29 fn82
PX4885		WLC_FRANKLIN_0000134381	WLC_FRANKLIN_0000134386	6	Parke-Davis Memorandum: Minutes, January 17, 1995, Neurontin Development Team Meeting	Expert Report: King III, Charles 10/22/07 p29 fn82
PX4886		WLC_FRANKLIN_0000134376	WLC_FRANKLIN_0000134380	5	Parke-Davis Memorandum: Meeting Minutes, February 21, 1995, Neurontin Development Team Meeting	Expert Report: King III, Charles 10/22/07 p29 fn82
PX4887		WLC_FRANKLIN_0000134368	WLC_FRANKLIN_0000134373	6	Parke-Davis Memorandum: Meeting Minutes, March 14, 1995, Neurontin Development Team Meeting	Expert Report: King III, Charles 10/22/07 p12 fn34; p29 fn85
PX4888		WLC_FRANKLIN_0000134331	WLC_FRANKLIN_0000134335	5	Parke-Davis Memorandum: Meeting Minutes, November 14, 1995, Neurontin Development Team Meeting	Expert Report: King III, Charles 10/22/07 p30 fn89
PX4889		WLC_FRANKLIN_0000112124	WLC_FRANKLIN_0000112148	25	1998 Neurontin Tactics	Expert Report: King III, Charles 10/22/07 p33 fn106
PX4890		WLC_FRANKLIN_0000111583	WLC_FRANKLIN_0000111583	1	Articles on Antiepileptic Drug Use in Epilepsy and Other Disorders Project Status as of July 18, 1997	Expert Report: King III, Charles 10/22/07 p30 fn87
PX4891		WLC_FRANKLIN_0000111303	WLC_FRANKLIN_0000111307	5	Invoices #: 7094, 7093, 7014, 7065, 7064	Expert Report: King III, Charles 10/22/07 p32 fn102
PX4892		WLC_FRANKLIN_0000108236	WLC_FRANKLIN_0000108252	17	Neurontin Northeast CBU 1997	Expert Report: King III, Charles 10/22/07 p33 fn106
PX4893		WLC_FRANKLIN_0000096534	WLC_FRANKLIN_0000096539	6	Presentation: ACE Inhibitor South East Share	Expert Report: King III, Charles 10/22/07 p30 fn87
PX4894		WLC_FRANKLIN_0000096525	WLC_FRANKLIN_0000096533	9	Neurontin 1996 SE CBU Plan	Expert Report: King III, Charles 10/22/07 p30 fn87
PX4895		WLC_FRANKLIN_0000062105	WLC_FRANKLIN_0000062110	6	1998 Strategic Plan and A and P Allocation Grid Neurontin	Expert Report: King III, Charles 10/22/07 p30 fn97
PX4896		WLC_FRANKLIN_0000111581	WLC_FRANKLIN_0000111582	2	Parke-Davis Memorandum: Selected Physician Titration Update	Expert Report: King III, Charles 10/22/07 p30 fn87

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX4897		WLC_FRANKLIN_0000089885	WLC_FRANKLIN_0000089885	1	Parke-Davis Memorandum: Neurontin Verbatims	Expert Report: King III, Charles 10/22/07 p30 fn96
PX4898		WLC_FRANKLIN_0000056748	WLC_FRANKLIN_0000056760	13	Northeast CBU 1997 Situation Analysis	Expert Report: King III, Charles 10/22/07 p33 fn106, fn107
PX4899		WLC_FRANKLIN_0000056316	WLC_FRANKLIN_0000056352	37	Emerging Applications in the Uses of AEDs, An Educational Proposal	Expert Report: King III, Charles 10/22/07 p31 fn98
PX4900		WLC_FRANKLIN_0000068350	WLC_FRANKLIN_0000068353	5	Neurontin Article Series	Expert Report: King III, Charles 10/22/07 p32 fn102 *Author wrote V06976326
PX4901		WLC_FRANKLIN_0000081254	WLC_FRANKLIN_0000081279	26	Parke-Davis Memorandum: Neurontin Marketing Assessment (included)	Expert Report: King III, Charles 10/22/07 p12 fn34; p29 fn85
PX4902		WLC_FRANKLIN_0000085334	WLC_FRANKLIN_0000085339	6	Parke-Davis Memorandum: Minutes/Action Items from Marketing Council Meeting February 28 - March 2, 1995, Lyon, France	Expert Report: King III, Charles 10/22/07 p29 fn85
PX4903		WLC_FRANKLIN_0000089332	WLC_FRANKLIN_0000089373	42	Marketing Assessment: Neurontin in Psychiatric Disorders	Expert Report: King III, Charles 10/22/07 p29 fn82, fn85
PX4904		WLC_FRANKLIN_0000089884	WLC_FRANKLIN_0000089884	1	Parke-Davis Memorandum: Neurontin Details	Expert Report: King III, Charles 10/22/07 p30 fn96
PX4905		WLC_FRANKLIN_0000056353	WLC_FRANKLIN_0000056357	5	Emerging Applications in the Use of AEDs	Expert Report: King III, Charles 10/22/07 p31 fn98
PX4906		IND_28454_SUB_004_0101			Research Report No: RR 4192-0166	Expert Report: Kruszewski, Stefan P 00/00/2007 p21 fn42
PX4907		PFIZER_CPACELLA_0009404	PFIZER_CPACELLA_0009421	18	Behavioural Disturbance with Gabapentin by Professor Michael Trimble	Expert Report: Kruszewski, Stefan P 00/00/2007 p23 fn1 13
PX4908		MAA_MISC_030_0077			Parke-Davis Memorandum: Gabapentin MAA-Product Profile	Expert Report: Kruszewski, Stefan P 00/00/2007 p21 fn62
PX4909		PFIZER_Psur_0001882	PFIZER_Psur_0002014	133	Periodic Report: Drug Safety Gabapentin / Neurontin	Expert Report: Kruszewski, Stefan P 00/00/2007 p23 fn1 12
PX4910		MAA_MISC_028_0224			Email sent from Charlie Taylor re: Neurontin pharmacology (re: France)	Expert Report: Kruszewski, Stefan P 00/00/2007 p21 fn54
PX4911		RR 740-02866			RR 740-02866; Affinity of Gabapentin in Various Receptor Binding Assays	Expert Report: Pages from Ex 8 Trimble General Causation report REF MATERIALS
PX4912		RR 740-03545			RR 740-03545; Monoamine Neuronal Reuptake Affinities of Gabapentin and Pregabalin	Expert Report: Pages from Ex 8 Trimble General Causation report REF MATERIALS
PX4928		PFIZER_SCRISTO_0000513	PFIZER_SCRISTO_0000519		PMP Minutes (16 Jan 03) [Pfizer_Scristo_0000513 to 19]	Expert Report: Ruggieri002 87
PX4929		PFIZER_GGRIBKO_0002762			May 4, 2004 E-mail from Greg Gribko to Douglas Kargman [Pfizer_GGribko_0002762]	Expert Report: Ruggieri002 99
PX4930					Neurontin label (revised September 2003)	Expert Report: Ruggieri002 4
PX4931		PFIZER_LCASTRO_0076898	PFIZER_LCASTRO_0076900		RMWG Minutes (16 Jan 02) [Pfizer_LCastro_0076898 to 900]	Expert Report: Ruggieri002 97
PX4932		PFIZER_LKNAPP_0025486	PFIZER_LKNAPP_0025490		RMWG Minutes (24 Sep 01) [Pfizer_LKnapp_0025486 to 90]	Expert Report: Ruggieri002 96
PX4933		PFIZER_RGLANZMAN_0036788	PFIZER_RGLANZMAN_0036792		RMWG Minutes (12 Jun 01) [Pfizer_Rglanzman_0036788 to 92]	Expert Report: Ruggieri002 95
PX4934		PFIZER_LCASTRO_0084739	PFIZER_LCASTRO_0084741		PMP Labeling CWG Minutes (4 Mar 04) [Pfizer_Lcastro_0084739 to 41]	Expert Report: Ruggieri002 94

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX4935		PFIZER_MEVERTSZ_0015747	PFIZER_MEVERTSZ_0015748		PMP Labeling CWG Minutes (1 Mar 04) [Pfizer_Mevertsz_0015747 to 48]	Expert Report: Ruggieri002 93
PX4937		PFIZER_RGLANZMAN_0166311	PFIZER_RGLANZMAN_0166314		PMP Labeling CWG Minutes (25 Jul 02) [Pfizer_RGlanzman_0166311 to 14]	Expert Report: Ruggieri002 89
PX4939		PFIZER_GGRIBKO_0002764	PFIZER_GGRIBKO_0002835		Periodic Safety Update Report (Gabapentin), United Kingdom, February 1, 2003 through January 31, 2004 [Pfizer_Ggribko_0002764 to 835]	Expert Report: Ruggieri002 100
PX4949					Neurontin label (December 30,1993)	Expert Report: Ruggieri002 2
PX4951					Neurontin label (revised July 2001)	Expert Report: Ruggieri002 3
PX4952		RR 720-03322			RR-REG 720-03322 (December 14,1993)	Expert Report: Ruggieri002 123
PX4953		RR 720-03132			RR-REG 720-03132 (December 30,1992)	Expert Report: Ruggieri002 121
PX4954		RR 720-03079			RR-REG 720-03079 (May 29,1992)	Expert Report: Ruggieri002 120
PX4957					"Gabapentin and Suicide" by Jeffrey Mohan (October 2005)	Expert Report: Ruggieri002 9
PX4958					"Gabapentin and Suicide" by Tina Ho (August 2004)	Expert Report: Ruggieri002 6
PX4959					Neurontin label (revised December 2005)	Expert Report: Ruggieri002 5
PX4963		PFIZER_THO_0001634			E-mail from Lesia Tontisakis to Michael Campbell (January 16, 2003, 4:19 PM) [Pfizer_THO_0001634]	Expert Report: Ruggieri002 69
PX4964		PFIZER_THO_0001633			E-mail from Cathy Sigler to Tina Ho (January 9, 2003, 4:54 PM) [Pfizer_THO_0001633]	Expert Report: Ruggieri002 68
PX4969		PFIZER_MEVERTSZ_00131185	PFIZER_MEVERTSZ_00131202		February 2000 Review of the Neuropsychiatric Adverse Events Reported in Association with the Use of Gabapentin During the Period 1: January 1996 to 31 December 1999, Warner-Lambert's Drug Safety Surveillance [Pfizer_Mevertsz_00131185 to 202]	Expert Report: Ruggieri002 57
PX4970		PFIZER_LCASTRO_0015365	PFIZER_LCASTRO_0015371		PMP Minutes (17 Oct 02) [Pfizer_Lcastro_0015365 to 71]	Expert Report: Ruggieri002 86
PX4974		PFIZER_LKNAPP_0135257	PFIZER_LKNAPP_0135258		E-mail from James Leonard to Elizabeth Garofalo (February 8,2000) Pfizer_Lknapp_0135257 to 58	Expert Report: Ruggieri002 52
PX4980		PFIZER_ELUCZAK_0067016			Pfizer Worldwide Development Safety and Risk Management: Master Document on Pharmacovigilance (August 2005) Pfizer_Eluczak_0067016-0067016	Expert Report: Ruggieri002 44
PX4981		PFIZER_ELUCZAK_0067211	PFIZER_ELUCZAK_0067255		Pfizer Worldwide Development Safety and Risk Management: Master Document on Pharmacovigilance (October 2004) Pfizer_Eluczak_0067211- 0067255	Expert Report: Ruggieri002 43
PX4989		PFIZER_LCASTRO_0015331	PFIZER_LCASTRO_0015338		PMP Minutes (19 Jul 01) [Pfizer_Lcastro_0015331 to 38]	Expert Report: Ruggieri002 81
PX4991		PFIZER_MEVERTSZ_0091472	PFIZER_MEVERTSZ_0091478		Tabular Summary of the Indications and Medical History in Cases Reporting Patients Who Committed Suicide or Attempted Suicide While Receiving Gabapentin, by Jigna Shaw, Pharm. D., July 28, 2006 [Pfizer_Mevertsz_0091472 to 78]	Expert Report: Ruggieri002 79
PX4993		PFIZER_JSU_0026449			E-mail from Linda LaMoreaux to Julia Su (November 6, 2003, 2:02 PM) [Pfizer_Jsu_0026449]	Expert Report: Ruggieri002 76
PX4994		PFIZER_BPARSONS_0134014			E-mail from Bruce Parsons to Claire Wohlhuter (October 14, 2003, 4:04 PM) [Pfizer_Bparsons_0134014]	Expert Report: Ruggieri002 75
PX4995		PFIZER_SDOFT_0056764			E-mail from Suzanne Doft to Jill Bruzga, et al. (October 9, 2003, 5:07 PM) [Pfizer_SDoft_0056764]	Expert Report: Ruggieri002 72
PX4997		PFIZER_SDOFT_0055890			E-mail from Ed Whalen to Claire Wohlhuter, et al. (October 9, 2003, 7:08 PM) [Pfizer_Sdoft_0055890]	Expert Report: Ruggieri002 73
PX5028		PFIZER_MCLAUSSEN_0003564	PFIZER_MCLAUSSEN_0003569	6	Neurontin (gabapentin) Pharmacology-General mechanism of drug	Expert Report: Trimble, Michael

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
					action	00/00/2007 p23; p28
PX5029		PFIZER_CTAYLOR_0011499	PFIZER_CTAYLOR_0011502	4	Comparison of pharmacology of gabapentin and vigabatrin	Expert Report: Trimble, Michael 00/00/2007 p31
PX5030		PFIZER_CTAYLOR_0001612	PFIZER_CTAYLOR_0001643	32	Report: Mechanisms of Action of Gabapentin by Charles Taylor	Expert Report: Trimble, Michael 00/00/2007 p34
PX5031		PFIZER_CTAYLOR_0001567	PFIZER_CTAYLOR_0001611	45	Report: Mechanisms of Action of Gabapentin by Charles Taylor (draft)	Expert Report: Trimble, Michael 00/00/2007 p30
PX5032		PFIZER_CTAYLOR_0000094	PFIZER_CTAYLOR_0000121	28	The Biology and Pharmacology of Calcium Channel (alpha-2-gamma) Proteins (Presentation)	Expert Report: Trimble, Michael 00/00/2007 p32
PX5033		PFIZER_LCASTRO_0071507	PFIZER_LCASTRO_0071885	379	Neurontin Annual Report (August 19, 2003-August 19, 2004)	Expert Report: Trimble, Michael 00/00/2007 p35
PX5034		PFIZER_CTAYLOR_0020168	PFIZER_CTAYLOR_0020179	12	Executive Summary: Mechanisms of Action Data-Sharing Meeting	Expert Report: Trimble, Michael 00/00/2007 p35
PX5057		RR 720-03850			Research Report 720-03 850 (March 19, 1999) (social phobia study)	Expert Report: Weiss-Smith002- Reliance Materials
PX5063		RR 720-03851			Research Report 720-0385 1 (April 9, 1999) (panic disorder study)	Expert Report: Weiss-Smith002- Reliance Materials
PX5083					PFOENIX	MISC
PX5084	19921201	120192QUERY	120192QUERY		Memorandum: Committee Mailing-Neurontin (Gabapentin) NDA 20-235	MISC
PX5101	19920330	MAA_MISC_0030_0075	MAA_MISC_0030_0077		Parke-Davis Memorandum: Gabapentin MAA-Product Profile	MISC
PX5102	20020531	MDL_PL_0002	MDL_PL_0005		USMI Standard Monthly Reports re: US Medical Information Standard Monthly Reports	MISC
PX5105		NEURONTI_SR_80047AC8	NEURONTI_SR_80047AC8		Suicide Clinical Communications Letter	MISC
PX5106	19910618	PATENT_DEPRESSION	PATENT_DEPRESSION		United States Patent	MISC
PX5108	20020522	PFIZER_AGARRITY_0002266	PFIZER_AGARRITY_0002269		Email sent from John Marino re: Neurontin labeling, Ground rules and Agenda, Meeting, May 22	MISC
PX5109	20010524	PFIZER_AGARRITY_0005216	PFIZER_AGARRITY_0005217		5/24/2001 Email from Pande to Distribution	MISC
PX5112	20041026	PFIZER_APANDE_0003795	PFIZER_APANDE_0003813		Letter to Douglas Throckmorton, Russell Katz, and Bob Rappaport from Jonathon Parker re: Lyrica (pregabalin) Capsules, etc.	MISC
PX5114	20011031	PFIZER_CGROGAN_0012289	PFIZER_CGROGAN_0012289		10/31/2001 Email from Piron to Doft et al	MISC
PX5115	20020221	PFIZER_CGROGAN_0012492	PFIZER_CGROGAN_0012492		Email sent from John Marino re: NEU-0032890 Labeling Subcommittee Review of Gabapentin Neuropathic Pain BOP	MISC
PX5116		PFIZER_CGROGAN_0012493	PFIZER_CGROGAN_0012590		BOP Labeling_Neurontin	MISC
PX5121		PFIZER_CTAYLOR_0000204	PFIZER_CTAYLOR_0000220		Gabapentin PPT slides	MISC
PX5123		PFIZER_CTAYLOR_0000414	PFIZER_CTAYLOR_0000414		Gabapentin PPT slides	MISC
PX5124		PFIZER_CTAYLOR_0005341	PFIZER_CTAYLOR_0005389		Gabapentin: Pharmacology Written Summary	MISC
PX5127		PFIZER_CTAYLOR_0010827	PFIZER_CTAYLOR_0010860		PPT Presentation Slides: Clinical Development in the Slipstream of Gabapentin	MISC
PX5128	00000100	PFIZER_CTAYLOR_0011178	PFIZER_CTAYLOR_0011184		Neurontin Usage PPT slides	MISC
PX5129		PFIZER_CTAYLOR_0011878	PFIZER_CTAYLOR_0011899		Query after 1st Review Gabapentin	MISC
PX5133	20000905	PFIZER_CTAYLOR_0012843	PFIZER_CTAYLOR_0012843		Gabapentin Mechanism Work Group Team Chapter	MISC
PX5135	20020523	PFIZER_CTAYLOR_0017228	PFIZER_CTAYLOR_0017229		Email sent from Drusilla Scott re: Neurontin PHN SNDA; status and labeling	MISC

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX5144	20040425	PFIZER_GDIECK_0000142	PFIZER_GDIECK_0000142		Email sent from Manfred Hauben re: FDA request for teleconference with Pfizer to discuss safety concerns with Neurontin	MISC
PX5145	00000002	PFIZER_GDIECK_0002605	PFIZER_GDIECK_0002614		Neurontin Medical Initiatives for 2002 PPT slides	MISC
PX5149	19910618	PFIZER_INRE_0002701	PFIZER_INRE_0002704		United States Patent	MISC
PX5150	19950519	PFIZER_JMARINO_0001274	PFIZER_JMARINO_0001316		Parke-Davis Memorandum: Neurontin Marketing Assessment	MISC
PX5154		PFIZER_LCASTRO_0003585	PFIZER_LCASTRO_0003653		Clinical Expert Report and Written Summary of Clinical Studies: Gabapentin for the Treatment of Neuropathic Pain	MISC
PX5155	20020515	PFIZER_LCASTRO_0011438	PFIZER_LCASTRO_0011519	82	Investigator's Brochure Addendum for Epilepsy Neurontin (Gabapentin), May 2002	MISC
PX5160	20040816	PFIZER_LCASTRO_0041975	PFIZER_LCASTRO_0042547	573	Gabapentin and Suicide Report	MISC
PX5163	20001113	PFIZER_LESLIETIVE_0020922	PFIZER_LESLIETIVE_0020945		Email sent to Leslie Tive from Angela Crespo re: Revised draft of publication for 945-224	MISC
PX5164	20020301	PFIZER_LKNAPP_0012750	PFIZER_LKNAPP_0012773	24	Research Report No: RR-MEMO 720-30106	MISC
PX5171	20041001	PFIZER_LKNAPP_0103774	PFIZER_LKNAPP_0103781	8	Suicide Rates in Neurontin Treated Populations	MISC
PX5173	00000019	PFIZER_LTIVE_0005147	PFIZER_LTIVE_0005148		Mechanisms of Action of anticonvulsants	MISC
PX5174	20020403	PFIZER_LTIVE_0006479	PFIZER_LTIVE_0006497		Email sent to Michelle Mays from Leslie Tive re: Neurontin Information	MISC
PX5185	20010910	PFIZER_LTIVE_0012408	PFIZER_LTIVE_0012414		Psychiatrist Use of Anticonvulsants Discussion Guide	MISC
PX5187		PFIZER_LTIVE_0028530	PFIZER_LTIVE_0028540		PPT slides	MISC
PX5188		PFIZER_LTIVE_0028559	PFIZER_LTIVE_0028571		PPT slides Gabapentin	MISC
PX5190	20030321	PFIZER_LTIVE_0040120	PFIZER_LTIVE_0040940	821	Periodic Safety Update Report Gabapentin February 1, 1998 through January 31, 2003	MISC
PX5193	20030613	PFIZER_MCLAUSSEN_0001790	PFIZER_MCLAUSSEN_0001826	37	Neurontin PPT Presentation by Michelle Clausen and Yuan Wang	MISC
PX5198	20040806	PFIZER_MCLAUSSEN_0005652	PFIZER_MCLAUSSEN_0005736	85	Adverse Event Reporting Rate (PT)	MISC
PX5200	20010305	PFIZER_MDONG_0000061	PFIZER_MDONG_0000069		Drugs in Clinical Development for Epilepsy	MISC
PX5201	20000301	PFIZER_MDONG_0000112	PFIZER_MDONG_0000114		Project Operating Plan (POP)	MISC
PX5202	20000225	PFIZER_MEVERTSZ_0013185	PFIZER_MEVERTSZ_0013202		Review of the Neuropsychiatric Adverse Events Reported in Association with the Use of Gabapentin during the Period January 1, 1996 to December 31, 1999	MISC
PX5203		PFIZER_MEVERTSZ_0015802	PFIZER_MEVERTSZ_0015811		Increase Frequency Analysis	MISC
PX5204	20000806	PFIZER_MEVERTSZ_0015812	PFIZER_MEVERTSZ_0015813		Neurontin (gabapentin) Tablets Single Moiety Increased Frequency Analysis NDA#20-882	MISC
PX5205	20060607	PFIZER_MEVERTSZ_0079561	PFIZER_MEVERTSZ_0079568		Neurontin Suicidality Overview Table	MISC
PX5210	20021014	PFIZER_RGLANZMAN_0022069	PFIZER_RGLANZMAN_0022072		Pfizer Memorandum: Gabapentin Product Maintenance and Pharmacovigilance (PMP) Labeling Core Working Group (CWG)	MISC
PX5211	20071022	PFIZER_RGLANZMAN_0022073	PFIZER_RGLANZMAN_0022075		Pfizer Memorandum: Gabapentin Product Maintenance and Pharmacovigilance (PMP) Labeling Core Working Group (CWG)	MISC
PX5212	20010913	PFIZER_RGLANZMAN_0040003	PFIZER_RGLANZMAN_0040004		9/13/2001 Email from Mutisya to Murphy et al	MISC
PX5213	20010914	PFIZER_RGLANZMAN_0040032	PFIZER_RGLANZMAN_0040033		Email sent from Kirk Taylor re: GBP-post amputation pain	MISC
PX5215	20010418	PFIZER_RGLANZMAN_0095109	PFIZER_RGLANZMAN_0095118		Neurontin: Safety Surveillance	MISC

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX5216	20021121	PFIZER_RGLANZMAN_0121697	PFIZER_RGLANZMAN_0121700		Email sent from Angela Crespo re: Backonja	MISC
PX5219		PFIZER_THO_0000145	PFIZER_THO_0000150	6	Adverse Event Reporting Rate (PT)	MISC
PX5220		PFIZER_THO_0000197	PFIZER_THO_0000198	2	FDA Contact Report	MISC
PX5223		PFIZER_THO_0000248	PFIZER_THO_0000249	2	Costart Report	MISC
PX5224		PFIZER_THO_0000746	PFIZER_THO_0000756	11	Email sent from Kay Samulak re: Gabapentin MEB assessment	MISC
PX5226	20040818	PFIZER_THO_0001943	PFIZER_THO_0001957	15	MedWatch Mfr Report #041-0912-860001-01	MISC
PX5227	20031009	PFIZER_THO_0004952	PFIZER_THO_0004953		Email sent from Julia Su re: Neurontin and Suicide	MISC
PX5228	20031009	PFIZER_THO_0004954	PFIZER_THO_0004954		Email sent from Tina Ho re: Neurontin and Suicide	MISC
PX5230	20040802	PFIZER_THO_0005023	PFIZER_THO_0005056	34	MedWatch Mfr Report #001-0945-900031-00	MISC
PX5231	20040802	PFIZER_THO_0005057	PFIZER_THO_0005057	1	MedWatch Mfr Report #001-0945-940103-00	MISC
PX5234	20040902	PFIZER_THO_0006829	PFIZER_THO_0006830	2	Narrative Line Listing AER Number: 032-0945-M0000010	MISC
PX5235	20040902	PFIZER_THO_0006831	PFIZER_THO_0006833	3	Narrative Line Listing AER Number: 001-0945-940009	MISC
PX5239	20031104	PFIZER_THO_0008019	PFIZER_THO_0008168	150	Serious Adverse Events Gabapentin Clinical Study Cases 01/01/1980-15/10/2003	MISC
PX5240	20030904	PFIZER_THO_0008296	PFIZER_THO_0008300		Letter from Jovi Bacud-van der Kallen re: Periodic Safety Update Report (PSUR) February 1, 1998 through January 31, 2003 Neurontin (gabapentin)	MISC
PX5242	20020331	PFIZER_THO_0011189	PFIZER_THO_0011194		Hallucinations and Gabapentin Report (draft)	MISC
PX5247	20031024	PFIZER_THO_0024852	PFIZER_THO_0024856	5	MedWatch Mfr Report #001-0945-880004-01	MISC
PX5249	20051130	PFIZER_TMF_CRF_001124	PFIZER_TMF_CRF_001132	9	Warner-Lambert Company WAERS Composite Report Event No: 13089	MISC
PX5250	20051130	PFIZER_TMF_CRF_001133	PFIZER_TMF_CRF_001138	6	Warner-Lambert Memorandum: Routing Slip: WAERS Reports	MISC
PX5251	20051130	PFIZER_TMF_CRF_001139	PFIZER_TMF_CRF_001140	2	Warner-Lambert Company WAERS Composite Report Event No: 14362	MISC
PX5252	20051130	PFIZER_TMF_CRF_001141	PFIZER_TMF_CRF_001148	8	Warner-Lambert Memorandum: Routing Slip: WAERS Reports	MISC
PX5253	20051130	PFIZER_TMF_CRF_001149	PFIZER_TMF_CRF_001151	3	Warner-Lambert Memorandum: Routing Slip: WAERS Reports	MISC
PX5254	20051130	PFIZER_TMF_CRF_001152	PFIZER_TMF_CRF_001153	2	Warner-Lambert Company WAERS Composite Report Event No: 22288	MISC
PX5255	20051130	PFIZER_TMF_CRF_001154	PFIZER_TMF_CRF_001160	7	Warner-Lambert Memorandum: Routing Slip: WAERS Reports	MISC
PX5256	20051130	PFIZER_TMF_CRF_001168	PFIZER_TMF_CRF_001169	2	Warner-Lambert Company WAERS Composite Report Event No: 14801	MISC
PX5257	20051130	PFIZER_TMF_CRF_001177	PFIZER_TMF_CRF_001179	3	Warner-Lambert Memorandum: Routing Slip: WAERS Reports	MISC
PX5258	20051130	PFIZER_TMF_CRF_001180	PFIZER_TMF_CRF_001184	5	Parke-Davis Memorandum: Follow-up Adverse Event Report	MISC
PX5259	20051130	PFIZER_TMF_CRF_001196	PFIZER_TMF_CRF_001201	6	Warner-Lambert Memorandum: Routing Slip: WAERS Reports	MISC
PX5260	20051130	PFIZER_TMF_CRF_001202	PFIZER_TMF_CRF_001208	7	Warner-Lambert Memorandum: Routing Slip: WAERS Reports	MISC
PX5261	20051130	PFIZER_TMF_CRF_001290	PFIZER_TMF_CRF_001296	7	Warner-Lambert Memorandum: Routing Slip: WAERS Reports	MISC
PX5262	20051130	PFIZER_TMF_CRF_001297	PFIZER_TMF_CRF_001298	2	Warner-Lambert Company WAERS Composite Report Event No: 25691	MISC

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX5263	20051130	PFIZER_TMF_CRF_001319	PFIZER_TMF_CRF_001321	3	Warner-Lambert Memorandum: Routing Slip: WAERS Reports	MISC
PX5264	20051130	PFIZER_TMF_CRF_001809	PFIZER_TMF_CRF_001820	12	Statprobe, Inc.data Clarification Form-Gabapentin CI945-94	MISC
PX5265	20051201	PFIZER_TMF_CRF_002765	PFIZER_TMF_CRF_002766	2	Warner-Lambert Adverse Event Report Form	MISC
PX5266	20051201	PFIZER_TMF_CRF_002767	PFIZER_TMF_CRF_002773	7	Parke-Davis Memorandum: Initial Adverse Event Report	MISC
PX5267	20051201	PFIZER_TMF_CRF_002841	PFIZER_TMF_CRF_002842	2	Letter addressed to David Dunner re: study of Gabapentin in Bipolar Disorder	MISC
PX5268	19970609	RESPONSE	RESPONSE		Letter addressed to Lesley Frank re: MACMIS File ID #4162 NDA-20-235, Neurontin (gabapentin capsules)	MISC
PX5269	20010709	RR 720-30077			Research Report No: RR-REG 720-30077	MISC
PX5270	20011128	RR 720-30134			Research Report No: RR-REG 720-30134	MISC
PX5271	20021105	RR 720-30154			Research Report No: RR 720-30154	MISC
PX5272	20010719	RR 740-03550			Research Report No: RR-REG 740-03550	MISC
PX5275		WLC_CBU_000152	WLC_CBU_000153		Medical Mania	MISC
PX5279		WLC_CBU_007901	WLC_CBU_007901	1	Letter from William Sigmund re: Neurontin	MISC
PX5283	19960515	WLC_FRANKLIN_0000020869	WLC_FRANKLIN_0000020878		Assessing New Clinical Uses for Neurontin: A Meeting for Neurology and Psychiatry Consultants	MISC
PX5285	19950726	WLC_FRANKLIN_0000038501	WLC_FRANKLIN_0000038502		Parke-Davis Memorandum: Selected Physician Titration Analysis	MISC
PX5287		WLC_FRANKLIN_0000166566	WLC_FRANKLIN_0000166607		PD Marketing Assessment Neurontin in Psychiatric Disorders	MISC
PX5289		WLC_JTURNER_000524	WLC_JTURNER_000527	4	Record of FDA Contact	MISC
PX5290		WLC_JTURNER_000535	WLC_JTURNER_000539	5	Record of FDA Contact	MISC
PX5291		WLC_JTURNER_000757	WLC_JTURNER_000758	2	Record of FDA Contact	MISC
PX5292		WLC_JTURNER_000826	WLC_JTURNER_000828	3	Record of FDA Contact	MISC
PX5293		WLC_JTURNER_000936	WLC_JTURNER_000937	2	Record of FDA Contact	MISC
PX5294		WLC_JTURNER_000952	WLC_JTURNER_000954	3	Record of FDA Contact	MISC
PX5296		WLC_JTURNER_002791	WLC_JTURNER_002792	2	Record of FDA Contact	MISC
PX5299	20030401	PFIZER_LTIVE_0032827	PFIZER_LTIVE_0032828	2	1000 Days of NEURONTIN	MISC
PX5300	20040127	PFIZER_LALPHS_0011639	PFIZER_LALPHS_0011710	72	2	MISC
PX5301	20010214	PFIZER_LTIVE_0027716	PFIZER_LTIVE_0027784	69	945-186	MISC
PX5303	19971003	PFIZER_CTAYLOR_0008068	PFIZER_CTAYLOR_0008116	49	A SUMMARY OF MECHANISTIC HYPOTHESES OF GABAPENTIN PHARMACOLOGY	MISC
PX5309					ALPHS VIDEO	MISC
PX5310		PFIZER_CTAYLOR_0008905	PFIZER_CTAYLOR_0008922		An Update on the Possible Mechanisms of Action of Gabapentin	MISC
PX5311					ARISGDatabase	MISC
PX5313					Audio Alphs	MISC
PX5314					Audio Pande	MISC

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX5315					Audiofiles	MISC
PX5316					Betsy	MISC
PX5318	20011115	PFIZER_LKNAPP_0028682	PFIZER_LKNAPP_0028704	23	C O N F I D E N T I A L	MISC
PX5319					Clary Audio File	MISC
PX5320		PFIZER_LTIVE_0008792	PFIZER_LTIVE_0008813	22	CLINICAL PLAN-LT#1/MEDICAL	MISC
PX5323					CMMS	MISC
PX5324					Crognale CMMS and Sherlock Notes	MISC
PX5325					Crognale NDC Data	MISC
PX5326	20040817	PFIZER_THO_0004368	PFIZER_THO_0004380		CTD-pe v[g	MISC
PX5330					Declaration of Joshua Peteet Dated April 14, 2009	MISC
PX5334					FDADatabase	MISC
PX5336	20030409	PFIZER_MCLAUSSEN_0001678	PFIZER_MCLAUSSEN_0001678	1	For the month of March, Neurontin remained one of the top 10 requested products in US Medical Information, with approximately	MISC
PX5338	20041213	PFIZER_CTAYLOR_0021218	PFIZER_CTAYLOR_0021221	4	FW: **REMINDER DUE MONDAY** ACTION REQUIRED: MOA Publications Working Group please review - Heteroaromatic Side-chain Analogs manuscript - Due: 12/6	MISC
PX5341	20030512	PFIZER_LTIVE_0032991	PFIZER_LTIVE_0032992	2	Fw: Professor Martin Koltzenburg question	MISC
PX5343	20010514	PFIZER_CTAYLOR_0015156	PFIZER_CTAYLOR_0015157	2	GABA Modulator	MISC
PX5344	19980317	PFIZER_CTAYLOR_0008781	PFIZER_CTAYLOR_0008797	17	Gabapentin	MISC
PX5349		PFIZER_LLAMOREAUX_0031285	PFIZER_LLAMOREAUX_0031638	354	GBP FOI DOCUMENTS	MISC
PX5351					Goldman CMMS and Sherlock Notes	MISC
PX5352					Goldman NDC Data	MISC
PX5353					IMSData	MISC
PX5354	20040617	PFIZER_LCASTRO_0028634	PFIZER_LCASTRO_0028728	95	Investigator Brochure	MISC
PX5357		PFIZER_LTIVE_0007534	PFIZER_LTIVE_0007592	59	LABELING-LT#4/MAJOR MARKETS/USA	MISC
PX5358		PFIZER_LTIVE_0007630	PFIZER_LTIVE_0007638	9	LEGAL-LT#4/MAJOR MARKETS/USA	MISC
PX5359		PFIZER_LCASTRO_0074739	PFIZER_LCASTRO_0074741	3	LUCY CASTRO DAY FILE 2002	MISC
PX5361					Pfizer Neurontin Medical Lit Database	MISC
PX5362	20040813	PFIZER_LCASTRO_0041937	PFIZER_LCASTRO_0041938	2	MISSING NARRATIVES	MISC
PX5364	20040116	PFIZER_LALPHS_0011499	PFIZER_LALPHS_0011534	36	Narratives of Adverse Events Occurring During Clinical Pharmacology and Clinical Studies Considered Serious by	MISC
PX5365					NDC	MISC
PX5373	20010615	PFIZER_CTAYLOR_0012930	PFIZER_CTAYLOR_0012976	47	Neurontin Capsules, Tablets and Oral Solution	MISC
PX5378		PFIZER_LTIVE_0009068	PFIZER_LTIVE_0009091	24	NEURONTIN INVESTIGATIONAL BROCHURE-LT#1/MEDICAL	MISC

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX5381	20030116	PFIZER_LTIVE_0031180	PFIZER_LTIVE_0031180	1	Neurontin Monthly US Performance Report	MISC
PX5386	20001020	PFIZER_LTIVE_0027152	PFIZER_LTIVE_0027169	18	No Slide Title	MISC
PX5388	20010906	PFIZER_LTIVE_0028397	PFIZER_LTIVE_0028475	79	No Slide Title	MISC
PX5389	20020114	PFIZER_LTIVE_0028729	PFIZER_LTIVE_0028757	29	No Slide Title	MISC
PX5392	20010315	PFIZER_MHAUBEN_0000123	PFIZER_MHAUBEN_0000125	3	Objective: With the post marketing use of gabapentin with patients other than epilepsy it is important to identify whether these popuylations may be particularly susceptible to specific to specific advdrser drug effects goth labeled and unlabeled and to i	MISC
PX5394					MERLIN	MISC
PX5395					Pande Audio	MISC
PX5397	19970328			293	Pfizer Inc - PFE Annual report which provide a comprehensive overview of the company for year ending 12/31/1996	SEC
PX5398	19990326			140	Pfizer Inc - PFE Annual report which provide a comprehensive overview of the company for year ending 12/31/1998	SEC
PX5399	20000327			141	Pfizer Inc - PFE Annual report which provide a comprehensive overview of the company for year ending 12/31/1999	SEC
PX5400	20020328			137	Pfizer Inc - PFE Annual report which provide a comprehensive overview of the company for year ending 12/31/2001	SEC
PX5401	20030327			156	Pfizer Inc - PFE Annual report which provide a comprehensive overview of the company for year ending 12/31/2002	SEC
PX5402	20040310			169	Pfizer Inc - PFE Annual report which provide a comprehensive overview of the company for year ending 12/31/2003	SEC
PX5403	20050328			200	Pfizer Inc - PFE Annual report which provide a comprehensive overview of the company for year ending 12/31/2004	SEC
PX5404	20050301			184	Pfizer Inc - PFE Annual report which provide a comprehensive overview of the company for year ending 12/31/2005	SEC
PX5405	20070301			191	Pfizer Inc - PFE Annual report which provide a comprehensive overview of the company for year ending 12/31/2006	SEC
PX5406	20080229			223	Pfizer Inc - PFE Annual report which provide a comprehensive overview of the company for year ending 12/31/2007	SEC
PX5407					Pfizer Inc - PFE Annual report which provide a comprehensive overview of the company for year ending 12/31/2008	SEC
PX5408	20040507			51	Pfizer Inc - PFE Quarterly report which provides a continuing view of the company's financial position for quarter ending 03/28/2004	SEC
PX5409					Pfizer Inc - PFE Quarterly report which provides a continuing view of the company's financial position for quarter ending 03/29/2009	SEC
PX5410	20020515			42	Pfizer Inc - PFE Quarterly report which provides a continuing view of the company's financial position for quarter ending 03/31/2002	SEC
PX5411	20010515			46	Pfizer Inc - PFE Quarterly report which provides a continuing view of the company's financial position for quarter ending 04/01/2001	SEC
PX5412	20030813			42	Pfizer Inc - PFE Quarterly report which provides a continuing view of the company's financial position for quarter ending 06/29/2003	SEC
PX5413	20010814			52	Pfizer Inc - PFE Quarterly report which provides a continuing view of the company's financial position for quarter ending 07/01/2001	SEC
PX5414	20000815			38	Pfizer Inc - PFE Quarterly report which provides a continuing view of the company's financial position for quarter ending 07/02/2000	SEC
PX5415	20031112			54	Pfizer Inc - PFE Quarterly report which provides a continuing view of the company's financial position for quarter ending 09/28/2003	SEC

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX5416	20021113			53	Pfizer Inc - PFE Quarterly report which provides a continuing view of the company's financial position for quarter ending 09/29/2002	SEC
PX5417	20011113			53	Pfizer Inc - PFE Quarterly report which provides a continuing view of the company's financial position for quarter ending 09/30/2001	SEC
PX5418	20001115			39	Pfizer Inc - PFE Quarterly report which provides a continuing view of the company's financial position for quarter ending 10/01/2000	SEC
PX5423	20000922	PFIZER_LTIVE_0027070	PFIZER_LTIVE_0027085	16	PMO-Pillar Training	MISC
PX5424		PFIZER_LTIVE_0010009	PFIZER_LTIVE_0010015	7	PMP	MISC
PX5426	20011101	PFIZER_LKNAPP_0014452	PFIZER_LKNAPP_0014476	25	PowerPoint Presentation	MISC
PX5432	20030303	PFIZER_CTAYLOR_0019237	PFIZER_CTAYLOR_0019238	2	RE: GABAergic"" & a2d compounds""	MISC
PX5434	20010914	PFIZER_RGLANZMAN_0040034	PFIZER_RGLANZMAN_0040036	3	RE: GBP - post amputation pain	MISC
PX5436	20030612	PFIZER_LTIVE_0033369	PFIZER_LTIVE_0033369	1	RE: names of reviewers for Neurontin publications	MISC
PX5437	20030612	PFIZER_LTIVE_0033375	PFIZER_LTIVE_0033375	1	RE: names of reviewers for Neurontin publications	MISC
PX5438	20030117	PFIZER_LTIVE_0031255	PFIZER_LTIVE_0031257	3	Re: National Public Radio- NEURONTIN Story to be aired TONIGHT	MISC
PX5440	20040823	PFIZER_THO_0005259	PFIZER_THO_0005260	2	RE: Neurontin FDA Response	MISC
PX5441	20020523	PFIZER_CTAYLOR_0017230	PFIZER_CTAYLOR_0017231	2	RE: Neurontin PHN sNDA; labeling; mechanism of action	MISC
PX5449					RR Database	MISC
PX5450		PFIZER_LTIVE_0009745	PFIZER_LTIVE_0009746	2	SAFETY	MISC
PX5451					ShelockDatabase	MISC
PX5452	20010214	PFIZER_LTIVE_0027785	PFIZER_LTIVE_0027811	27	SOP 6-010	MISC
PX5453	20040116	PFIZER_LALPHS_0011484	PFIZER_LALPHS_0011498	15	Study Number	MISC
PX5651		PFIZER_LTIVE_0013173	PFIZER_LTIVE_0013176	4	UNTITLED	MISC
PX5652		PFIZER_LTIVE_0013442	PFIZER_LTIVE_0013445	4	UNTITLED	MISC
PX5653					Verispan	MISC
PX5654					"All it takes is one" audio file	MISC
PX5655					"Neurontin Push" audio file	MISC
PX5656					"Liason Use" audio file	MISC
PX5657					Letter to Robert Gibbons From J.T. Coyle Dated 2/2/2009	Expert Report: Greenland, Sander 05/31/2009
PX5658					Letter to Robert Gibbons From J.T. Coyle Dated 4/27/2009	Expert Report: Greenland, Sander 05/31/2009
PX5659					Letter from Robert Gibbons to the editor of Archives of General Psychiatry dated 3/15/2009	Expert Report: Greenland, Sander 05/31/2009
PX5661		PFIZER_MEVERTSZ_0131355	PFIZER_MEVERTSZ_0133814		Neurontin Periodic Report 8/19/2005 to 8/18/2006	MISC
PX5662	20071206			48	PPT Presentation_Tetrabenazine New Drug Application 21-894	MISC
PX5664	20040513			15	Sentencing of case_USA v. Warner-Lambert Company, LLC	MISC

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX5665					September 2008 FDA Health Case Alert on Phenergan (Promethazine)	MISC
PX5666	20081217			3	Internet Article_Suicidal Thoughts and Behavior: Antiepileptic Drugs-Full Version	MISC
PX5667				23	Research Report_Supplemental Data Gabapentin Receptor (alpha-2-delta)-1 Is a Neuronal Thrombospondin Receptor Responsible for Excitatory CNS Synaptogenesis	MISC
PX5669					PLEA AGREEMENT	MISC
PX5670	20090505			3	U.S. Food and Drug Administration Internet Article_Suicidal Behavior and Ideation and Antiepileptic Drugs	MISC
PX5671	20090828			48	Settlement Agreement with Pfizer	MISC
PX5672	20040609			3	Judgement of case_USA v. Warner-Lambert Company, LLC	MISC
PX5673	20040513			8	Letter sent from Michael Sullivan_re: Warner-Lambert Company LLC	MISC
PX5674		MDL_VENDORS_008830	MDL_VENDORS_008898	69	Parke-Davis Pain AD Board	MISC
PX5675		MDL_VENDORS_052129	MDL_VENDORS_052261	133	Antiepileptic Drug Trials III 3/14/96	MISC
PX5676		MDL_VENDORS_064908	MDL_VENDORS_064910	3	Neurobehavioral Sciences Working Group	MISC
PX5677		MDL_VENDORS_103396	MDL_VENDORS_103399	4	5/7/99 Intramed Fax	MISC
PX5678		PFIZER_AFANNON_0008510	PFIZER_AFANNON_0008539	30	7/31/95 Neurontin Marketing Assessment	MISC
PX5679	20021111	Pfizer_BParsons_0002523	Pfizer_BParsons_0002525	3	Email sent from Allison Fannon_re: Gabapentin Chapter Review-Treatment of Epilepsy	MISC
PX5680		Pfizer_BParsons_0022962	Pfizer_BParsons_0022965	4	Neurontin 2004 US Strategic Clinical Operating Plan Draft	MISC
PX5681	20011005	Pfizer_BParsons_0092302	Pfizer_BParsons_0092375	74	Neurontin 2002 Operating Plan	MISC
PX5682		PFIZER_CGROGAN_0015433	PFIZER_CGROGAN_0015434	2	Neurontin Speaker Training 8/10/2002	MISC
PX5683		Pfizer_CWohlhuter_0013192	Pfizer_CWohlhuter_0013238	48	Presentation Slides	MISC
PX5684	20031121	Pfizer_CWohlhuter_0045553	Pfizer_CWohlhuter_0045553	2	Email sent to Allison Fannon; Timothy Hsu from Claire Wohlhuter_re: Joint NeP/Fibro/LCP	MISC
PX5685		PFIZER_DPROBERT_0016950	PFIZER_DPROBERT_0016983	34	Neurontin National Meeting Roster	MISC
PX5686	20020222	Pfizer_DProbert_0024907	Pfizer_DProbert_0024919	13	Neuropathic Pain Advisory Board Meeting_General Sessions and Workshops Summary	MISC
PX5687	20001012	Pfizer_DProbert_0028501	Pfizer_DProbert_0028501	1	Letter addressed to Allison Fannon_re: Progress in Pain Management for Primary Care Physicians	MISC
PX5688		Pfizer_DProbert_0028563	Pfizer_DProbert_0028627	65	Neurontin Action Plan_POA2-2004	MISC
PX5689		Pfizer_JBurrell_000073	Pfizer_JBurrell_000073	1	Neurontin POA Goals Marketing Contest Flyer	MISC
PX5690	20010816	Pfizer_JSu_0032011	Pfizer_JSu_0032016	6	Email sent from Susanne Batesko_re: Neurontin Publications Report	MISC
PX5691	20030514	Pfizer_LCastro_0043191	Pfizer_LCastro_0043231	41	Final Report_Pfizer Italia S.r.l._Double-Blind, placebo controlled, randomized, multicenter study on the efficacy and safety of gabapentin (Neurontin) as adjuvant analgesic in neuropathic pain in patients with malignancies_Protocol No. 945-420276	MISC
PX5692	19990601	Pfizer_LeslieTive_0008869	Pfizer_LeslieTive_0009673	805	Clinical Expert Report_Neurontin Neuropathic Pain	MISC
PX5693	20030108	Pfizer_LeslieTive_0076467	Pfizer_LeslieTive_0076479	13	Presentation Slides_Neurontin Global Goal Alignment 2003	MISC

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX5694	20011107	Pfizer_LKnapp_0050948	Pfizer_LKnapp_0050948	1	Email sent from Lloyd Knapp_re: QOL abstract for AAN	MISC
PX5695		Pfizer_MDL_Shearer_0043422	Pfizer_MDL_Shearer_0043429	8	PHN Advisory Board Meeting Summary	MISC
PX5696		Pfizer_MDL_Shearer_0043430	Pfizer_MDL_Shearer_0043430	1	Attendee List	MISC
PX5697		Pfizer_Mfagan_0000001	Pfizer_Mfagan_00000037	37	Presentation_Treating the Migraine Patient: An Internist's Perspective by Redonda Miller	MISC
PX5698		Pfizer_Mfagan_00000038	Pfizer_Mfagan_00000041	4	Presentation Slides_Neurontin vs. Lyrica	MISC
PX5699	20030617	Pfizer_Mfagan_00000042	Pfizer_Mfagan_00000042	1	Email sent from Alisaar Tubolino_re: Neurontin + Opioids	MISC
PX5700	19981130	Pfizer_Mfagan_00000043	Pfizer_Mfagan_00000050	8	Internet Article_Gabapentin as an Adjuvant to Opioid Analgesia for Neuropathic Cancer Pain	MISC
PX5701		Pfizer_Mfagan_00000051	Pfizer_Mfagan_0000244	194	Michael Fagan's Entire Custodial File	MISC
PX5702	20030627	Pfizer_MPatel_0013990	Pfizer_MPatel_0014082	93	A Double-blind Placebo-controlled trial of Gabapentin for treatment of Painful diabetic peripheral neuropathy	MISC
PX5703	20010115	Pfizer_RGlanzman_0063383	Pfizer_RGlanzman_0063417	35	Protocol Template	MISC
PX5704		Pfizer_RGlanzman_0135187	Pfizer_RGlanzman_0135198	12	Neurontin Indication Discussion Slides	MISC
PX5705		Pfizer_SDoft_0022494	Pfizer_SDoft_0022505	12	Neuropathic Pain Advisory Board Meeting_General Session Summary	MISC
PX5706		PFIZER_SDOFT_0064445	PFIZER_SDOFT_0064445	1	3/29/2004 Memo From Suzanne Doft	MISC
PX5707		Pfizer_SPiron_0024807	Pfizer_SPiron_0025033	227	Neurontin Educational Slide Kit	MISC
PX5708		PFIZER_THO_0000863	PFIZER_THO_0000868	6	Backonja, M. et. al. Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients with Diabetes Mellitus. JAMA 1998; 280(21): 1831-1836.	MISC
PX5709		Pfizer_Wohlber_012522	Pfizer_Wohlber_012531	10	Gibbons' Neurontin Study Proposal 2008	MISC
PX5710		Pfizer_Wohlber_012772	Pfizer_Wohlber_012773	2	Notes from 2008 Harvard Presentation of Robert Gibbons	MISC
PX5711		Pfizer_Wohlberg_013808	Pfizer_Wohlberg_013815	8	PFE Neurontin Back-up Slides	MISC
PX5712	20080423	Pfizer_Wohlberg_019343	Pfizer_Wohlberg_019344	2	Email sent from Kevin Phelan_re: BD Section on AED Usage	MISC
PX5713	20080404	Pfizer_Wohlberg_019526	Pfizer_Wohlberg_019527	2	Email sent to Christopher Wohlberg from Ed Whalen_re: update	MISC
PX5714	20060811	Pfizer_Wohlberg_050250	Pfizer_Wohlberg_050261	12	Clinical Protocol Synopsis_Protocol Number A0081047	MISC
PX5715		RR 720-03495			Research Report 720-03495	MISC
PX5716	19930501	WLC_CBU_000000	WLC_CBU_000000	3	Neurontin Product Monograph	MISC
PX5717		WLC_CBU_000168	WLC_CBU_000172	5	Broadening the Neuropathic Pain Algorithm Invitation 12/7/98	MISC
PX5718		WLC_CBU_032919	WLC_CBU_032922	4	12/1/98 Press Release	MISC
PX5719		WLC_CBU_092827	WLC_CBU_092830	4	12/3/98 Fax from K. Lewis to Laura Johnson	MISC
PX5720		WLC_CBU_132158	WLC_CBU_132248	91	12/8/97 Memo From Vic Delimata	MISC
PX5721		WLC_CBU_170739	WLC_CBU_170744	6	3/14/95 Meeting Minutes	MISC
PX5722		WLC_FRANKLIN_0000031981	WLC_FRANKLIN_0000031992	12	3/22/96 Meeting Participant List	MISC
PX5723		WLC_FRANKLIN_0000039703	WLC_FRANKLIN_0000039710	8	7/12/95 Letter from Frary to Rizzo	MISC

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX5724	19950412	WLC_FRANKLIN_0000039703	WLC_FRANKLIN_0000039710	8	letter from Tracy Frary (Miguara Kaplan Assoc) to J Rizzo (P-D) re: topline assessment of the results of the Quantitative Evaluation of the Opportunity for Neurontin	MISC
PX5725		WLC_FRANKLIN_0000042225	WLC_FRANKLIN_0000042225	1	P-D Portfolio Management Dinners	MISC
PX5726		WLC_FRANKLIN_0000053520	WLC_FRANKLIN_0000053526	7	9/18/95 Memo From Griffin to Ulrich	MISC
PX5727		WLC_FRANKLIN_0000063467	WLC_FRANKLIN_0000063474	8	8/6/97 Letter from Johnson to Dobson	MISC
PX5728		WLC_FRANKLIN_0000067262	WLC_FRANKLIN_0000067277	16	3/4/96 Memo from Johnson to Krukar	MISC
PX5729		WLC_FRANKLIN_0000072447	WLC_FRANKLIN_0000072448	2	Neurontin Advocates	MISC
PX5730		WLC_FRANKLIN_0000087766	WLC_FRANKLIN_0000087900	135	PD Post Investigators Meeting 945-211	MISC
PX5731		WLC_FRANKLIN_0000092062	WLC_FRANKLIN_0000092082	21	Epilepsy Disease Speakers Bureau	MISC
PX5732	19950519	WLC_FRANKLIN_0000223121	WLC_FRANKLIN_0000223180	60	Neurontin Marketing Assessment in Psychiatric Disorders	MISC
PX5733		WLC_FRANKLIN_0000223121	WLC_FRANKLIN_0000223180	60	5/19/95 Neurontin Marketing Assessment Psych Disorders	MISC
PX5747		N/A	N/A		USA vs. Warner-Lambert Company LLC	Depo Exhibit: Taylor, Charles 8/27/2009 EX:032
PX5748		N/A	N/A		Judgement for USA vs. Warner-Lambert Company LLC	Depo Exhibit: Taylor, Charles 8/27/2009 EX:033
PX5749		Pfizer_CTaylor_0001427	Pfizer_CTaylor_0001429		Pfizer Global Research and Development Memorandum: A capsule history of the alpha-2-delta story	Depo Exhibit: Taylor, Charles 8/27/2009 EX:035
PX5750		Pfizer_CTaylor_0017041	Pfizer_CTaylor_0017069		PPT: The Q3 alpha-2-delta Ligand Project	Depo Exhibit: Taylor, Charles 8/27/2009 EX:039
PX5752		Pfizer_LTive_0031181	Pfizer_LTive_0031182		Email (January 16, 2003) from John Marino_subj: National Public Radio- Neurontin Story to be aired Tonight	Depo Exhibit: Taylor, Charles 8/27/2009 EX:040
PX5753		N/A	N/A		Chart: GABA Elevation Does Not Predict Mechanism of Action or Effects	Depo Exhibit: Taylor, Charles 8/27/2009 EX:043A
PX5754		N/A	N/A		Fax of Depression Study Results	Depo Exhibit: Taylor, Charles 8/27/2009 EX:044
PX5760	5/9/2003	Pfizer_BParsons_0192267	Pfizer_BParsons_0192268	2	Pfizer Meeting Agenda	MISC
PX5761	6/10/2000	MDL_Vendors_056885	MDL_Vendors_056887	3	Faculty Statement of Financial Interests and Affiliations	MISC
PX5762	12/29/1998	Pfizer_LCastro_0075698	Pfizer_LCastro_0075892	2	Parke-Davis Research Report No: RR 995-00070	MISC
PX5763	1/18/2001	Pfizer_LTive_0013795	Pfizer_LTive_0013795	1	Letter from David Murphy re: Pain Disease State Management Proposal from Key Opinion Leader	MISC
PX5764		WLC_CBU_000168	WLC_CBU_000172	5	Invitation to dinner program: Broadening the Neuropathic Pain Treatment Algorithm	MISC
PX5765	11/6/2002	Pfizer_CWohlhuter_0011993	Pfizer_CWohlhuter_0012012	20	Neurontin Publication Planning and Execution	MISC
PX5766		Pfizer_TMF_CRF_074113	Pfizer_TMF_CRF_074125	13	Curriculum Vitae of Edgar L. Ross	MISC
PX5767	4/22/1996	Pfizer_TMF_CRF_074177	Pfizer_TMF_CRF_074178	2	Parke-Davis Medical Research Protocol for Clinical Research Trial	MISC
PX5768	5/12/1999	WLC_CBU_028618	WLC_CBU_028624	7	Memorandum re: Updated Speaker Lists	MISC
PX5769	2/1/2002	Pfizer_SDoft_0012058	Pfizer_SDoft_0012059	2	MAP-PM 2002 Advisory Board Meeting Agenda	MISC
PX5770	08/00/2000	Pfizer_DProbert_0028466	Pfizer_DProbert_0028473	8	Article:Neuropathic Pain: The Evolving Role of Anticonvulsants in Pain Management	MISC
PX5771		WLC_CBU_045720	WLC_CBU_045727	8	PPT NeuroBehavioral Working Group	MISC

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX5772		WLC_CBU_072904	WLC_CBU_072923	20	The Evolving Role of Anticonvulsants in Pain Management by Edgar L. Ross	MISC
PX5773	1/18/2001	Pfizer_LTive_0013795	Pfizer_LTive_0013821	27	Letter from David Murphy re: Pain Disease State Management Proposal from Key Opinion Leader	MISC
PX5774	6/7/2000	MDL_Vendors_073013	MDL_Vendors_073017	5	Letter sent from E. Ross to Marilyn Abel re: Pain Programs in July	MISC
PX5775	5/31/2000	WLC_CBU_040534	WLC_CBU_040579	46	Neurontin Update	MISC
PX5776	6/8/2000	MDL_Vendors_073009	MDL_Vendors_073012	4	Letter sent from Marilyn Abel to E. Ross re: Re your checks	MISC
PX5777	8/15/2006			11	Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents	MISC
PX5778	03/12/2001	Pfizer_MDL_Shearer_0007920	Pfizer_MDL_Shearer_0007926		Letter from James Rouhandeh to Susan Hanson-Philbrick	MISC
PX5779	03/29/2004	Pfizer_MDL_Shearer_0043422	Pfizer_MDL_Shearer_0043429		PHN Advisory Board Meeting	MISC
PX5780	00/00/0000	Pfizer_MDL_Shearer_0043430	Pfizer_MDL_Shearer_0043430		Attendee List	MISC
PX5781	01/31/2008	Pfizer_Wohlberg_011886	Pfizer_Wohlberg_011887		Communications Action Plan re: FDA Review of Labelling	MISC
PX5782	00/00/0000	Pfizer_Wohlberg_011914	Pfizer_Wohlberg_011923		Pfizer Response To FDA Alert on Suicidality	MISC
PX5783	03/14/2008	Pfizer_Wohlberg_012085	Pfizer_Wohlberg_012101		AED Executive Committee Presentation	MISC
PX5784	04/11/2008	Pfizer_Wohlberg_012157	Pfizer_Wohlberg_012171		AED EC Update	MISC
PX5785	04/18/2008	Pfizer_Wohlberg_012172	Pfizer_Wohlberg_012182		ELT Update	MISC
PX5786	02/10/2008	Pfizer_Wohlberg_012224	Pfizer_Wohlberg_012226		Minutes of Lyrica/Neurontin Product Meeting	MISC
PX5787	00/00/0000	Pfizer_Wohlberg_012522	Pfizer_Wohlberg_012531		Study Protocol	MISC
PX5788	00/00/0000	Pfizer_Wohlberg_012772	Pfizer_Wohlberg_012773		Statistical Issues in Drug Safety: The curious case of anti-depressants, anti-epilepsy drugs?? and suicide	MISC
PX5789	10/14/2009	Pfizer_Wohlberg_013717	Pfizer_Wohlberg_013752		PowerPoint Presentation: Suicidality and Anti-Epileptic Drugs	MISC
PX5790	12/19/2008	Pfizer_Wohlberg_013756	Pfizer_Wohlberg_013807		PhRMA Suicidality White Paper	MISC
PX5791	06/19/2008	Pfizer_Wohlberg_013997	Pfizer_Wohlberg_013997		Chart of Gabapentin Reporting Rates	MISC
PX5792	06/23/2008	Pfizer_Wohlberg_014100	Pfizer_Wohlberg_014141		Presentation to Pharmacovigilance Working Party	MISC
PX5793	00/00/0000	Pfizer_Wohlberg_018662	Pfizer_Wohlberg_018672		AED Advisory Committee Communications Plan	MISC
PX5794	04/23/2008	Pfizer_Wohlberg_019343	Pfizer_Wohlberg_019344		Email from Phelan to Hakkinen	MISC
PX5795	04/04/2008	Pfizer_Wohlberg_019526	Pfizer_Wohlberg_019527		Email from Whalen to Wohlberg Re: update	MISC
PX5796	03/22/2008	Pfizer_Wohlberg_019883	Pfizer_Wohlberg_019886		Email From Romano to Phelan ReL Update on Israel MOH request	MISC
PX5797	02/18/2008	Pfizer_Wohlberg_020042	Pfizer_Wohlberg_020044		Email from Scheer to Wohlberg Re: Russ Portenoy	MISC
PX5798	02/04/2008	Pfizer_Wohlberg_020237	Pfizer_Wohlberg_020238		Email from Knapp to Wohlberg Rel FDA Alert	MISC
PX5799	02/01/2008	Pfizer_Wohlberg_020294	Pfizer_Wohlberg_020298		Email from Barrett to Wohlberg	MISC
PX5800	07/21/1999	Pfizer_Wohlberg_020650	Pfizer_Wohlberg_020651		Email from Wohlberg to Rodriguez Re: Social phobia	MISC
PX5801	02/01/2008	Pfizer_Wohlberg_021482	Pfizer_Wohlberg_021483		Email from Wohlberg to Bykoriz Re: Postmarketing Reports	MISC
PX5802	03/19/2008	Pfizer_Wohlberg_022265	Pfizer_Wohlberg_022272		Memo from Eng to Suicidality Assessment Work Group	MISC

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX5803	07/10/2008	Pfizer_Wohlberg_023026	Pfizer_Wohlberg_023028		Email from Wlberg to Bijlani ReL FYI AC Members	MISC
PX5804	06/09/2008	Pfizer_Wohlberg_023676	Pfizer_Wohlberg_023677		Email from Wohlberg to French Re: Suicidality and AED meeting.	MISC
PX5805	06/05/2008	Pfizer_Wohlberg_023702	Pfizer_Wohlberg_023703		Email from Wohlberg to Cox Re: Lyrica	MISC
PX5806	06/02/2008	Pfizer_Wohlberg_023812	Pfizer_Wohlberg_023813		Suicidality and Anti-Epileptic Drugs Agenda	MISC
PX5807	00/00/0000	Pfizer_Wohlberg_023835	Pfizer_Wohlberg_023835		Faculty	MISC
PX5808	00/00/0000	Pfizer_Wohlberg_024478	Pfizer_Wohlberg_024484		Minutes from the March 23-24, 2009 Suicidality Consensus Conference	MISC
PX5809	03/31/2009	Pfizer_Wohlberg_025059	Pfizer_Wohlberg_025059		Email from Wohlberg to Brandicourt re: FDA teleconference	MISC
PX5810	06/25/2008	Pfizer_Wohlberg_025176	Pfizer_Wohlberg_025189		PhVWP Review of AEDs	MISC
PX5811	08/18/2008	Pfizer_Wohlberg_025239	Pfizer_Wohlberg_025308		Letter from Bartley to Gonzales: Response to Outstanding Questions	MISC
PX5812	00/00/0000	Pfizer_Wohlberg_026046	Pfizer_Wohlberg_026057		Antiepileptics and suicide-related PTs/SMQs FDA FOI AERS Q4 2007 Non clinical trial cases	MISC
PX5813	06/19/2008	Pfizer_Wohlberg_026328	Pfizer_Wohlberg_026328		Reporting Rate For Suicide Chart	MISC
PX5814	06/19/2008	Pfizer_Wohlberg_026329	Pfizer_Wohlberg_026329		Report Rate For Suicide Chart	MISC
PX5815	06/19/2008	Pfizer_Wohlberg_026430	Pfizer_Wohlberg_026430		Reporting Reate For Suicide Chart	MISC
PX5816	06/19/2008	Pfizer_Wohlberg_026431	Pfizer_Wohlberg_026431		Reporting Rate For Suicide	MISC
PX5817	02/15/2008	Pfizer_Wohlberg_027104	Pfizer_Wohlberg_027109		Dear Investigator Letter	MISC
PX5818	02/12/2008	Pfizer_Wohlberg_028308	Pfizer_Wohlberg_028311		Email from Garofalo to Knapp re: Safety Alert	MISC
PX5819	07/10/2008	Pfizer_Wohlberg_030690	Pfizer_Wohlberg_030713		Presentation to Combined Advisory Committee	MISC
PX5820	06/05/2008	Pfizer_Wohlberg_030855	Pfizer_Wohlberg_030856		email from Cox to Wohlberg Re: Slide 8	MISC
PX5821	06/02/2008	Pfizer_Wohlberg_031382	Pfizer_Wohlberg_031383		Email from Chappell to Wohlberg re: AED and FDA	MISC
PX5822	09/26/2007	Pfizer_Wohlberg_037687	Pfizer_Wohlberg_037688		Email from Zeiher to Wohlberg re: Feedback Appreciated	MISC
PX5823	06/19/2007	Pfizer_Wohlberg_038121	Pfizer_Wohlberg_038121		Email from Schwizer to Wohlberg Re: Neurontin Project	MISC
PX5824	07/06/2007	Pfizer_Wohlberg_038159	Pfizer_Wohlberg_038161		Email from Whalen to Gooch	MISC
PX5825	04/03/2009	Pfizer_Wohlberg_038879	Pfizer_Wohlberg_038880		Email from Feltner to Wohlberg re: Jackie French suicidality methods study	MISC
PX5826	04/03/2009	Pfizer_Wohlberg_038885	Pfizer_Wohlberg_038887		Email from Wohlberg to Knapp Re: Jackie French suicidality methods study	MISC
PX5827	12/15/2008	Pfizer_Wohlberg_046322	Pfizer_Wohlberg_046322		email from Richardson to Wohlberg Rel AED EC Agenda	MISC
PX5828	00/00/2005	Pfizer_Wohlberg_069373	Pfizer_Wohlberg_069390		Strategic Risk Management Plan	MISC
PX5829	05/08/2006	Pfizer_Wohlberg_078291	Pfizer_Wohlberg_078291		Email from Wohlberg to Garcia: ReL So I'm having trouble going to sleep	MISC
PX5830	04/22/2009	Pfizer_Wohlberg_080303	Pfizer_Wohlberg_080306		Lyrica/AED Class Labeliing Media Statement	MISC
PX5831	01/31/2008	Pfizer_Wohlberg_082643	Pfizer_Wohlberg_082644		Communications Action Plan re:Fda Alert	MISC
PX5832	06/04/2008	Pfizer_Wohlberg_090003	Pfizer_Wohlberg_090004		Email from Roman to Wohlberg re: WSJ Blog	MISC
PX5833	12/17/2008	Pfizer_Wohlberg_095326	Pfizer_Wohlberg_095326		Email from Cox re: Summary of AED Media Coverage	MISC

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX5834	01/28/2009	Pfizer_Wohlberg_102618	Pfizer_Wohlberg_102642		Pfizer Product Training-Lyrica	MISC
PX5835	11/04/2008	Pfizer_Wohlberg_106408	Pfizer_Wohlberg_106427		Gabapentin RMC Meeting	MISC
PX5836	01/30/2008	Pfizer_Wohlberg_109329	Pfizer_Wohlberg_109332		Email from Kremer to Glue re: Assessment of Suicidality	MISC
PX5837	00/00/0000	Pfizer_Wohlberg_109409	Pfizer_Wohlberg_109421		Regulatory Update for AED Executive Committee Meeting	MISC
PX5838	00/00/0000	Pfizer_Wohlberg_111103	Pfizer_Wohlberg_111103		Email from Stampf to DL-Lyrica re : 2005 Lyrica GPP	MISC
PX5839	03/14/2004	Pfizer_Wohlberg_111104	Pfizer_Wohlberg_111111		Lyrica 2005 Global Product Plan	MISC
PX5840	02/23/2009	Pfizer_Wohlberg_114129	Pfizer_Wohlberg_114130		CIOMS-I Report	MISC
PX5841	03/07/2006	Pfizer_Wohlberg_114137	Pfizer_Wohlberg_114158		Lyrica Clinical Trial Evaluation	MISC
PX5842	04/24/2006	Pfizer_Wohlberg_114312	Pfizer_Wohlberg_114365		Lyrica Additional Clinical Trials	MISC
PX5843	00/00/0000	Pfizer_Wohlberg_114814	Pfizer_Wohlberg_114887		Post-Marketing Gabapentin Cumulative Review of Suicidality	MISC
PX5844	00/00/0000	Pfizer_Wohlberg_115238	Pfizer_Wohlberg_115240		AED AC BOP Scenarios	MISC
PX5845	03/22/2009	Pfizer_Wohlberg_155923	Pfizer_Wohlberg_155925		McNamara Email Re: ROC	MISC
PX5846	00/00/0000	Pfizer_Wohlberg_155938	Pfizer_Wohlberg_155943		FDA ANALYSIS ON ANTIEPILEPTIC DRUGS AND RISK OF SUICIDALITY	MISC
PX5847	00/00/0000	Pfizer_Wohlberg_157544	Pfizer_Wohlberg_157545		Medication Guide	MISC
PX5848	01/24/2001	Pfizer_Wohlberg_162524	Pfizer_Wohlberg_162530		Email from McKinnell re: Fourth quarter and Full Year 2000 Financial Results	MISC
PX5849		WLC_CBU_123550	WLC_CBU_123553		Neurontin Studies/ JAMA Video News Release	MISC
PX5850					MAC Communications Neurontin Powerpoint Dated 10/21/2002	
PX5851		Pfizer_Lcastro_0073854	Pfizer_Lcastro_0073858		Article: The Effect of Gabapentin on Brain Gamma-aminobutyric Acid in Patients with Epilepsy	Depo Exhibit: Glenmullen, Joseph 1/11/2010 EX:007
PX5852		Pfizer_CTaylor_0007138	Pfizer_CTaylor_0007139		Article: Gabapentin raises human brain GABA within thirty minutes	Depo Exhibit: Glenmullen, Joseph 1/11/2010 EX:008
PX5853		N/A	N/A		Review and Evaluation of Clinical Data re: Neurontin	Depo Exhibit: Hynes, Wilfred 11/13/2009 EX:010
PX5854		N/A	N/A		Settlement Agreement	Depo Exhibit: Hynes, Wilfred 11/13/2009 EX:007
PX5855		Pfizer_CWohlhuter_0029851	Pfizer_CWohlhuter_0029894	44	Neurontin Mid-POA1 February 3, 2004	MISC
PX5856		Pfizer_LeslieTive_0068871	Pfizer_LeslieTive_0068922	52	Neurontin 2003 Strategic Planning Meeting	MISC
PX5857		Pfizer_RGlanzman_0072024	Pfizer_RGlanzman_0072150	127	Neurontin 2001 US Operating Plan October 11, 2000	MISC
PX5858		Pfizer_SPiron_0023041	Pfizer_SPiron_0023042	2	Email sent from John Marino October 16, 2001 re: Gabapentin Neuropathic Pain Indication	MISC
PX5859		Pfizer_TMF_CRF_045908		1	Handwritten Notes re: Meeting with Leslie and Paula P.	MISC
PX5860		WLC_CBU_011128	WLC_CBU_011141	14	Gabapentin Presentation	MISC
PX5861		WLC_CBU_089566	WLC_CBU_089575	10	Precision Marketing Fax to Edda Guerrero from Lawton Griffin 8/21/1995 re: AED report on the STEPS Physicians	MISC
PX5862		WLC_CBU_091696	WLC_CBU_091700	5	Parke-Davis Memo to John Marino 7/24/2000 re: Neurontin Market Research: Rheumatologists and Orthopedists who prescribe Neurontin	MISC
PX5863		WLC_CBU_106901	WLC_CBU_106906	6	1998 Strategic Plan and A&P Allocation Grid for Neurontin	MISC

Ex#	Date	Beg Bates	End Bates	Pages	Description	Exhibit Source
PX5864		WLC_CBU_166434		1	SE-CBU Neurontin 2000 A&P Budget	MISC
PX5865		WLC_CBU_166593	WLC_CBU_166599	7	Boron-Lepore Neurontin Conferences_132 MDs with ME#, Events held in Oct 97	MISC
PX5866		WLC_FRANKLIN_0000091673	WLC_FRANKLIN_0000091737	65	Parke-Davis Email with attachments sent to Field Sales Colleagues from Epilepsy Disease Team re: AEDs Early Adopters	MISC
PX5867		WLC_FRANKLIN_0000197869	WLC_FRANKLIN_0000197909	41	Neurontin Presentation	MISC
PX5868		WLC_FRANKLIN_0000238095	WLC_FRANKLIN_0000238191	97	Parke-Davis Neurontin Promotional Analyses Presentation_March 13, 1995	MISC
PX5869					Antiepileptic drugs and risk of suicide: a nationwide study. Olesen et al. Pharmaceutical and Drug Safety 2010.	MISC
PX5870					Anticonvulsant Medications and the Risk of Suicide, Attempted Suicide, or Violent Death. Patorno et al. JAMA 303:14 1401	MISC